

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2018246235 B2**

(54) Title
Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapy

(51) International Patent Classification(s)
C07K 14/705 (2006.01) **A61K 38/00** (2006.01)
A01N 63/00 (2006.01) **C07K 14/725** (2006.01)
A61K 35/17 (2015.01) **C12N 5/0783** (2010.01)

(21) Application No: **2018246235** (22) Date of Filing: **2018.03.27**

(87) WIPO No: **WO18/183385**

(30) Priority Data

(31) Number	(32) Date	(33) Country
62/477,335	2017.03.27	US
62/628,774	2018.02.09	US

(43) Publication Date: **2018.10.04**

(44) Accepted Journal Date: **2023.12.21**

(71) Applicant(s)
National University of Singapore;Nkarta, Inc.

(72) Inventor(s)
Leong, Jun Hao;Shimasaki, Noriko;Seow, See Voon;Campana, Dario;Trager, James Barnaby;Lazetic, Alexandra Leida Liana;Guo, Chao;Buren, Luxuan Guo;Masrani, Shyam Sashikant

(74) Agent / Attorney
AJ PARK, GPO Box 2513, Sydney, NSW, 2001, AU

(56) Related Art
SENTMAN, C. ET AL: "NKG2D CARs as Cell Therapy for Cancer :", CANCER JOURNAL, vol. 20, no. 2, 1 January 2014, pages 156 - 159
WO 2017024131 A1
Hombach, A. et al., "Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28—OX40 signalling", Int. J. Canc. 129:2935-2944, 2011.
Sahm, C. et al., "Expression of IL-15 in N K cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor," Cancer Immunol. Immunother.
WO 2018124766 A2



(51) International Patent Classification:

A61K 35/17 (2015.01) C07K 14/725 (2006.01)
A61K 38/00 (2006.01) C07K 14/705 (2006.01)
A01N 63/00 (2006.01) C12N 5/0783 (2010.01)

(21) International Application Number:

PCT/US2018/024650

(22) International Filing Date:

27 March 2018 (27.03.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/477,335 27 March 2017 (27.03.2017) US
62/628,774 09 February 2018 (09.02.2018) US

(71) Applicants: NATIONAL UNIVERSITY OF SINGAPORE [SG/SG]; 21 Lower Kent Ridge Road, Singapore 119077 (SG). NKARTA, INC. [US/US]; 329 Oyster Point Boulevard, 3rd Floor, South San Francisco, CA 94080 (US).

(72) Inventors: LEONG, Jun, Hao; c/o National University Of Singapore, 21 Lower Kent Ridge Road, Singapore 119077 (SG). SHIMASAKI, Noriko; c/o National University Of Singapore, 21 Lower Kent Ridge Road, Singapore 119077 (SG). SEOW, See, Voon; c/o National University Of Singapore, 21 Lower Kent Ridge Road, Singapore 119077 (SG). CAMPANA, Dario; c/o National University Of Singapore, 21 Lower Kent Ridge Road, Singapore 119077 (SG). TRAGER, James, Barnaby; c/o Nkarta, Inc., 329

Oyster Point Boulevard, 3rd Floor, South San Francisco, CA 94080 (US). LAZETIC, Alexandra, Leida Liana; c/o Nkarta, Inc., 329 Oyster Point Boulevard, 3rd Floor, South San Francisco, CA 94080 (US). GUO, Chao; c/o Nkarta, Inc., 329 Oyster Point Boulevard, 3rd Floor, South San Francisco, CA 94080 (US). BUREN, Luxuan, Guo; c/o Nkarta, Inc., 329 Oyster Point Boulevard, 3rd Floor, South San Francisco, CA 94080 (US). MASRANI, Shyam, Sashikant; c/o Nkarta, Inc., 329 Oyster Point Boulevard, 3rd Floor, South San Francisco, CA 94080 (US).

(74) Agent: CARROLL, Alice, O. et al.; Hamilton, Brook, Smith & Reynolds, P.C., 530 Virginia Rd., P.O. Box 9133, Concord, MA 01742-9133 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: TRUNCATED NKG2D CHIMERIC RECEPTORS AND USES THEREOF IN NATURAL KILLER CELL IMMUNOTHERAPY




FIG. 1B

(57) Abstract: Several embodiments disclosed herein relate to the compositions comprising engineered Natural Killer (NK) cells that express a chimeric receptor, the chimeric receptor imparting to the NK cells an enhanced ability to target specific cells, such as cancerous cells or those affected by an infectious disease. Several embodiments relate to NK cells that target cells expressing natural ligands of NKG2D, where the NK cells comprise transmembrane and/or signaling domains that lead to cytotoxic and/or cytolytic effects when the NK cells bind a target cell. Uses of NK cell compositions to treat diseases are also provided for in several embodiments.



TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

TRUNCATED NKG2D CHIMERIC RECEPTORS AND USES THEREOF IN
NATURAL KILLER CELL IMMUNOTHERAPY

RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 62/477,335, filed on March 27, 2017 and U.S. Provisional Application No. 62/628,774, filed on February 9, 2018. The entirety of each of the above-listed applications is incorporated by reference herein.

INCORPORATION BY REFERENCE OF MATERIAL IN ASCII TEXT FILE

[0002] This application incorporates by reference the Sequence Listing contained in the following ASCII text file being submitted concurrently herewith:

- a) File name: 44591144002SequenceListing.txt; created March 27, 2018, 186 KB in size.

BACKGROUND

[0003] The emergence and persistence of many diseases is characterized by an insufficient immune response to aberrant cells, including malignant and virally infected cells. Immunotherapy is the use and manipulation of the patient's immune system for treatment of various diseases.

SUMMARY

[0004] Immunotherapy presents a new technological advancement in the treatment of disease, wherein immune cells are engineered to express certain targeting and/or effector molecules that specifically identify and react to diseased or damaged cells. This represents a promising advance due, at least in part, to the potential for specifically targeting diseased or damaged cells, as opposed to more traditional approaches, such as chemotherapy, where all cells are impacted, and the desired outcome is that sufficient healthy cells survive to allow the patient to live. One immunotherapy approach is the recombinant expression of chimeric receptors in immune cells to achieve the targeted recognition and destruction of aberrant cells of interest.

[0005] To address this need for specifically targeting and destroying, disabling or otherwise rendering inert diseased or infected cells, it is an object of the present invention to provide polynucleotides, amino acids, and vectors that encode chimeric receptors that impart enhanced targeting and cytotoxicity to cells, such as natural killer cells; to provide methods for producing the cells, and methods of using the cells to target and destroy diseased or damaged cells; to provide a polynucleotide encoding a chimeric receptor comprising an extracellular receptor domain and an effector domain comprising a transmembrane region and an intracellular signaling domain, wherein the extracellular receptor domain comprises a peptide that binds native ligands of Natural Killer Group 2 member D (NKG2D), wherein the peptide that binds native ligands of NKG2D is a fragment of NKG2D; and/or to at least provide the public with a useful choice.

[0005a] In a first aspect the present invention provides a polynucleotide encoding a chimeric receptor expressed by a cell, the chimeric receptor comprising:

(a) an extracellular receptor domain,

wherein said extracellular receptor domain comprises a peptide that binds native ligands of Natural Killer Group 2 member D (NKG2D),

wherein the peptide that binds native ligands of NKG2D is encoded by a polynucleotide: (i) having at least 95% sequence identity to SEQ ID NO. 2, or (ii) having at least 95% sequence identity to SEQ ID NO. 3; and

(b) an effector domain comprising a transmembrane region and an intracellular signaling domain,

wherein the transmembrane region comprises a CD8a hinge region and a CD8a transmembrane domain,

wherein the intracellular signaling domain comprises CD3zeta and OX40,

wherein CD3zeta is encoded by a polynucleotide having at least 95% sequence identity to SEQ ID NO. 13 and

wherein the polynucleotide further encodes a membrane-bound interleukin 15 (mbIL15).

[0005b] In a second aspect the present invention provides a vector comprising the polynucleotide of the first aspect.

[0005c] In a third aspect the present invention provides a chimeric receptor encoded by the polynucleotide of the first aspect.

[0005d] In a fourth aspect there is provided a chimeric receptor comprising:

- (a) an extracellular receptor domain,
 - wherein said extracellular receptor domain comprises a peptide that binds native ligands of Natural Killer Group 2 member D (NKG2D),
 - wherein the peptide that binds native ligands of NKG2D comprises an amino acid sequence encoded by SEQ ID NO. 2, and
- (b) an effector domain comprising a transmembrane region and an intracellular signaling domain,
 - wherein the transmembrane region comprises a CD8a hinge region and a CD8a transmembrane domain,
 - wherein the CD8a hinge region consists of the amino acid sequence encoded by SEQ ID NO. 5
 - wherein the intracellular signaling domain comprises CD3zeta and OX40, and
 - wherein CD3zeta comprises an amino acid sequence encoded by SEQ ID NO. 13.

[0005e] In a fifth aspect the present invention provides an immune cell expressing the chimeric receptor of the third or fourth aspects, wherein the cell expresses membrane-bound interleukin 15 (mbIL15).

[0005f] In a sixth aspect there is provided a method of generating a population of immune cells expressing a chimeric receptor for the treatment of cancer, the method comprising:

delivering to a population of immune cells the vector of the second aspect.

[0005g] In a seventh aspect there is provided a method of treating a cancer using immunotherapy, the method comprising:

administering to a subject having a cancer expressing a ligand of Natural Killer Group 2 member D (NKG2D) a population of immune cells that express the chimeric receptor of the fifth aspect.

[0005h] In an eighth aspect there is provided a use of a population of immune cells that express the chimeric receptor of the fifth aspect in the manufacture of a medicament for the treatment of a subject having a cancer expressing a ligand of Natural Killer Group 2 member D (NKG2D).

[0005i] In this specification where reference has been made to patent specifications, other external documents, or other sources of information, this is generally for the purpose of providing a context for discussing the features of the invention. Unless

specifically stated otherwise, reference to such external documents is not to be construed as an admission that such documents, or such sources of information, in any jurisdiction, are prior art, or form part of the common general knowledge in the art.

[0005j] In the description in this specification reference may be made to subject matter that is not within the scope of the claims of the current application. That subject matter should be readily identifiable by a person skilled in the art and may assist in putting into practice the invention as defined in the claims of this application.

BRIEF DESCRIPTION

[0006] In several embodiments, there is provided a polynucleotide encoding a chimeric receptor comprising one or both of: (a) an extracellular receptor domain and (b) an effector domain comprising a transmembrane region and an intracellular signaling domain. In several embodiments, the extracellular receptor domain comprises a peptide that binds native ligands of Natural Killer Group 2 member D (NKG2D). In several embodiments, the peptide that binds native ligands of NKG2D is a fragment of NKG2D, for example, a fragment of NKG2D is encoded by a polynucleotide comprising SEQ ID NO. 2. As disclosed, herein, additional NKG2D fragments are also used, depending on the embodiment. In several embodiments, the intracellular signaling domain comprises CD3zeta. In one embodiment, the CD3zeta is encoded by a polynucleotide comprising SEQ ID NO. 13, though, as disclosed herein, sequences that differ from CD3zeta, but share similar function may also be used, depending on the embodiment.

[0007] In several embodiments, the transmembrane region of the effector domain comprises a CD8a transmembrane domain. In one embodiment, the transmembrane region of the effector domain further comprises a CD8a hinge region. In several embodiments, the CD8a hinge region is encoded by a polynucleotide comprising SEQ ID NO: 5. In several embodiments, the intracellular signaling domain further comprises 4-1BB. In one embodiment, the 4-1BB is encoded by a polynucleotide comprising SEQ ID NO. 12, though, as disclosed herein, sequences that differ from 4-1BB, but share similar function may also be used, depending on the embodiment.

[0008] In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to CD8a, 4-1BB and CD3z. In several embodiments, such a chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO. 18. In additional embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID

NO. 108, though, as disclosed herein, sequences that differ from SEQ ID NO. 108, but share similar function may also be used, depending on the embodiment. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO. 19.

[0009] In several embodiments, any of chimeric receptors disclosed herein can also be co-expressed with membrane-bound interleukin 15 (mbIL15). In some embodiments, the mbIL15 is encoded by a polynucleotide comprising SEQ ID NO. 16. In some embodiments, the mbIL15 comprises an amino acid sequence of SEQ ID NO: 17. Other sequences for mbIL15 may also be used, depending on the embodiment. In some embodiments, the mbIL15 is bicistronically expressed on the same polynucleotide as the chimeric receptor. In other embodiments, the mbIL15 is co-expressed on a separate construct. In several embodiments, the intracellular signaling domain is further enhanced by coupling its expression with that of membrane-bound interleukin 15 (mbIL15).

[0010] In several embodiments, the effector domain further comprises an OX-40 domain. In several embodiments, the OX-40 domain is either in place of, or in addition to mbIL15. In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to a CD8a hinge, a CD8a transmembrane domain, the OX-40 domain, and the CD3zeta. In some embodiments, the polynucleotide construct is configured to bicistronically co-express mbIL15. In some such embodiments, the polynucleotide construct comprises one or more cleavage sites (e.g., T2A, P2A, E2A, and/or F2A cleavage site(s)) recognized and cleaved by, for example, a cytosolic protease. In some embodiments, the mbIL15 is coupled to the chimeric receptor by a cytosolic protease cleavage site. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 90 coupled to the mbIL15 encoded by SEQ ID NO. 16 by a cytosolic protease cleavage site. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 109 coupled to the mbIL15 encoded by SEQ ID NO. 16 by a cytosolic protease cleavage site. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 91 and is co-expressed with mbIL15 comprising the amino acid sequence of SEQ ID NO. 17. As disclosed herein, sequences that differ from SEQ ID NOs: 90, 91, 109, 16, and/or 16, but share similar function may also be used, depending on the embodiment.

[0011] In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to a IgG4 hinge, a CD8a transmembrane domain, the OX-40 domain, and the CD3zeta. In some embodiments, the polynucleotide construct is configured to

bicistronically co-express mbIL15 with the chimeric receptor. In some such embodiments, the polynucleotide construct comprises one or more cleavage sites (e.g., T2A, P2A, E2A, and/or F2A cleavage site(s)) recognized and cleaved by a cytosolic protease. In some embodiments, the mbIL15 is coupled to the chimeric receptor by a cytosolic protease cleavage site. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 100 coupled to the mbIL15 encoded by SEQ ID NO. 16 by a cytosolic protease cleavage site. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 101 and is co-expressed with mbIL15 comprising the amino acid sequence of SEQ ID NO. 17. As disclosed herein, sequences that differ from SEQ ID NOs: 100, 101 and/or 16, but share similar function may also be used, depending on the embodiment.

[0012] In several embodiments, there are provided methods for treating cancer, comprising administering to a subject having a cancer a composition comprising a Natural Killer (NK) cell expressing the chimeric receptor encoded by the polynucleotides described above, or elsewhere herein.

[0013] In one embodiment, the NK cells are autologous cells isolated from a patient having a cancer or an infectious disease. In additional embodiments, the NK cells are allogeneic cells isolated from a donor.

[0014] Also provided for herein is use of a polynucleotide as described above, or elsewhere herein, in the manufacture of a medicament for enhancing NK cell cytotoxicity in a mammal in need thereof. In several embodiments, there is provided for the use of a polynucleotide as described above, or elsewhere herein, in the manufacture of a medicament for treating or preventing cancer or an infectious disease in a mammal in need thereof.

[0015] According to several embodiments, there is provided a polynucleotide encoding a chimeric receptor, the chimeric receptor comprising an extracellular receptor domain an effector domain comprising a transmembrane region and an intracellular signaling domain. As discussed in more detail herein, the extracellular receptor domain serves to recognize and bind ligands on a target cell. The effector domain serves to transmit signals (upon binding of a target cell by the extracellular domain) that set in motion a signal cascade that leads to cytotoxic activity against the target cell. In accordance with several embodiments, the polynucleotide encodes a chimeric receptor that provides unexpectedly increased cytotoxicity as compared to non-engineered NK cells.

[0016] In several embodiments, the extracellular receptor domain comprises a peptide that binds native ligands of Natural Killer Group 2 member D (NKG2D). According to several embodiments, the peptide that binds native ligands of NKG2D is a functional fragment of NKG2D (e.g., a truncation, fragment or portion of full length NKG2D). As used, herein the terms, “fragment”, “truncation”, and “portion” shall be given their ordinary meanings and shall also be interchangeable with one another. For example, in several embodiments, the fragment of NKG2D is encoded by a polynucleotide comprising a fragment of the sequence of SEQ ID NO: 1. In several embodiments, the fragment of NKG2D comprises the sequence of SEQ ID NO: 2, while in additional embodiments, the fragment encoding NKG2D is codon optimized, and comprises, for example, the sequence of SEQ ID NO: 3. In additional embodiments, the fragment encoding NKG2D is codon optimized, and comprises, for example, the sequence of SEQ ID NO: 68.

[0017] In several embodiments, the effector domain comprises one or more of CD16, NCR1, NCR2, NCR3, 4-1BB, NKp80, CD3zeta and 2B4. In several embodiments, these effector domains are coupled to CD8 alpha.

[0018] In several embodiments, the chimeric receptor comprises a fragment of NKG2D coupled to CD16. As used herein, coupled shall be given its ordinary meaning and shall also refer to direct (e.g., a first nucleotide followed directly by a second nucleotide) or indirect (e.g., sequences are in frame with one another but separated by intervening nucleotides) linkage of nucleotide sequences in a manner that allows for expression of the nucleotide sequences in, for example, an *in vitro* transcription/translation system, a host cell (e.g., *in vitro* and/or *in vivo*). As used herein, “linked” and “coupled” are used interchangeably. In several embodiments, the NKG2D/CD16 chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 23. In several embodiments, the NKG2D/CD16 chimeric receptor comprises the amino acid sequence of SEQ ID NO: 24. In several embodiments, the chimeric receptor comprises a fragment of NKG2D coupled to NCR1. In several embodiments, such a chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 27. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 28.

[0019] As discussed above, in several embodiments, the NKG2D fragment is coupled to NCR2, and the resultant chimeric receptor comprises at least a portion of the amino acid sequence of SEQ ID NO: 21. Several embodiments provide for a chimeric

receptor comprising a fragment of NKG2D coupled to NCR3. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO. 29, and the chimeric receptor comprises the amino acid sequence of SEQ ID NO. 30.

[0020] As discussed in more detail below, combinations of transmembrane and intracellular domains are used in several embodiments and provide for synergistic interactions between the components of the chimeric receptor and yield enhanced cytotoxic effects. In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to a CD16 transmembrane/intracellular domain and 4-1BB. In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to a CD8a hinge, a CD16 transmembrane/intracellular domain and 4-1BB. In several embodiments, such a chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 25. In several embodiments, the resultant chimeric receptor comprises the amino acid sequence of SEQ ID NO: 26.

[0021] In several embodiments, NCR1 is used in conjunction with the NKG2D fragment. In several embodiments, the NKG2D fragment is linked to NCR1 alone. In additional embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to NCR1 and 4-1BB. In some such embodiments, the chimeric receptor comprises the NCR1 amino acid sequence of SEQ ID NO: 20.

[0022] In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to CD8a, 4-1BB and CD3z. In several embodiments, such an NKG2D/CD8a/4-1bb/CD3z chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO. 18. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO. 19.

[0023] In several embodiments, NCR3 is included in the chimeric receptor. For example, an NKG2D/NCR3 construct is provided for in several embodiments. The resultant chimeric receptor thereby comprises the NCR3 amino acid sequence of SEQ ID NO: 22. In several embodiments, the chimeric receptor comprises a NKG2D/NCR2/4-1BB construct or an NKG2D/NCR3/4-1BB construct.

[0024] In several embodiments, linkers, hinges, or other “spacing” elements are provided for in the chimeric receptor constructs. For example, in several embodiments, the effector domain comprises a linker. In several embodiments, the polynucleotides encode a GS linker between the portions of the construct, such as between any of 4-1BB, CD16, NCR1, NCR3, 2B4 or NKp80. In several embodiments, one or more GS linkers are provided for, for example, 1, 2, 3, 4, 5, 6, or more. In several embodiments, there is

provided for a chimeric receptor comprising a hinge region. Depending on the location within a particular construct, a hinge region can be synonymous with a linker region, and vice versa. In several embodiments, the hinge region is encoded by the nucleic acid sequence of SEQ ID NO: 5. In some embodiments, the hinge region can be truncated to a desired length and is therefore encoded by a fragment of the nucleic acid sequence of SEQ ID NO: 5. In several embodiments, a glycine-serine motif is used as a hinge. In several embodiments, the hinge region comprises a glycine-serine repeating motif having the amino acid sequence of (GGGGS)_n (SEQ ID NO: 31) where n is the number of repeats. In several embodiments, 9 repeats are used, resulting in a hinge region comprising the amino acid sequence of SEQ ID NO: 33. In several embodiments, 3 repeats are used, resulting in a hinge region comprising the amino acid sequence of SEQ ID NO: 34.

[0025] In several embodiments, two separate molecules can be used as a hinge or linker, such as the amino acid sequence of SEQ ID NO: 32 (CD8a/GS3). In several embodiments, portions of a beta adrenergic receptor are used as a hinge or linker. In several embodiments, portions of the beta-2 adrenergic receptor are used. In one embodiment, an extracellular domain of the beta-2 adrenergic receptor is used, which is encoded by the nucleic acid sequence of SEQ ID NO: 40. In some embodiments, the first transmembrane helix of the beta-2 adrenergic receptor is used, which is encoded by the nucleic acid sequence of SEQ ID NO: 42. Depending on the embodiment, these two beta-2 adrenergic receptor portions are used together in the chimeric receptor. In several embodiments, the extracellular receptor domain further comprises a CD8a signal peptide, wherein the signal peptide comprises the nucleic acid sequence of SEQ ID NO. 4. Other signal peptides are optionally used, depending on the embodiment. Signal peptides may be employed in a multimeric format, according to some embodiments.

[0026] In several embodiments, the effector domain comprises one or more hemi-ITAM sequences. In some such embodiments, the hemi-ITAM comprises the amino acid motif DGYXXL (where X is any amino acid; SEQ ID NO: 14). Multiple hemi-ITAMs are used in some embodiments. In several embodiments, the hemi-ITAM comprises NKp80. In several embodiments, the effector domain comprises one or more ITSM sequences. ITSM sequences are used in conjunction with hemi-ITAM motifs in several embodiments. In several embodiments, the ITSM comprises the amino acid motif S/TXYXXL/I (where X is any amino acid; SEQ ID NO. 15). In several embodiments, the effector comprises a 2B4 domain.

[0027] In several embodiments, the chimeric receptor comprises a fragment of NKG2D coupled to a GS3 linker, a CD8a hinge, a CD16 transmembrane/intracellular domain and 4-1BB. In several embodiments, the chimeric receptor comprises a fragment of NKG2D coupled to a GS3 linker, a CD16 transmembrane/intracellular domain and 4-1BB. In several embodiments, the chimeric receptor comprises a fragment of NKG2D coupled to a CD16 transmembrane/intracellular domain and 4-1BB. In several embodiments, the chimeric receptor comprises a fragment of NKG2D coupled to a CD8a hinge, a CD8a transmembrane domain, 4-1BB, and 2B4. In several embodiments, the chimeric receptor comprises a fragment of NKG2D coupled to a beta-adrenergic extracellular domain, a beta-adrenergic transmembrane domain, 4-1BB, and 2B4. In several embodiments, the chimeric receptor comprises a fragment of NKG2D coupled to a CD8a hinge, a CD8a transmembrane domain, 4-1BB, 2B4, a GS3 linker, and NKp80. In several embodiments, the chimeric receptor comprises a fragment of NKG2D coupled to a CD8a hinge, a CD8a transmembrane domain, 4-1BB, a GS3 linker, and NKp80. In several embodiments, the chimeric receptor comprises a fragment of NKG2D, wherein the fragment is encoded by a sequence that is codon optimized coupled to a GS3 linker, an additional NKG2D fragment, a beta-adrenergic extracellular domain, a beta-adrenergic transmembrane domain, 4-1BB, an additional GS3 linker, and NKp80. In several embodiments, the chimeric receptor comprises a fragment of NKG2D that is codon optimized coupled to a GS3 linker, an additional NKG2D fragment, a CD8a hinge, a CD8a transmembrane domain, 4-1BB, an additional GS3 linker, and NKp80. In several embodiments, the chimeric receptor comprises a fragment of NKG2D that is codon optimized coupled to a GS3 linker, an additional NKG2D fragment, a CD8a hinge, a CD16 transmembrane/intracellular domain, and 4-1BB. In several embodiments, the chimeric receptor comprises a fragment of NKG2D coupled to a CD8a hinge, a CD16 transmembrane/intracellular domain, 4-1BB, and 2B4. In several embodiments, the chimeric receptor comprises a fragment of NKG2D coupled to a CD8a hinge, a CD16 transmembrane/intracellular domain, 4-1BB, a GS3 linker, and NKp80. In several embodiments, the chimeric receptor comprises a fragment of NKG2D that is coupled to a CD8a hinge and a CD8a transmembrane domain. In several embodiments, the effector comprises 4-1BB. In some such embodiments the effector comprises 4-1BB optionally in conjunction with one or more of NKp80, 2B4, CD3zeta, Dap10, Dap12, CD28, or other signaling domains provided for herein). In several embodiments, the effector domain further comprises CD3zeta. In several embodiments, the effector domain comprises an

intracellular domain of 2B4. In several embodiments, the effector domain further comprises an intracellular domain of DAP10.

[0028] In several embodiments, the chimeric receptor comprises a fragment of NKG2D coupled to a CD8a hinge, a CD8a transmembrane domain, 4-1BB, 2B4, and CD3zeta. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 58. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 59.

[0029] Additionally, any of chimeric receptors disclosed herein can also be co-expressed with membrane-bound interleukin 15 (mbIL15). For example, provided for in several embodiments is a polynucleotide encoding a chimeric receptor comprising an extracellular receptor domain, wherein the extracellular receptor domain comprises a peptide that binds native ligands of NKG2D, wherein the peptide that binds native ligands of NKG2D is a fragment of NKG2D, a transmembrane region, an effector domain, the polynucleotide being co-expressed with an additional construct encoding membrane-bound interleukin 15 (mbIL15). In several embodiments, chimeric receptors as discussed herein are co-expressed with mbIL-15. In several embodiments, the effector domain comprises 4-1BB and CD3 zeta, and the transmembrane region comprises CD8a.

[0030] In several embodiments, the chimeric receptors are engineered such that they do not include DNAX-activating protein 10 (DAP10). Additionally, in several embodiments, the chimeric receptors are engineered such that they do not include an ITAM motif.

[0031] In several embodiments, there is provided a polynucleotide encoding a chimeric receptor comprising, one, two, or all of: (a) an extracellular receptor domain comprising a fragment of NKG2D that binds native ligands of NKG2D, (b) a transmembrane region, wherein the transmembrane region comprises CD8a, and (c) an effector domain, wherein the effector domain comprises 4-1BB and the intracellular domain of 2B4 or DAP10. In several embodiments, the effector domain comprises 2B4 followed by 4-1BB. In additional embodiments, the effector domain comprises 4-1BB followed by 2B4. In several embodiments, the effector domain comprises DAP10 followed by 4-1BB. In additional embodiments, the effector domain comprises 4-1BB followed by DAP10. In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to a CD8a hinge, a CD8a transmembrane domain, 4-1BB, and DAP10. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 60. In several embodiments, the chimeric receptor

comprises the amino acid sequence of SEQ ID NO: 61. In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to a CD8a hinge, a CD8a transmembrane domain, 4-1BB, 2B4, and DAP10. In several embodiments, the effector domain comprises 4-1BB, followed by DAP10, followed by 2B4. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 62. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 63. In several embodiments, the effector domain comprises 4-1BB, followed by 2B4, followed by DAP10. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 64. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 65.

[0032] In several embodiments, the chimeric receptor comprises a codon-optimized fragment of NKG2D coupled to an intracellular effector domain. In several embodiments, multiple fragments of NKG2D are employed, for example, an additional NKG2D fragment (optionally codon optimized) is coupled to the first fragment by, for example, a GS3 linker. In several embodiments, such chimeric receptors further comprise a CD8a hinge, a CD8a transmembrane domain, 4-1BB, and CD3zeta. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 66. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 67. In several embodiments, the polynucleotide is co-expressed with an additional construct encoding membrane-bound interleukin 15 (mbIL15).

[0033] In several embodiments, there is provided a polynucleotide encoding a chimeric receptor comprising an extracellular receptor domain, comprising a fragment of NKG2D that binds a native ligand of NKG2D and is encoded by a fragment of SEQ ID NO: 1, a transmembrane region comprising a CD3zeta transmembrane region, and an effector domain. In several embodiments, there is provided a polynucleotide encoding a chimeric receptor comprising an extracellular receptor domain, comprising a fragment of NKG2D that binds a native ligand of NKG2D and is encoded by SEQ ID NO. 2, a transmembrane region comprising a CD3zeta transmembrane region, and an effector domain. In several embodiments, there is provided a polynucleotide encoding a chimeric receptor comprising an extracellular receptor domain, comprising a fragment of NKG2D that binds a native ligand of NKG2D and is encoded by SEQ ID NO. 3, a transmembrane region comprising a CD3zeta transmembrane region, and an effector domain. In several embodiments, there is provided a polynucleotide encoding a chimeric receptor

comprising an extracellular receptor domain, comprising a fragment of NKG2D that binds a native ligand of NKG2D and is encoded by SEQ ID NO. 68, a transmembrane region comprising a CD3zeta transmembrane region, and an effector domain. In several embodiments, fragments of the NKG2D encoded by any of SEQ ID NO. 2, 3, or 68 may also be used. In several embodiments, the CD3zeta transmembrane region comprises the amino acid sequence of SEQ ID NO: 69. Fragments of the sequence of SEQ ID NO: 69 are also use, in several embodiments, the fragments retaining the ability to transduce at least about 65%, about 75%, about 85%, or about 95% of the signal transduction of a native CD3 zeta subunit (including dimers). In several embodiments, the extracellular receptor domain further comprises additional resides adjacent to the CD3zeta transmembrane region. In several embodiments, the additional amino acids are extracellular residues of a native CD3zeta sequence. In other embodiments, the additional amino acids are randomly selected. In several embodiments, there are 2, 3, 4, 5, 6, 8, 10, 15, or 20 additional amino acids. In several embodiments, the chimeric receptor domain comprises a hinge region, which in several embodiments, a CD8a hinge encoded by the nucleic acid sequence of SEQ ID NO: 5. In several embodiments, the hinge region is a CD8a hinge encoded by a fragment of the nucleic acid sequence of SEQ ID NO: 5. Depending on the embodiment, the fragment is about 75%, about 80%, about 85%, about 90%, about 95% of the length of the nucleic acid sequence of SEQ ID NO: 5. Depending on the embodiment, the fragment is about 75%, about 80%, about 85%, about 90%, about 95%, about 98%, or about 99% homologous to the nucleic acid sequence of SEQ ID NO: 5. In several embodiments, the extracellular receptor domain further comprises a CD8a signal peptide, which, depending on the embodiment, can comprise the nucleic acid sequence of SEQ ID NO. 4. In several embodiments, the effector domain comprises 4-1BB. In several embodiments, the effector domain comprises a CD16 intracellular domain. In several embodiments, the effector domain comprises 4-1BB and CD16 (with either moiety being “first” vs. “second” in the construct). In several embodiments, repeats of one or more of 4-1BB and/or CD16 are used.

[0034] In several embodiments, the chimeric receptor comprises a fragment of NKG2D that is codon optimized and is coupled to a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising 4-1BB. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 78. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 79.

[0035] In several embodiments, the chimeric receptor comprises a fragment of NKG2D that is codon optimized coupled to a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising CD16 followed by 4-1BB. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 71. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 70.

[0036] In several embodiments, the chimeric receptor comprises a fragment of NKG2D that is codon optimized and coupled to a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising 4-1BB followed by CD16, optionally coupled by a GS3 linker. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 85. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 84.

[0037] In several embodiments, the chimeric receptor comprises a fragment of NKG2D that is codon optimized and is coupled to a GS3 linker, an additional NKG2D fragment, a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising a CD16 and 4-1BB. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 72. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 73.

[0038] In several embodiments, the effector domain includes NKp80. In several embodiments, the effector domain is NKp80. In several embodiments, the chimeric receptor comprises a fragment of NKG2D that is coupled to a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising a CD16, 4-1BB, and NKp80, and optionally including a GS3 linker. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 74. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 75. In several embodiments, the chimeric receptor comprises the fragment of NKG2D that is codon optimized and is coupled to a GS3 linker, an additional NKG2D fragment (optionally codon optimized), a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising a CD16, 4-1BB, and NKp80, and optionally including a GS3 linker. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 76. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 77. In several embodiments, the chimeric receptor comprises a fragment of NKG2D that is codon optimized and is coupled to a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising 4-1BB and NKp80,

and optionally including a GS3 linker. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 82. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 83.

[0039] In several embodiments, the effector domain comprises CD3zeta. In several embodiments, the chimeric receptor comprises a fragment of NKG2D that is codon optimized and is coupled to a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising 4-1BB and CD3zeta. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 80. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 81.

[0040] In several embodiments, the effector domain comprises FcR γ . In several embodiments, the chimeric receptor comprises a fragment of NKG2D coupled to a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising 4-1BB and FcR γ . In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 86. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 87.

[0041] In several embodiments, the effector domain comprises CD28. In several embodiments, the chimeric receptor comprises a fragment of NKG2D coupled to a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising CD28 and CD3zeta. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 102. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 103.

[0042] In several embodiments, the effector domain comprises a GS linker.

[0043] In several embodiments, the polynucleotides disclosed herein are co-expressed with membrane-bound interleukin 15 (mbIL15).

[0044] In several embodiments, a polynucleotide encoding a chimeric receptor comprising an extracellular receptor domain comprising a fragment of NKG2D that is capable of binding a native ligand of NKG2D and is encoded by a fragment of any one of the sequence of SEQ ID NO: 1, of SEQ ID NO. 2, of SEQ ID NO. 3, or SEQ ID NO. 68, and an effector domain comprising a transmembrane region and an intracellular signaling domain. In several embodiments, there is provided a polynucleotide encoding a chimeric receptor comprising an extracellular receptor domain comprising a fragment of NKG2D that is capable of binding a native ligand of NKG2D and is encoded by (i) a fragment of the sequence of SEQ ID NO: 1, (ii) the sequence of SEQ ID NO. 2, (iii) the sequence of

SEQ ID NO. 3, or (iv) the sequence of SEQ ID NO. 68, and an effector domain comprising a transmembrane region and an intracellular signaling domain. In several embodiments, a polynucleotide encoding a chimeric receptor comprising an extracellular receptor domain comprising a fragment of NKG2D that is capable of binding a native ligand of NKG2D and is encoded by the sequence of SEQ ID NO. 2, and an effector domain comprising a transmembrane region and an intracellular signaling domain. In several embodiments, a polynucleotide encoding a chimeric receptor comprising an extracellular receptor domain comprising a fragment of NKG2D that is capable of binding a native ligand of NKG2D and is encoded by the sequence of SEQ ID NO. 3, and an effector domain comprising a transmembrane region and an intracellular signaling domain. In several embodiments, a polynucleotide encoding a chimeric receptor comprising an extracellular receptor domain comprising a fragment of NKG2D that is capable of binding a native ligand of NKG2D and is encoded by a fragment of the sequence of SEQ ID NO. 68, and an effector domain comprising a transmembrane region and an intracellular signaling domain. In several embodiments, the extracellular receptor domain comprises a hinge region. In several embodiments, the hinge region is a CD8a hinge encoded by the nucleic acid sequence of SEQ ID NO: 5, or optionally a fragment of the nucleic acid sequence of SEQ ID NO: 5 (e.g., a fragment having about 75%, about 85%, about 95% homology to SEQ ID NO: 5). In several embodiments, the hinge region is an Immunoglobulin G4 (IgG4) hinge encoded by the nucleic acid sequence of SEQ ID NO: 104. In several embodiments, the hinge region is an Immunoglobulin G4 (IgG4) hinge encoded by a fragment of the nucleic acid sequence of SEQ ID NO: 104 (e.g., a fragment having about 75%, about 85%, about 95% homology to SEQ ID NO: 104). In several embodiments, the extracellular receptor domain further comprises a CD8a signal peptide, wherein the signal peptide comprises the nucleic acid sequence of SEQ ID NO. 4. In several embodiments, the effector domain comprises at least one signaling domains selected from the group consisting of OX40 (CD134), CD3zeta, 4-1BB, CD28 and DAP12. In several embodiments, the chimeric receptor transmembrane domain comprises a CD8 transmembrane domain. In several embodiments, the chimeric receptor comprises IL-15 linked (optionally by a GS3 linker) to the fragment of NKG2D coupled to a CD8a hinge, a CD8a transmembrane domain, 4-1BB, and CD3z. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 88. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 89.

[0045] In several embodiments, the chimeric receptor comprises a fragment of NKG2D coupled to an IgG4 hinge, a CD8a transmembrane domain, 4-1BB, and CD3zeta. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 96. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 97.

[0046] In several embodiments, the effector domain comprises OX40. In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to a CD8a hinge, a CD8a transmembrane domain, OX40, and CD3z. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 90. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 109. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 91. In several embodiments, the chimeric receptor comprises a fragment of NKG2D coupled to an IgG4 hinge, a CD8a transmembrane domain, OX40 and CD3zeta. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 100. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 101.

[0047] In several embodiments, the chimeric receptor comprises a CD28 transmembrane/intracellular domain. In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to a CD8a hinge, a CD28 transmembrane/intracellular domain, and CD3zeta. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 92. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 93.

[0048] In several embodiments, the chimeric receptor comprises a fragment of NKG2D coupled to a CD8a hinge, a CD28 transmembrane/intracellular domain, 4-1BB, and CD3zeta. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 94. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 95.

[0049] In several embodiments, the chimeric receptor comprises a fragment of NKG2D coupled to an IgG4 hinge, a CD28 transmembrane/intracellular domain and CD3zeta. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 98. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 99.

[0050] In several embodiments, the effector domain comprises a GS linker. In several embodiments, the polynucleotides disclosed herein are configured to be co-expressed (either on the same polynucleotide, or another polynucleotide) with membrane-bound interleukin 15 (mbIL15).

[0051] Any of the chimeric receptors can optionally include an extracellular receptor domain that includes a second peptide that binds native ligands of NKG2D. In several embodiments, the second peptide is homologous with NKG2D, while in other embodiments, the second peptide is heterologous with respect to the NKG2D. Whether the chimeric receptor includes a dimerized extracellular receptor domain, the extracellular receptor domains can recognize at least the following native ligands of NKG2D: MICA, MICB, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5 or ULBP6.

[0052] As discussed in more detail below, functional variants of the NKG2D ligand binding domains are employed in several embodiments. For example the peptide that binds native ligands of NKG2D has, in several embodiments, at least 80% homology to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 68. In several embodiments, the peptide that binds native ligands of NKG2D has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homology to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 68.

[0053] Additionally provided for herein in several embodiments are vectors for expressing the chimeric receptors. In several embodiments, the polynucleotides provided for herein are mRNA and can include an operable linkage to least one regulatory element for the expression of the chimeric receptor. In several embodiments, the polynucleotides further include one or more internal ribosome entry site (IRES). In several embodiments, the vector is a retrovirus.

[0054] Engineered natural killer cells are also provided for, in several embodiments, that express any of the chimeric receptor constructs disclosed herein, the engineered NK cells exhibiting enhanced cytotoxic effects against target cells. Enhanced cytotoxic effects include, but are not limited to, higher affinity for target (e.g., cancerous) cells as compared to normal (e.g., non-cancerous) cells, a greater killing effect directed against target cells, reduced off-target effects, increased duration of cytotoxic effects, more efficient cytotoxicity, and the like. Such enhanced effects can be identified through the use of various in vitro cytotoxicity assays (e.g., measurement of cytokine production, etc.), measurement of target cell death, or through various clinical outcomes (e.g., reduction in tumor burden). In several embodiments, the engineered NK cells are an

autologous cell isolated from a patient. In additional embodiments, the engineered NK cells are generated from allogeneic cells isolated from a donor. Such engineered NK cells as disclosed herein are used, in several embodiments, to enhance NK cell cytotoxicity in a mammal in need thereof, by administering the NK cells. These engineered NK cells are used, in several embodiments for treating or preventing cancer or an infectious disease in a mammal. The polynucleotides encoding, the vectors carrying, and the NK cells expressing the various chimeric receptors disclosed herein can also be used, in several embodiments in the manufacture of a medicament for enhancing NK cell cytotoxicity (e.g., to treat or prevent cancer or an infectious disease). In several embodiments, the chimeric receptor constructs disclosed herein do not significantly increase the cytotoxicity of the engineered NK cells against normal cells and, as described herein, are advantageously improved as compared to non-engineered NK cells. In several embodiments, there is provided a polynucleotide encoding a chimeric receptor comprising an extracellular receptor domain, a transmembrane region, and an effector domain. In several embodiments, the extracellular receptor domain comprises a peptide that binds native ligands of Natural Killer Group 2 member D (NKG2D), wherein the peptide that binds native ligands of NKG2D is a fragment of NKG2D. Several embodiments, relate to a polynucleotide encoding a chimeric receptor comprising: (a) an extracellular receptor domain, wherein said extracellular receptor domain comprises a peptide that binds native ligands of Natural Killer Group 2 member D (NKG2D), wherein the peptide that binds native ligands of NKG2D is a fragment of NKG2D, wherein the fragment of NKG2D is encoded by a polynucleotide comprising: (i) a fragment of the sequence of SEQ ID NO: 1, (ii) the sequence of SEQ ID NO. 2, (iii) the sequence of SEQ ID NO. 3, or (iv) the sequence of SEQ ID NO. 68, (b) a transmembrane region, and (c) an effector domain.

[0055] In several embodiments, there is provided a polynucleotide encoding a chimeric receptor comprising: (a) an extracellular receptor domain, wherein said extracellular receptor domain comprises a peptide that binds native ligands of Natural Killer Group 2 member D (NKG2D), wherein the peptide that binds native ligands of NKG2D is a fragment of NKG2D, wherein the fragment of NKG2D is encoded by a polynucleotide comprising: (i) a fragment of the sequence of SEQ ID NO: 1, (ii) the sequence of SEQ ID NO. 2, (iii) the sequence of SEQ ID NO. 3, (iv) or the sequence of SEQ ID NO. 68; and (b) an effector domain comprising a transmembrane region and an intracellular signaling domain.

[0056] In several embodiments, the transmembrane region comprises a CD3zeta transmembrane region. In several embodiments, the CD3zeta transmembrane region comprises the amino acid sequence of SEQ ID NO: 69. In several embodiments, the transmembrane region comprises CD8a. In several embodiments, the effector domain comprises 4-1BB, an intracellular domain of 2B4, NKp80, a CD16 intracellular domain, Natural Cytotoxicity Triggering Receptor 1 (NCR1), Natural Cytotoxicity Triggering Receptor 2 (NCR2), Natural Cytotoxicity Triggering Receptor 3 (NCR3), and/or an intracellular domain of DAP10. In one embodiment, the effector domain comprises 4-1BB and CD16. In several embodiments, the effector domain comprises 4-1BB and CD3 zeta. In several embodiments, the effector domain comprises 4-1BB and an intracellular domain of 2B4 or DAP10. In several embodiments, the effector domain comprises 2B4 followed by 4-1BB while in other embodiments the effector domain comprises 4-1BB followed by 2B4. In several embodiments, the effector domain comprises DAP10 followed by 4-1BB. In several embodiments, the effector domain comprises 4-1BB followed by DAP10. In several embodiments, the effector domain further comprises CD3zeta. In several embodiments, the effector domain comprises at least one signaling domain selected from the group consisting of OX40 (CD134), CD3zeta, 4-1BB, CD28 and DAP12. In several embodiments the effector domain comprises one or more hemi-ITAM sequences. In several embodiments, the hemi-ITAM comprises the amino acid sequence of SEQ ID NO. 14. In several embodiments, the hemi-ITAM comprises the amino acid sequence of SEQ ID NO. 37. In several embodiments, the effector domain comprises one or more ITSM sequences. In several embodiments, the ITSM comprises the amino acid sequence of SEQ ID NO. 15 or the amino acid sequence of SEQ ID NO. 35

[0057] In several embodiments, the chimeric receptor comprises a fragment of NKG2D coupled to a CD8a hinge, a CD8a transmembrane domain, 4-1BB, 2B4, and CD3zeta. In one embodiment, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 58. In one embodiment, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 59. In several embodiments, the chimeric receptor comprises a fragment of NKG2D coupled to a CD8a hinge, a CD8a transmembrane domain, 4-1BB, and DAP10. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 60 and comprises the amino acid sequence of SEQ ID NO: 61.

[0058] In several embodiments, the chimeric receptor comprises a fragment of NKG2D coupled to a CD8a hinge, a CD8a transmembrane domain, 4-1BB, 2B4, and DAP10. In several embodiments, the effector domain comprises 4-1BB, followed by DAP10, followed by 2B4. In some embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 62 and the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 63. In several embodiments, the effector domain comprises 4-1BB, followed by 2B4, followed by DAP10. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 64 and the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 65.

[0059] In several embodiments, the chimeric receptor comprises a fragment of NKG2D that is codon optimized coupled to a GS3 linker, an additional NKG2D fragment, a CD8a hinge, a CD8a transmembrane domain, 4-1BB, and CD3zeta. In one embodiment, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 66. In several embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 67.

[0060] In several embodiments, the chimeric receptor comprises a fragment of NKG2D that is codon optimized coupled to a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising 4-1BB, is encoded by the nucleic acid sequence of SEQ ID NO: 78 and/or comprises the amino acid sequence of SEQ ID NO: 79.

[0061] In several embodiments, the chimeric receptor comprises a fragment of NKG2D that is codon optimized coupled to a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising CD16 followed by 4-1BB. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 70 and/or comprises the amino acid sequence of SEQ ID NO: 71.

[0062] In several embodiments, the chimeric receptor comprises a fragment of NKG2D that is codon optimized coupled to a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising 4-1BB followed by a GS3 linker and CD16. In one embodiment, the chimeric receptor comprises the amino acid sequence of SEQ ID NO: 85 and/or is encoded by the nucleic acid sequence of SEQ ID NO: 84.

[0063] In several embodiments, the chimeric receptor comprises a fragment of NKG2D that is codon optimized coupled to a GS3 linker, an additional NKG2D fragment, a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising a CD16 and 4-1BB. In one embodiment, the chimeric receptor is encoded by

the nucleic acid sequence of SEQ ID NO: 72 and/or comprises the amino acid sequence of SEQ ID NO: 73.

[0064] In several embodiments, the chimeric receptor comprises IL-15 linked by a GS3 linker to the fragment of NKG2D coupled to a CD8a hinge, a CD8a transmembrane domain, 4-1BB, and CD3zeta, is encoded by the nucleic acid sequence of SEQ ID NO: 88 and/or comprises the amino acid sequence of SEQ ID NO: 89.

[0065] In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to a IgG4 hinge, a CD8a transmembrane domain, 4-1BB, and CD3zeta is encoded by the nucleic acid sequence of SEQ ID NO: 96, and/or comprises the amino acid sequence of SEQ ID NO: 97.

[0066] In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to a CD8a hinge, a CD8a transmembrane domain, OX40, and CD3zeta, is encoded by the nucleic acid sequence of SEQ ID NO: 90, and/or comprises the amino acid sequence of SEQ ID NO: 91.

[0067] In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to an IgG4 hinge, a CD8a transmembrane domain, OX40 and CD3zeta, is encoded by the nucleic acid sequence of SEQ ID NO: 100, and/or comprises the amino acid sequence of SEQ ID NO: 101.

[0068] In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to a CD8a hinge, a CD28 transmembrane/intracellular domain, and CD3zeta, is encoded by the nucleic acid sequence of SEQ ID NO: 92, and/or comprises the amino acid sequence of SEQ ID NO: 93.

[0069] In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to a CD8a hinge, a CD28 transmembrane/intracellular domain, 4-1BB, and CD3zeta, is encoded by the nucleic acid sequence of SEQ ID NO: 94, and/or comprises the amino acid sequence of SEQ ID NO: 95.

[0070] In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to an IgG4 hinge, a CD28 transmembrane/intracellular domain and CD3zeta, is encoded by the nucleic acid sequence of SEQ ID NO: 98, and/or comprises the amino acid sequence of SEQ ID NO: 99.

[0071] In several embodiments, the chimeric receptor comprises a fragment of NKG2D coupled to a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising a CD16, 4-1BB, a GS3 linker, and NKp80. In one embodiment, the

chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 74 and/or comprises the amino acid sequence of SEQ ID NO: 75.

[0072] In several embodiments, the chimeric receptor comprises the fragment of NKG2D that is codon optimized coupled to a GS3 linker, an additional NKG2D fragment, a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising a CD16, 4-1BB, a GS3 linker, and NKp80. In one embodiment, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 76 and/or comprises the amino acid sequence of SEQ ID NO: 77. In several embodiments, the chimeric receptor comprises a fragment of NKG2D that is codon optimized coupled to a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising 4-1BB, a GS3 linker, and NKp80. In one embodiment, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 82 and/or comprises the amino acid sequence of SEQ ID NO: 83.

[0073] In several embodiments, the chimeric receptor comprises a fragment of NKG2D that is codon optimized coupled to a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising 4-1BB and CD3zeta. In one embodiment, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 80 and/or comprises the amino acid sequence of SEQ ID NO: 81.

[0074] Depending on the embodiment, the effector domain may also comprise FcR γ . For example, in several embodiments, the chimeric receptor comprises a fragment of NKG2D coupled to a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising 4-1BB and FcR γ . In one embodiment, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 86 and/or comprises the amino acid sequence of SEQ ID NO: 87.

[0075] Depending on the embodiment, the effector domain may also comprise CD28. For example, in several embodiments, the chimeric receptor comprises a fragment of NKG2D coupled to a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising CD28 and CD3zeta. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 102 and/or comprises the amino acid sequence of SEQ ID NO: 103.

[0076] In several embodiments, the effector domain comprises a GS linker.

[0077] In several embodiments, the extracellular receptor domain further comprises a CD8a signal peptide, wherein the signal peptide comprises the nucleic acid sequence of SEQ ID NO. 4. In several embodiments, the extracellular receptor domain

further comprises 2 extracellular residues of CD3zeta directly adjacent to the CD3zeta transmembrane region. In several embodiments, the extracellular receptor domain comprises a CD8a signal peptide, wherein the signal peptide comprises the nucleic acid sequence of SEQ ID NO. 4.

[0078] In several embodiments, the chimeric receptor comprises one or more GS3 linkers. In several embodiments, the chimeric receptor domain comprises a hinge region. In several embodiments, the hinge region is encoded by the nucleic acid sequence of SEQ ID NO: 5, while in some embodiments, the hinge region is encoded by a fragment of the nucleic acid sequence of SEQ ID NO: 5. In several embodiments, the hinge region is a CD8a hinge. In several embodiments, the hinge region comprises a glycine-serine repeating motif having the amino acid sequence of SEQ ID NO: 31. In several embodiments, the hinge region comprises the amino acid sequence of SEQ ID NO: 32 and in some embodiments, the hinge region comprises the amino acid sequence of SEQ ID NO: 33. In additional embodiments, the hinge region is encoded by the nucleic acid sequence of SEQ ID NO: 34. In several embodiments, the hinge region comprises a portion of the beta-adrenergic receptor. In some such embodiments, the hinge region is encoded by the nucleic acid sequence of SEQ ID NO: 40. In additional embodiments, the hinge region is encoded by the nucleic acid sequence of SEQ ID NO: 42. In several embodiments, the hinge region is Immunoglobulin G4 (IgG4) hinge encoded by the nucleic acid sequence of SEQ ID NO: 104. In several embodiments, the hinge region is a Immunoglobulin G4 (IgG4) hinge encoded by a fragment of the nucleic acid sequence of SEQ ID NO: 104. In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to a CD8a hinge and a CD8a transmembrane domain.

[0079] In one embodiment, the chimeric receptor comprises the fragment of NKG2D coupled to CD16, is encoded by the nucleic acid sequence of SEQ ID NO: 23, and/or comprises the amino acid sequence of SEQ ID NO: 24. In one embodiment, the chimeric receptor comprises the fragment of NKG2D coupled to NCR1. In some such embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 27 and/or comprises the amino acid sequence of SEQ ID NO: 28. In several embodiments, the chimeric receptor comprises at least a portion of the amino acid sequence of SEQ ID NO: 21. In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to NCR3, in several embodiments is encoded by the nucleic acid sequence of SEQ ID NO. 29 and/or comprises the amino acid sequence of SEQ ID NO. 30.

[0080] In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to a CD16 transmembrane/intracellular domain and 4-1BB. In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to a CD8a hinge, a CD16 transmembrane/intracellular domain and 4-1BB, is encoded by the nucleic acid sequence of SEQ ID NO: 25, and/or comprises the amino acid sequence of SEQ ID NO: 26.

[0081] In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to NCR1 and 4-1BB, wherein the chimeric receptor comprises the NCR1 amino acid sequence of SEQ ID NO: 20.

[0082] In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to CD8a, 4-1BB and CD3z, is encoded by the nucleic acid sequence of SEQ ID NO. 18 and/or comprises the amino acid sequence of SEQ ID NO. 19.

[0083] In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to NCR3 and 4-1BB, and wherein the NCR3 comprises the amino acid sequence of SEQ ID NO: 22. In one embodiment, the chimeric receptor comprises one or more of the NCR1 transmembrane/intracellular domain of SEQ ID NO: 20 or the NCR3 transmembrane/intracellular domain of SEQ ID NO: 22.

[0084] In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to a GS3 linker, a CD8a hinge, a CD16 transmembrane/intracellular domain and 4-1BB. In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 43. In several embodiments, the chimeric receptors comprises the fragment of NKG2D coupled to a GS3 linker, a CD16 transmembrane/intracellular domain and 4-1BB. In one embodiment, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 44.

[0085] In several embodiments, the the chimeric receptor comprises the fragment of NKG2D coupled to a CD16 transmembrane/intracellular domain and 4-1BB and is encoded by the nucleic acid sequence of SEQ ID NO: 45.

[0086] In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to a CD8a hinge, a CD8a transmembrane domain, 4-1BB, and 2B4 and is encoded by the nucleic acid sequence of SEQ ID NO: 46.

[0087] In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to a beta-adrenergic extracellular domain, a beta-adrenergic transmembrane domain, 4-1BB, and 2B4 and is encoded by the nucleic acid sequence of SEQ ID NO: 47.

[0088] In several embodiments the chimeric receptor comprises the fragment of NKG2D coupled to a CD8a hinge, a CD8a transmembrane domain, 4-1BB, 2B4, a GS3 linker, and NKp80 and is encoded by the nucleic acid sequence of SEQ ID NO: 48.

[0089] In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to a CD8a hinge, a CD8a transmembrane domain, 4-1BB, a GS3 linker, and NKp80 and is encoded by the nucleic acid sequence of SEQ ID NO: 49.

[0090] In several embodiments, the chimeric receptor comprises the fragment of NKG2D that is codon optimized coupled to a GS3 linker, an additional NKG2D fragment, a beta-adrenergic extracellular domain, a beta-adrenergic transmembrane domain, 4-1BB, an additional GS3 linker, and NKp80 and is encoded by the nucleic acid sequence of SEQ ID NO: 50.

[0091] In several embodiments, the chimeric receptor comprises the fragment of NKG2D that is codon optimized coupled to a GS3 linker, an additional NKG2D fragment, a CD8a hinge, a CD8a transmembrane domain, 4-1BB, an additional GS3 linker, and NKp80 and is encoded by the nucleic acid sequence of SEQ ID NO: 51.

[0092] In several embodiments, the chimeric receptor comprises the fragment of NKG2D that is codon optimized coupled to a GS3 linker, an additional NKG2D fragment, a CD8a hinge, a CD16 transmembrane/intracellular domain, and 4-1BB and is encoded by the nucleic acid sequence of SEQ ID NO: 52.

[0093] In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to a CD8a hinge, a CD16 transmembrane/intracellular domain, 4-1BB, and 2B4 and is encoded by the nucleic acid sequence of SEQ ID NO: 53.

[0094] In several embodiments, the chimeric receptor comprises the fragment of NKG2D coupled to a CD8a hinge, a CD16 transmembrane/intracellular domain, 4-1BB, a GS3 linker, and NKp80 and is encoded by the nucleic acid sequence of SEQ ID NO: 54.

[0095] In several embodiments, the chimeric receptor constructs are encoded by a polynucleotide that encodes a chimeric receptor wherein the extracellular receptor domain comprises a second peptide that binds native ligands of NKG2D, (e.g., one or more of MICA, MICB, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5 or ULBP6. Depending on the embodiment, the peptide that binds native ligands of NKG2D has at least 80% homology to SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO. 3.

[0096] In several embodiments, the polynucleotide is co-expressed with an additional construct encoding membrane-bound interleukin 15 (mbIL15). In several embodiments, the chimeric receptor is encoded by the nucleic acid sequence of SEQ ID

NO: 18. In several embodiments, the chimeric receptor is encoded by the amino acid sequence of SEQ ID NO: 19.

[0097] According to several embodiments, the chimeric receptor does not comprise DNAX-activating protein 10 (DAP10) and/or the chimeric receptor does not encode an immunoreceptor tyrosine-based activation (ITAM) motif.

[0098] In several embodiments, the polynucleotides disclosed herein are mRNA. Additionally, in several embodiments, the polynucleotide disclosed herein are operably linked to at least one regulatory element for the expression of the chimeric receptor.

[0099] Also provided for herein are vectors that comprise the polynucleotides disclosed herein. In several embodiments, the polynucleotide is operatively linked to at least one regulatory element for expression of the chimeric receptor. In several embodiments, the vector is a retrovirus.

[00100] Also provided for herein are genetically engineered natural killer cells comprising the any one or more of the polynucleotides disclosed herein. In several embodiments, the natural killer cells are for autologous use, while in some embodiments they are for allogeneic use.

[00101] Also provided for herein are methods of enhancing NK cell cytotoxicity in a mammal in need thereof, comprising administering to the mammal NK cells, wherein said NK cells express a chimeric receptor encoded by a polynucleotide disclosed herein.

[00102] Additionally, there are provided methods for treating or preventing cancer or an infectious disease in a mammal in need thereof, said method comprising administering to said mammal a therapeutically effective amount of NK cells, wherein said NK cells express a chimeric receptor encoded by a polynucleotide disclosed herein. As disclosed above, the NK cells can be allogeneic or autologous.

[00103] There is provided a use of a polynucleotide as disclosed herein in the manufacture of a medicament for enhancing NK cell cytotoxicity in a mammal in need thereof. Further there is provided a use of a polynucleotide in the manufacture of a medicament for treating or preventing cancer or an infectious disease in a mammal in need thereof.

[00104] Also provided is the use of a vector comprising a polynucleotide disclosed herein in the manufacture of a medicament for enhancing NK cell cytotoxicity in a mammal in need thereof. Also provided is the use of a vector comprising a

polynucleotide disclosed herein in the manufacture of a medicament for treating or preventing cancer or an infectious disease in a mammal in need thereof.

[00105] Also provided is the use of an isolated genetically engineered natural killer cell expressing a chimeric receptor as disclosed herein for enhancing NK cell cytotoxicity in a mammal in need thereof. Also provided is the use of an isolated genetically engineered natural killer cell expressing a chimeric receptor as disclosed herein for treating or preventing cancer or an infectious disease in a mammal in need thereof.

[00106] The compositions and related methods summarized above and set forth in further detail below describe certain actions taken by a practitioner; however, it should be understood that they can also include the instruction of those actions by another party. Thus, actions such as “administering a population of NK cells expressing a chimeric receptor” include “instructing the administration of a population of NK cells expressing a chimeric receptor.”

BRIEF DESCRIPTION OF THE DRAWINGS

[00107] The descriptions of the figures below are related to experiments and results that represent non-limiting embodiments of the inventions disclosed herein.

[00108] FIGs. 1A-1C depict schematic representations of the chimeric receptors according to several embodiments disclosed herein. FIG. 1A depicts endogenous NKG2D, FIG. 1B depicts NKG2D-DAP10-CD3 ζ , and FIG. 1C depicts NKG2D-41BB-CD3 ζ .

[00109] FIGs. 2A-2B depict schematic representations of the chimeric receptors, according to several embodiments disclosed herein. FIG. 2A depicts NKG2D-CD16 and FIG. 2B depicts NKG2D-CD16-41BB.

[00110] FIGs. 3A-3B depict plasmid maps illustrating the point of insertion of certain constructs according to several embodiments into the plasmids, illustrated is a Murine Stem Cell Virus (MSCV) plasmid. FIG. 3A shows gene constructs for NKG2D-DAP10-CD3 ζ and NKG2D-41BB-CD3 ζ that were inserted into the EcoRI and NotI restriction sites, with removal the IRES-GFP sequence in the vector. FIG. 3B depicts the plasmids for NKG2D-CD16 and NKG2D-CD16-41BB that were inserted into EcoRI and XhoI restriction sites located in the multiple cloning site (MCS). IRES-GFP sequence in the vector allows for the tracing of transduction efficiency.

[00111] FIGs. 4A-4C depict data related to the expression of NKG2D-DAP10-CD3 ζ and NKG2D-41BB-CD3 ζ in NK cells. FIG. 4A shows flow cytometry data illustrating the percentage of NKG2D-positive NK cells after transduction. FIG. 4B shows a dot plots summarizing the percentage of NKG2D-positive NK cells. FIG. 4C shows data related to the mean fluorescence intensity (MFI) in different group of NK cells after transduction.

[00112] FIGs. 5A-5C depict data related to the cytotoxicity of the various constructs generated from NK cells from Donor 1, Donor 2, and Donor 3 (FIGs. 5A, 5B, and 5C, respectively) against cultured REH cells.

[00113] FIGs. 6A-6C depict data related to the cytotoxicity of the various constructs generated from NK cells from Donor 1, Donor 2, and Donor 3 (FIGs. 6A, 6B, and 6C, respectively) against cultured U-2 OS cells.

[00114] FIGs. 7A-7B depict data related to the production of interferon-gamma by NK cells expressing various NKG2D constructs in the presence and absence of stimulation with REH cells. FIG. 7A depicts the relative amount of IFN γ in the different groups of NK cells with or without stimulation by REH cells. FIG. 7B depicts levels of IFN γ between different groups of NK cells after stimulation (median values represented).

[00115] FIGs. 8A-8C depict data related to the expression of NKG2D-DAP10-CD3 ζ and NKG2D-CD16 in NK cells. FIG. 8A shows flow cytometry data illustrating the percentage of NKG2D-positive NK cells after transduction. FIG. 8B shows a dot plots summarizing the percentage of NKG2D-positive NK cells. FIG. 8C shows data related to the mean fluorescence intensity (MFI) in different group of NK cells after transduction.

[00116] FIGs. 9A-9C depict data related to the cytotoxicity of the various constructs generated from NK cells from 3 donors (FIGs. 9A, 9B, and 9C, respectively) against cultured REH cells.

[00117] FIGs. 10A-10C depict data related to the cytotoxicity of the various constructs generated from NK cells from 3 donors (FIGs. 10A, 10B, and 10C, respectively) against cultured U-2 OS cells.

[00118] FIG. 11 depicts data related to the production of interferon-gamma by NK cells expressing various NKG2D constructs in the presence and absence of stimulation with REH cells.

[00119] FIGs. 12A-12B depict data related to expression of NKG2D-DAP10-CD3 ζ and NKG2D-CD16-41BB in NK cells. FIG. 12A shows flow cytometry

data illustrating the percentage of NKG2D-positive NK cells after transduction. FIG. 12B shows a histogram related to relative amount of surface expression of the various constructs on NK cells.

[00120] FIGs. 13A-13B depict data related to the degree of cytotoxicity of various NKG2d constructs. FIG. 13A depicts the degree of cytotoxicity against cultured REH cells. FIG. 13B depicts the degree of cytotoxicity against cultured U2OS cells.

[00121] FIG. 14 schematically depicts construct maps of several NKG2D constructs according to some embodiments disclosed herein.

[00122] FIG. 15 schematically depicts construct maps of additional NKG2D constructs according to some embodiments disclosed herein.

[00123] FIGs. 16A-16C depict data related to the expression of the various NKG2D constructs in NK cells. FIG. 16A shows data related to the mean fluorescence intensity (MFI) of the various NKG2D constructs in NK cells. FIG. 16B shows flow cytometry data illustrating the percentage of NKG2D-positive and CD56-positive NK cells after transduction of various NKG2D constructs into the NK cells of two donors (505 and 870). FIG. 16C shows data related to the mean fluorescence intensity (MFI) in NK cells from 2 donors seven days after transduction.

[00124] FIG. 17 depicts data related to the cytotoxicity of the various NKG2D constructs 14 days post-transduction into NK cells at a 1:1 E:T ratio.

[00125] FIGs. 18A-18B depicts data related to the expression of the various NKG2D constructs following transduction into NK cells. FIG. 18A shows data related to the mean fluorescence intensity (MFI) in NK cells seven days after transduction. FIG. 18B shows data related to the fold-change in MFI of the various NKG2D constructs relative to the mock-transduced NK cells.

[00126] FIGs. 19A-19B depict data related to the cytotoxicity of the various NKG2D constructs. FIG. 19A shows data related to the cytotoxicity of the various NKG2D constructs transduced into NK cells at a 1:1 E:T ratio. FIG. 19B shows data related to the percent change in cytotoxicity of the various NKG2D constructs relative to the mock-transduced NK cells.

[00127] FIG. 20 depicts data related to the cytotoxicity of the various NKG2D constructs 14 days post-transduction into NK cells at a 1:1 E:T ratio. Prior to analysis NK cells were cultured in media supplemented with 40 IU of IL-2/mL.

[00128] FIG. 21 depicts data related to the cytotoxicity of the various NKG2D constructs 10 days post-transduction into Donor 238 NK cells (with 4 days of

culturing in media supplemented with 40 IU of IL-2/mL every two days) against cultured REH cells at 1:1 and 1:2 E:T ratios for two hours.

[00129] FIG. 22 schematically depicts construct maps of additional NKG2D constructs according to embodiments disclosed herein.

[00130] FIGs. 23A-23B depict data related to the persistence of the various NKG2D constructs generated from NK cells from two different donors (Donor 61 and Donor 103 in FIGs. 23A and 23B, respectively). NK cells were cultured in media supplemented with 40 IU of IL-2/mL.

[00131] FIG. 24 depicts data related to the expression of the various NKG2D constructs. NK cells were expanded from peripheral blood mononuclear cells (PBMC) of 4 healthy donors (224, 225, 362 and 363) and transduced with viruses directing the expression of the indicated constructs. Three days following transduction, NK cells were stained with a fluorescently labelled anti-NKG2D antibody and analyzed using flow cytometry. Relative NKG2D expression was assessed by mean fluorescence intensity (MFI) of labeled cells.

[00132] FIGs. 25A-25B depict data related to the cytotoxicity of NK cells transduced with various NKG2D constructs. NK cells were expanded from PBMC of 4 donors; Eight days after transduction, NK cytotoxicity against cultured REH and HL60 cells (FIGs. 25A and 25B, respectively) was measured at a 1:1 E:T ratio. NK cells were cultured in media supplemented with 40 IU of IL-2/mL prior to analysis.

[00133] FIGs. 26A-26C depict data related to the production of interferon-gamma (IFN γ), tumor necrosis factor-alpha (TNF α), and granulocyte-macrophage colony-stimulating factor (GM-CSF) by NK cells expressing various NKG2D constructs after overnight stimulation with REH tumor cells. Eight days after transduction with the indicated constructs, 1×10^5 NK cells were stimulated with 1×10^5 REH cells in individual wells of a 96-well round bottom plate; after overnight incubation, supernatants were harvested, and cytokine levels measured against relevant standards using a Meso Scale Discovery device. FIG. 26A depicts the accumulated levels of IFN γ , FIG. 26B depicts the levels of TNF α , and FIG. 26C depicts the levels of GM-CSF in the different groups of NK cells following stimulation. Prior to analysis NK cells were cultured in media supplemented with 40 IU of IL-2/mL.

[00134] FIGs. 27A-27B depict data related to the persistence of NK cells from two donors (donors 224 and 225 in FIGs. 27A and 27B, respectively) expressing the

various NKG2D constructs 7, 14, and 21 days post-transduction. Prior to analysis NK cells were cultured in media supplemented with 40 IU of IL-2/mL.

[00135] FIGs. 28A-28B depict data related to the cytotoxicity of NK cells transduced with the indicated NKG2D constructs. NK cytotoxicity was measured against U2OS cells stably transduced to express Red Fluorescent Protein; U2OS cells were cultured with NK cells at a 1:4 and 1:2 E:T ratios (FIGs. 28A and 28B, respectively). Live U2OS cells were counted every 60 minutes for 72 hours using an Incucyte S3 Live-Cell Analysis System. Prior to analysis NK cells were cultured in media supplemented with 40 IU of IL-2/mL.

DETAILED DESCRIPTION

General

[00136] The emergence and persistence of aberrant cells (including virally infected and malignant cells) underlying many diseases is enabled by an insufficient immune response to said aberrant cells. A goal of immunotherapy is to initiate or augment the response of the patient's immune system, for example, to boost the ability of immune cells, such as Natural Killer (NK) cells to damage, kill, or otherwise inhibit damaged or diseased cells. One immunotherapy approach is the recombinant expression of chimeric receptors in immune cells for targeted recognition and destruction of the aberrant cells. In general, chimeric receptors comprise an extracellular receptor domain that recognizes ligands on target cells, an anchoring transmembrane domain, and an effector domain that transduces activating signals upon ligand binding. Some embodiments disclosed herein utilize chimeric receptors having that general structure, or having variations in that general structure. Additionally, in several embodiments, the transmembrane domain and the effector domain are separate peptides fused together. In several other embodiments, the transmembrane and the effector domain are derived from the same peptide. In some such embodiments, the transmembrane and effector domains comprise a single peptide (e.g., one peptide that passes through the membrane and is also poised to initiate a signaling cascade). As discussed in more detail below, truncations, mutations, additional linkers/spacer elements, dimers, and the like are used to generate chimeric receptor constructs that exhibit a desired degree of expression in an immune cell (e.g., an NK cell), induce cytotoxic activity from the NK cell, balanced with a degree of target avidity that avoids adverse effects on non-target cells. The recombinant expression

of chimeric receptors as disclosed herein on the surface of immune cells can redirect the targeting of immune cells to aberrant cells of interest as well as augment the immune activation upon engagement.

NK Cells for Immunotherapy

[00137] One immunotherapy approach involves administering to patients T cells engineered to express chimeric receptors to elicit a positive immune response. However, a drawback of this approach is that it necessitates the use of autologous cells to prevent the induction of graft-versus-host-disease in the patient. As is provided in several embodiments disclosed herein, compositions comprising engineered NK cells enjoy several advantages. For example, either autologous or donor-derived allogeneic cells can be employed with an NK cell approach. Additionally, according to several embodiments, the engineered NK cells as provided for herein do not significantly increase cytotoxicity against normal cells. Further, NK cells have a significant cytotoxic effect, once activated. In view of this, it is unexpected that the engineered NK cells as provided for herein, are able to further elevate that cytotoxic effect, thus providing an even more effective means of selectively killing diseased target cells. Accordingly, in several embodiments, there is provided a method of treating or preventing cancer or an infectious disease, comprising administering a therapeutically effective amount of NK cells expressing the chimeric receptors described herein. In one embodiment, the NK cells administered are autologous cells. In a further embodiment, the NK cells administered are donor-derived (allogeneic) cells.

[00138] In several embodiments, engagement and activation of a recombinant NK cell (e.g., by binding to a ligand on a target cell) expressing a chimeric receptor leads to the direct killing of the stressed and/or aberrant cell (e.g., tumor cells, virally-infected cells, etc.) by cytolysis. Accordingly, in several embodiments, there is provided a method of enhancing NK cell cytotoxicity, comprising administering NK cells engineered to express the chimeric receptors described herein. In one embodiment, the NK cells administered are autologous cells. In a further embodiment, the NK cells are donor-derived (allogenic) cells. In several embodiments, engineered NK cells lead to indirect destruction or inhibition of stressed and/or aberrant cell (e.g., tumor cells, virally-infected cells, etc.).

Ligand Binding Domains

[00139] As mentioned above, in several embodiments NK cells recognize and destroy aberrant cells, including tumor cells and virally-infected cells. The cytotoxic activity of these innate immune cells is regulated by the balance of signaling from inhibitory and activating receptors, respectively, that reside on the cell surface. The former bind self-molecules expressed on the surface of healthy cells while the latter bind ligands expressed on aberrant cells. The increased engagement of activating receptors relative to inhibitory receptors leads to NK cell activation and target cell lysis. Natural killer Group 2 member D (NKG2D) is an important NK cell activating receptor that recognizes a number of ligands expressed on stressed and aberrant cells. The surface expression of various NKG2D ligands is generally low in healthy cells but is upregulated upon malignant transformation or viral infection. Non-limiting examples of ligands recognized by NKG2D include, but are not limited to, MICA, MICB, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, and ULBP6, as well as other molecules expressed on target cells that control the cytolytic or cytotoxic function of NK cells.

[00140] NKG2D's ability to recognize a plurality of surface markers of cell stress and infection make it a potentially useful component of a chimeric receptor-based immunotherapy approach. However, complicating the use of NKG2D as a chimeric receptor is its relationship with partner DAP10. NKG2D is a type II transmembrane glycoprotein that forms homodimers and assembles with two homodimers of DNAX-activating protein 10 (DAP10) to yield hexameric complexes on the membrane surface. This NKG2D-DAP10 association is necessary for both surface membrane expression of endogenous NKG2D as well as for transduction of the activation signal upon ligand binding. In several embodiments, a full length NKG2D is used. In one embodiment, full length NKG2D has the nucleic acid sequence of SEQ ID NO. 1. According to several embodiments disclosed herein, polynucleotides encoding chimeric receptors are provided wherein the extracellular receptor domain is a fragment of NKG2D that lacks its native transmembrane or intracellular domains yet advantageously retains its ability to bind native ligands of NKG2D, as well as transduce activation signals upon ligand binding. Thus, in several embodiments, the chimeric receptor encoded by the polypeptides disclosed herein does not comprise DAP10. In several embodiments, the NKG2D fragment is encoded by SEQ ID NO. 2. In several embodiments, the fragment of NKG2D is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with full-length wild-type NKG2D. In several embodiments, the fragment may have one or more additional mutations from SEQ ID NO. 2, but retains, or in some

embodiments, has enhanced, ligand-binding function. In several embodiments, the NKG2D fragment is provided as a dimer, trimer, or other concatameric format, such embodiments providing enhanced ligand-binding activity. In several embodiments, the sequence encoding the NKG2D fragment is optionally fully or partially codon optimized. In one embodiment, a sequence encoding a codon optimized NKG2D fragment comprises the sequence of SEQ ID NO. 3. Additionally, in several embodiments signal peptides are used. The species or sequence of the signal peptide can vary with the construct. However, in several embodiments, a signal peptide derived from CD8 is used. In one embodiment, the signal peptide is from CD8a and has the sequence of SEQ ID NO. 4. In one embodiment, a sequence encoding a codon optimized NKG2D fragment comprises the sequence of SEQ ID NO. 68. In several embodiments, the fragment may have one or more additional mutations from SEQ ID NO. 68, but retains ligand-binding function. In several embodiments, the fragment may have one or more additional mutations from SEQ ID NO. 68, but has improved ligand-binding function.

Transmembrane, Signaling and Combination Domains

[00141] As mentioned above, the general chimeric antigen receptor structure comprises at least one transmembrane domain, linking the ligand binding domain to a signaling domain(s). In several embodiments, however, a transmembrane domain can also serve to provide signaling function.

[00142] In several embodiments, the NKG2D fragment retains at least a portion of its normal transmembrane domain. In several embodiments, the transmembrane domain comprises at least a portion of CD8, which is a transmembrane glycoprotein normally expressed on both T cells and NK cells. In several embodiments, the transmembrane domain comprises CD8 α , while in some embodiments CD8 β is used. In several embodiments, the “hinge” of CD8 α has the sequence of SEQ ID NO. 5. In several embodiments, the CD8 α can be truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the CD8 α having the sequence of SEQ ID NO. 5. In several embodiments, CD8 β has the sequence of SEQ ID NO. 6. In several embodiments, the CD8 β can be truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the CD8 β having the sequence of SEQ ID NO. 6. In several embodiments, dimers of CD8 α and CD8 β are used.

[00143] In several embodiments, the transmembrane domain comprises CD16, which serves as a signaling domain as well. CD16 exists in two isoforms, a and b (also known as Fc gamma receptor IIIa and IIIb, respectively). These receptors normally bind to the Fc portion of IgG antibodies that in turn activates NK cells. Accordingly, in several embodiments, the transmembrane domain comprises CD16a, while in some embodiments CD16b is used. In several embodiments, CD16a has the sequence of SEQ ID NO. 7. In several embodiments, the CD16a can be truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the CD16a having the sequence of SEQ ID NO. 7. In several embodiments, CD16b has the sequence of SEQ ID NO. 8. In several embodiments, the CD16b can be truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the CD16b having the sequence of SEQ ID NO. 8. In several embodiments, dimers of CD16a and CD16b are used. In several embodiments the modifications to the CD16 transmembrane domain comprise additional nucleic acid residues to increase the length of the domain. Alternatively, CD16 may be shortened. The modifications to the length of CD16 advantageously can facilitate enhanced ligand-receptor interactions.

[00144] In several embodiments, the chimeric receptor comprises the Natural Killer Receptor 2B4 domain (referred to herein as “2B4”, and also known as CD244), which serves as a signaling domain as well. 2B4 is expressed on NK cells and regulates non-major histocompatibility complex (MHC) restricted killing through interactions between this receptor and its ligands on target cells. In several embodiments, the transmembrane domain comprises 2B4, while in several embodiments the 2B4 domain is an intracellular signaling domain. In several embodiments, 2B4 has the sequence of SEQ ID NO. 9. In several embodiments, the 2B4 can be truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the 2B4 having the sequence of SEQ ID NO. 9. In several embodiments, 2B4 is used as the sole transmembrane/signaling domain in the construct, however, in several embodiments, 2B4 can be used with one or more other domains. For example, combinations of CD16, 4-1BB, and/or 2B4 are used in some embodiments.

[00145] In some embodiments, signaling is achieved through DAP10, as mentioned above. In several embodiments, the fragment of NKG2D associates with DAP10 to provide pro-cytotoxic signals to the NK cell. In several embodiments, dimers

of DAP10 are used. In several embodiments, the transmembrane domain comprises DAP10. In several embodiments, DAP10 has the sequence of SEQ ID NO. 10. In several embodiments, DAP10 can be truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the DAP10 having the sequence of SEQ ID NO. 10. Similarly, in some embodiments, DAP12 can be used, as it can also transduce such signals. In several embodiments, DAP12 has the sequence of SEQ ID NO. 11. In several embodiments, DAP12 can be truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the DAP12 having the sequence of SEQ ID NO. 11. In several embodiments, heterodimers of DAP10 and DAP12 are used.

[00146] In several embodiments, signaling is provided through 4-1BB (also known as CD137 and tumor necrosis factor receptor superfamily member 9 (TNFRSF 9)). 4-1BB is a co-stimulatory immune checkpoint molecule, typically functioning as a stimulatory molecule for activated T cells (e.g., crosslinking of 4-1BB enhances T cell proliferation and cytolytic activity). However, in several embodiments, the function of 4-1BB is advantageously used in conjunction with NK cells. In several embodiments, 4-1BB has the sequence of SEQ ID NO. 12. In several embodiments, 4-1BB can be truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the 4-1BB having the sequence of SEQ ID NO. 12. In several embodiments, 4-1BB is the sole signaling domain, but as discussed above, in several embodiments, 4-1BB functions unexpectedly well in combination with one or more of the other transmembrane/signaling domains disclosed herein. For example, in several embodiments, CD16 in conjunction with 4-1BB provides synergistic stimulation effects, resulting in particularly effective (e.g., cytotoxic) NK cells. In several embodiments, DAP10 in conjunction with 4-1BB provides synergistic stimulation effects, resulting in particularly effective (e.g., cytotoxic) NK cells. In several embodiments, DAP10 in conjunction with 4-1BB and/or 2B4 provides synergistic stimulation effects, resulting in particularly effective (e.g., cytotoxic) NK cells. Other improved characteristics result, in several embodiments, such as improved expression, improved persistence, and the like.

[00147] In several embodiments, the signaling domain comprises at least a portion of the CD3 T cell receptor complex. The T cell receptor complex comprises multiple subunits, including the zeta, alpha, beta, gamma, delta, and epsilon subunits. In several embodiments, the NK cells engineered according to several embodiments

disclosed herein comprise at least one of these subunits (or a fragment thereof). In several embodiments, the signaling domain comprises the CD3 zeta subunit. In several embodiments, CD3 zeta has the sequence of SEQ ID NO. 13. In several embodiments, CD3 zeta can be truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the CD3 zeta having the sequence of SEQ ID NO. 13. In several embodiments, the CD3 zeta is mutated (e.g., amino acid mutations, insertions, or deletions) such that the domain no longer is consistent with the canonical immunoreceptor tyrosine-based activation motif or ITAM motif. Thus, in several embodiments, the NK cells comprise an engineered receptor that does not contain an ITAM motif. In some embodiments, the resultant engineered NK cells exhibit particularly enhanced cytotoxicity against target cells, with limited or reduced adverse side effects. This, in several embodiments, results from the synergistic interactions of the various portions of the chimeric receptor that are used in that given embodiment. In several embodiments, CD3zeta in conjunction with 4-1BB provides synergistic stimulation effects, resulting in particularly effective (e.g., cytotoxic) NK cells. In several embodiments, CD3zeta in conjunction with 2B4 provides synergistic stimulation effects, resulting in particularly effective (e.g., cytotoxic) NK cells. In several embodiments, CD3zeta in combination with 2B4 and 4-1BB provides synergistic stimulation effects, resulting in particularly effective (e.g., cytotoxic) NK cells. In several embodiments, the chimeric receptors leverage the dimerization of CD3zeta via its transmembrane domain. Thus, in several embodiments, the transmembrane domain comprises the CD3zeta transmembrane domain (or a fragment thereof). In some embodiments, 1, 2, 3, 4, 5, 6 or more extracellular CD3zeta residues (the “juxta-membrane portion”) are directly adjacent to the CD3zeta transmembrane domain. In some embodiments, CD3zeta transmembrane domain has the sequence of SEQ ID NO. 69. In several embodiments, the CD3zeta transmembrane domain can be truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the CD3zeta transmembrane domain having the sequence of SEQ ID NO. 69. In several embodiments the modifications to the CD3zeta transmembrane domain comprise additional nucleic acid residues to increase the length of the domain. In several embodiments, the CD3zeta transmembrane domain and CD3zeta juxta-membrane portion recruits full-length CD3zeta molecule to the synapse. In several embodiments, the recruitment of native CD3zeta to the engineered receptor (as compared to a receptor without a CD3zeta transmembrane domain) is increased by about 20%, by about 30%, by

about 40% by about 50%, or more, depending on the embodiment. In several embodiments, the CD3zeta transmembrane domain is coupled to an effector domain comprising one or more of CD16, NCR1, NCR2, NCR3, 4-1BB, NKp80, FcR γ , CD3zeta and 2B4.

[00148] In several embodiments, the chimeric receptor comprises a CD28 domain. In several embodiments, the transmembrane domain comprises CD28, while in several embodiments the CD28 domain is an intracellular signaling domain, while in several embodiments the CD28 domain is a transmembrane/intracellular signaling domain. In several embodiments, the CD28 transmembrane domain has the sequence of SEQ ID NO. 105. In several embodiments, the CD28 transmembrane domain can be truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the CD28 having the sequence of SEQ ID NO. 105. In several embodiments, the CD28 intracellular signaling domain has the sequence of SEQ ID NO. 106. In several embodiments, the CD28 intracellular signaling domain can be truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the CD28 having the sequence of SEQ ID NO. 106. In several embodiments, CD28 is used as the sole transmembrane/signaling domain in the construct, however, in several embodiments, CD28 can be used with one or more other domains. For example, combinations of CD28, OX40, 4-1BB, and/or CD3zeta are used in some embodiments.

[00149] In several embodiments, the chimeric receptor comprises an OX40 domain. In several embodiments the OX40 domain is an intracellular signaling domain. In several embodiments, the OX40 intracellular signaling domain has the sequence of SEQ ID NO. 107. In several embodiments, the OX40 intracellular signaling domain can be truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the OX40 having the sequence of SEQ ID NO. 107. In several embodiments, OX40 is used as the sole transmembrane/signaling domain in the construct, however, in several embodiments, OX40 can be used with one or more other domains. For example, combinations of CD28, OX40, 4-1BB, and/or CD3zeta are used in some embodiments.

[00150] In still further embodiments, the signaling portion of the chimeric receptor comprises a portion of an ITAM, for example a hemi-tam. In several embodiments, these portions do not make up the canonical ITAM sequence, but rather comprise a portion that still can convey the signal required for NK cell cytotoxicity. In

several embodiments, the hemi-tam has the sequence of SEQ ID NO. 14 (wherein X can be any residue). In several embodiments, the hemi-tam can be truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the hemi-tam having the sequence of SEQ ID NO. 14. In several embodiments, the chimeric receptor construct comprises the hemi-tam of SEQ ID NO. 14. In several embodiments, multiple hemi-tams can be used, for example in a head to tail, tail to head, head to head, or tail to tail configuration. In several embodiments, the presence of at least one hemi-tam confers enhanced signaling and cytotoxicity to the NK cells comprising a chimeric receptor employing the at least one hemi-tam. As discussed in more detail below, in several chimeric receptor comprises NKp80, which is one non-limiting example of a hemi-tam.

[00151] In several embodiments, additional signaling regions are used, including, for example, signaling regions derived from receptors of the signaling lymphocytic activation molecule (SLAM) family. These receptors include, but are not limited to 2B4 (discussed above). Receptors of the SLAM family share a consensus motif that is tyrosine-based, in their cytoplasmic tails. That motif is S/TxYxxL/I, which are referred to as immunoreceptor tyrosine-based switch motifs (ITSM) (SEQ ID NO. 15). These receptors transmit activation signals through the SLAM-associated protein (SAP, encoded by the gene SH2D1A), which recruits the tyrosine kinase Fyn. Thus, according to several embodiments, the signaling region comprise a polypeptide sequence (or the nucleic acid encoding the same) comprising an ITSM motif. In several embodiments, the ITSM motif need not be fully encoded, but the signaling region is able to transmit an activation signal through SAP (or another similar pathway). In several embodiments, the ITSM motif has the sequence of SEQ ID NO. 15 (wherein X can be any amino acid residue). In several embodiments, the ITSM motif can be truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the ITSM motif having the sequence of SEQ ID NO. 15. In several embodiments, the ITSM motif comprises the sequence of SEQ ID NO. 15.

[00152] In addition to these variations in the NKG2D receptor, the transmembrane domain and signaling domain (and the combination transmembrane/signaling domains), additional co-activating molecules can be provided, in several embodiments. For example, in several embodiments, the NK cells are engineered to express membrane-bound interleukin 15 (mbIL15). In such embodiments, the presence of the mbIL15 on the NK cell function to further enhance the cytotoxic

effects of the NK cell by synergistically enhancing the proliferation and longevity of the NK cells. In several embodiments, mbIL15 has the nucleic acid sequence of SEQ ID NO. 16. In several embodiments, mbIL15 can be truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the sequence of SEQ ID NO. 16. In several embodiments, the mbIL15 has the amino acid sequence of SEQ ID NO. 17. In conjunction with the chimeric receptors disclosed herein, such embodiments provide particularly effective NK cell compositions for targeting and destroying particular target cells.

Chimeric Receptor Constructs

[00153] In view of the disclosure provided herein, there are a variety of chimeric receptors that can be generated and expressed in NK cells in order to target and destroy particular target cells, such as diseased or cancerous cells. Non-limiting examples of such chimeric receptors are discussed in more detail below.

[00154] As discussed above, portions of the T cell receptor complex, in particular CD3zeta, serve as potent activators of immune signaling cascades. Likewise, the receptor 4-1BB, a tumor necrosis factor superfamily member, activates NK cells upon ligand binding. In several embodiments, these two signaling components act in a synergistic manner to activate NK cells upon binding of a ligand to the chimeric receptor. Thus, in several embodiments, there are provided polynucleotides encoding a NKG2D/CD8a/4-1BB/CD3zeta chimeric receptor, which comprises an NKG2D fragment extracellular receptor domain that binds native ligands of NKG2D, a CD8 transmembrane region, and an effector domain comprising the signaling domains of 4-1BB and CD3zeta. In one embodiment, this chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 18. In one embodiment, this chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 108. In yet another embodiment, the NKG2D-CD8a-4-1BB-CD3zeta chimeric receptor comprises the amino acid sequence of SEQ ID NO: 19. In several embodiments, this construct is particularly efficacious when the NK cells concurrently express mbIL15, the mbIL15 provides a further synergistic effect with respect to the activation and cytotoxic nature of the NK cells. In some embodiments, the sequence of the chimeric receptor may vary from SEQ ID NO. 18 (such as, for example, SEQ ID NO: 108), but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 18. In several embodiments, while the chimeric receptor may vary from SEQ ID NO. 18

(such as, for example, SEQ ID NO: 108), the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function.

[00155] The receptor 2B4 possesses several immunoreceptor tyrosine-based switch motifs (ITSMs) and has the potential to transduce activating signals. Likewise, signaling through the receptor 4-1BB, a tumor necrosis factor superfamily member, also activates NK cells upon ligand binding. Thus, capitalizing on the ability of these signaling molecules to cooperate to generate unexpectedly effectively cytotoxic NK cells, in several embodiments, there are provided polynucleotides encoding a NKG2D/CD8a/2B4/4-1BB chimeric receptor, which comprises an NKG2D fragment extracellular receptor domain that binds native ligands of NKG2D, a CD8a transmembrane region, and an effector domain comprising the signaling domains of 4-1BB and 2B4. Additionally, in several embodiments, this construct can optionally be co-expressed with mbIL15.

[00156] In several embodiments, combinations of 2B4 with CD3zeta are used with NK cells to generate enhanced cytotoxicity against target cells. Thus, in several embodiments, there are provided polynucleotides encoding a NKG2D/CD8a/2B4/CD3zeta chimeric receptor, which comprises an NKG2D fragment extracellular receptor domain that binds native ligands of NKG2D, a CD8a transmembrane region, and an effector domain comprising the signaling domains of CD3zeta and 2B4. Additionally, in several embodiments, this construct can optionally be co-expressed with mbIL15. As discussed above, 4-1BB, like CD3zeta and 2B4, can function as a potent activator of immune signaling cascades. In several embodiments, these three signaling components act in a synergistic manner to activate NK cells upon binding of a ligand to the chimeric receptor. Thus, in several embodiments, there are provided polynucleotides encoding a NKG2D/CD8a/4-1BB/2B4/CD3zeta chimeric receptor, which comprises an NKG2D fragment extracellular receptor domain that binds native ligands of NKG2D, a CD8 transmembrane region, and an effector domain comprising the signaling domains of 4-1BB, 2B4 and CD3zeta. In one embodiment, this chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 58. In yet another embodiment, the NKG2D-CD8a-4-1BB-CD3zeta chimeric receptor comprises the amino acid sequence of SEQ ID NO: 59. In several embodiments, this construct is particularly efficacious when the NK cells concurrently express mbIL15, the mbIL15 provides a further synergistic effect with respect to the activation and/or cytotoxic nature of the NK cells. In some embodiments, the sequence of the chimeric receptor may vary

from SEQ ID NO. 58, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 58. In several embodiments, while the chimeric receptor may vary from SEQ ID NO. 58, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function.

[00157] In several alternative embodiments, there are provided polynucleotides encoding a NKG2D/CD8a/DAP10/4-1BB chimeric receptor, which comprises an NKG2D fragment extracellular receptor domain that binds native ligands of NKG2D, a CD8a transmembrane region, and an effector domain comprising the signaling domains of 4-1BB and DAP10. In one embodiment, this chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 60. In yet another embodiment, the NKG2D-CD8a-4-1BB-DAP10 chimeric receptor comprises the amino acid sequence of SEQ ID NO: 61. Additionally, in several embodiments, this construct can optionally be co-expressed with mbIL15. In several embodiments, this construct is particularly efficacious when the NK cells concurrently express mbIL15, the mbIL15 provides a further synergistic effect with respect to the activation and cytotoxic nature of the NK cells. In some embodiments, the sequence of the chimeric receptor may vary from SEQ ID NO. 60, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 60. In several embodiments, while the chimeric receptor may vary from SEQ ID NO. 60, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function. Further, as discussed above, 2B4, like DAP10 and 4-1BB, is a potent activator of immune signaling cascades. In several embodiments, these three signaling components act in a synergistic manner to activate NK cells upon binding of a ligand to the chimeric receptor. Thus, in several embodiments, there are provided polynucleotides encoding a NKG2D/CD8a/4-1BB/DAP10/2B4 chimeric receptor, which comprises an NKG2D fragment extracellular receptor domain that binds native ligands of NKG2D, a CD8 transmembrane region, and an effector domain comprising the signaling domains of 4-1BB, 2B4 and DAP10, wherein 4-1BB is followed by DAP10, and DAP10 is followed by 2B4. In one embodiment, this chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 62. In yet another embodiment, the NKG2D-CD8a-4-1BB-CD3zeta chimeric receptor comprises the amino acid sequence of SEQ ID NO: 63. In several embodiments, this construct is particularly efficacious when the NK cells concurrently express mbIL15, the mbIL15 provides a further synergistic effect with

respect to the activation and cytotoxic nature of the NK cells. In some embodiments, the sequence of the chimeric receptor may vary from SEQ ID NO. 62, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 62. In several embodiments, while the chimeric receptor may vary from SEQ ID NO. 62, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function. In several other embodiments, there are provided polynucleotides encoding a NKG2D/CD8a/4-1BB/2B4/DAP10 chimeric receptor, which comprises an NKG2D fragment extracellular receptor domain that binds native ligands of NKG2D, a CD8 transmembrane region, and an effector domain comprising the signaling domains of 4-1BB, 2B4 and DAP10, wherein 4-1BB is followed by 2B4, and 2B4 is followed by DAP10. In one embodiment, this chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 64. In yet another embodiment, the NKG2D-CD8a-4-1BB-CD3zeta chimeric receptor comprises the amino acid sequence of SEQ ID NO: 65. In several embodiments, this construct is particularly efficacious when the NK cells concurrently express mbIL15, the mbIL15 provides a further synergistic effect with respect to the activation and cytotoxic nature of the NK cells. In some embodiments, the sequence of the chimeric receptor may vary from SEQ ID NO. 64, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 64. In several embodiments, while the chimeric receptor may vary from SEQ ID NO. 64, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function.

[00158] In several additional embodiments, transmembrane and effector domains (and associated function) of the chimeric receptor are derived from the same peptide. CD16 is a potent activating receptor expressed on the surface of NK cells. Thus, in several embodiments, polynucleotides are provided encoding a NKG2D/CD16 chimeric receptor, which comprises an NKG2D fragment extracellular receptor domain that binds native ligands of NKG2D and a CD16 peptide comprising both the transmembrane region and intracellular effector domain. In one embodiment, this chimeric receptor comprises the nucleic acid sequence of SEQ ID NO: 23. In yet another embodiment, this chimeric receptor is encoded by the amino acid sequence of SEQ ID NO: 24. In some embodiments, the sequence of the chimeric receptor may vary from SEQ ID NO. 23, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO.

23. In several embodiments, while the chimeric receptor may vary from SEQ ID NO. 23, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function. Additionally, in several embodiments, this construct can optionally be co-expressed with mbIL15.

[00159] In several additional embodiments, polynucleotides are provided encoding a NKG2D/CD16/4-1BB chimeric receptor, wherein the signaling domain of 4-1BB acts as a second transducer of activating signals in the effector domain. Additionally, in several embodiments, this construct can optionally be co-expressed with mbIL15.

[00160] CD3zeta dimerizes via its transmembrane domain. Thus, in several embodiments, chimeric receptors are provided wherein a CD3zeta transmembrane domain recruits full-length CD3zeta molecule to the synapse. In several embodiments, there are provided polynucleotides encoding a chimeric receptor which comprises a NKG2D fragment that binds native ligands of NKG2D, a CD8a hinge, 0, 1, 2, 3, 4, 5, 6 or more extracellular CD3zeta residues (the “juxta-membrane portion”) directly adjacent to a CD3zeta transmembrane domain, and an effector domain comprising one or more of CD16, NCR1, NCR2, NCR3, 4-1BB, NKp80, FcR γ , CD3zeta and 2B4.

[00161] In several embodiments, chimeric receptors are provided wherein a CD3zeta transmembrane domain is coupled to an effector domain comprising one or both of 4-1BB and CD16. Thus, in several embodiments, polynucleotides are provided encoding a NKG2D/CD3zetaTM/4-1BB chimeric receptor, which comprises a fragment of NKG2D that is codon optimized coupled to a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising 4-1BB. In one embodiment, this chimeric receptor comprises the nucleic acid sequence of SEQ ID NO: 78. In yet another embodiment, this chimeric receptor is encoded by the amino acid sequence of SEQ ID NO: 79. In some embodiments, the sequence of the chimeric receptor may vary from SEQ ID NO. 78, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 78. In several embodiments, while the chimeric receptor may vary from SEQ ID NO. 78, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function. Additionally, in several embodiments, this construct can optionally be co-expressed with mbIL15.

[00162] In several embodiments, polynucleotides are provided encoding a NKG2D/CD3zetaTM/CD16/4-1BB chimeric receptor, which comprises a fragment of

NKG2D that is codon optimized coupled to a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising CD16 followed by 4-1BB. In one embodiment, this chimeric receptor comprises the nucleic acid sequence of SEQ ID NO: 70. In yet another embodiment, this chimeric receptor is encoded by the amino acid sequence of SEQ ID NO: 71. In some embodiments, the sequence of the chimeric receptor may vary from SEQ ID NO. 70, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 70. In several embodiments, while the chimeric receptor may vary from SEQ ID NO. 70, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function. Additionally, in several embodiments, this construct can optionally be co-expressed with mbIL15. Further, in several embodiments, polynucleotides are provided encoding a NKG2D/CD3zetaTM/4-1BB/CD16 chimeric receptor, which comprises a fragment of NKG2D that is codon optimized coupled to a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising 4-1BB followed by CD16. In some embodiments, the effector domain further comprises a GS3 linker. In some embodiments, the GS3 linker is positioned between 4-1BB and CD16. In one embodiment, this chimeric receptor comprises the nucleic acid sequence of SEQ ID NO: 84. In yet another embodiment, this chimeric receptor is encoded by the amino acid sequence of SEQ ID NO: 85. In some embodiments, the sequence of the chimeric receptor may vary from SEQ ID NO. 84, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 84. In several embodiments, while the chimeric receptor may vary from SEQ ID NO. 84, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function. Additionally, in several embodiments, this construct can optionally be co-expressed with mbIL15. Further, in several embodiments, polynucleotides are provided encoding a NKG2Dx2/CD3zetaTM/CD16/4-1BB chimeric receptor, which comprises the fragment of NKG2D that is codon optimized coupled to a GS3 linker, an additional NKG2D fragment, a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising a CD16 and 4-1BB. In one embodiment, this chimeric receptor comprises the nucleic acid sequence of SEQ ID NO: 72. In yet another embodiment, this chimeric receptor is encoded by the amino acid sequence of SEQ ID NO: 73. In some embodiments, the sequence of the chimeric receptor may vary from SEQ ID NO. 72, but remains, depending on the embodiment, at least 70%, at least 75%,

at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 72. In several embodiments, while the chimeric receptor may vary from SEQ ID NO. 72, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function. Additionally, in several embodiments, this construct can optionally be co-expressed with mbIL15.

[00163] In several embodiments, chimeric receptors are provided wherein a CD3zeta transmembrane domain is coupled to an effector domain comprising NKp80. Thus, in several embodiments, polynucleotides are provided encoding a NKG2D/CD3zetaTM/CD16/4-1BB/NKp80 chimeric receptor, which chimeric receptor comprises a fragment of NKG2D coupled to a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising a CD16, 4-1BB, and NKp80. In some embodiments, the effector domain further comprises a GS3 linker. In some embodiments, the GS3 linker is positioned between 4-1BB and NKp80. In one embodiment, this chimeric receptor comprises the nucleic acid sequence of SEQ ID NO: 74. In yet another embodiment, this chimeric receptor is encoded by the amino acid sequence of SEQ ID NO: 75. In some embodiments, the sequence of the chimeric receptor may vary from SEQ ID NO. 74, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 74. In several embodiments, while the chimeric receptor may vary from SEQ ID NO. 74, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function. Additionally, in several embodiments, this construct can optionally be co-expressed with mbIL15. Further, in several embodiments, polynucleotides are provided encoding a 2xNKG2D/CD3zetaTM/ CD16/4-1BB/NKp80 chimeric receptor, which comprises the fragment of NKG2D that is codon optimized coupled to a GS3 linker, an additional NKG2D fragment, a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising a CD16, 4-1BB, and NKp80. In some embodiments, the effector domain further comprises a GS3 linker. In some embodiments, the GS3 linker is positioned between 4-1BB and NKp80. In one embodiment, this chimeric receptor comprises the nucleic acid sequence of SEQ ID NO: 76. In yet another embodiment, this chimeric receptor is encoded by the amino acid sequence of SEQ ID NO: 77. In some embodiments, the sequence of the chimeric receptor may vary from SEQ ID NO. 76, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 76. In several embodiments, while the chimeric receptor

may vary from SEQ ID NO. 76, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function. Additionally, in several embodiments, this construct can optionally be co-expressed with mbIL15. Further, in several embodiments, polynucleotides are provided encoding a NKG2D/CD3zetaTM/4-1BB/NKp80 chimeric receptor, which comprises a fragment of NKG2D that is codon optimized coupled to a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising 4-1BB and NKp80. In some embodiments, the effector domain further comprises a GS3 linker. In some embodiments, the GS3 linker is positioned between 4-1BB and NKp80. In one embodiment, this chimeric receptor comprises the nucleic acid sequence of SEQ ID NO: 82. In yet another embodiment, this chimeric receptor is encoded by the amino acid sequence of SEQ ID NO: 83. In some embodiments, the sequence of the chimeric receptor may vary from SEQ ID NO. 82, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 82. In several embodiments, while the chimeric receptor may vary from SEQ ID NO. 82, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function. Additionally, in several embodiments, this construct can optionally be co-expressed with mbIL15.

[00164] In several embodiments, chimeric receptors are provided wherein a CD3zeta transmembrane domain is coupled to an effector domain comprising CD3zeta. Thus, in several embodiments, polynucleotides are provided encoding a NKG2D/CD3zetaTM/4-1BB/CD3zeta chimeric receptor, which comprises a fragment of NKG2D that is codon optimized coupled to a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising 4-1BB and CD3zeta. In one embodiment, this chimeric receptor comprises the nucleic acid sequence of SEQ ID NO: 80. In yet another embodiment, this chimeric receptor is encoded by the amino acid sequence of SEQ ID NO: 81. In some embodiments, the sequence of the chimeric receptor may vary from SEQ ID NO. 80, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 80. In several embodiments, while the chimeric receptor may vary from SEQ ID NO. 80, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function. Additionally, in several embodiments, this construct can optionally be co-expressed with mbIL15.

[00165] In several embodiments, chimeric receptors are provided wherein a CD3zeta transmembrane domain is coupled to an effector domain comprising FcR γ . Thus, in several embodiments, polynucleotides are provided encoding a NKG2D/CD3zetaTM/4-1BB/FcR γ chimeric receptor, which comprises a fragment of NKG2D coupled to a CD8a hinge, a CD3zeta transmembrane region, and an effector domain comprising 4-1BB and FcR γ . In one embodiment, this chimeric receptor comprises the nucleic acid sequence of SEQ ID NO: 86. In yet another embodiment, this chimeric receptor is encoded by the amino acid sequence of SEQ ID NO: 87. In some embodiments, the sequence of the chimeric receptor may vary from SEQ ID NO. 86, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 86. In several embodiments, while the chimeric receptor may vary from SEQ ID NO. 86, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function. Additionally, in several embodiments, this construct can optionally be co-expressed with mbIL15.

[00166] In several embodiments, chimeric receptors are provided wherein a CD3zeta transmembrane domain is coupled to an effector domain comprising CD28. Thus, in several embodiments, polynucleotides are provided encoding a NKG2D/CD3zetaTM/CD28/CD3zeta chimeric receptor, which comprises an NKG2D fragment extracellular receptor domain that binds native ligands of NKG2D, a CD8a hinge, a CD3zeta transmembrane region, and intracellular effector domain comprising CD28 and CD3zeta. In one embodiment, this chimeric receptor comprises the nucleic acid sequence of SEQ ID NO: 102. In yet another embodiment, this chimeric receptor is encoded by the amino acid sequence of SEQ ID NO: 103. In some embodiments, the sequence of the chimeric receptor may vary from SEQ ID NO. 102, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 102. In several embodiments, while the chimeric receptor may vary from SEQ ID NO. 102, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function. Additionally, in several embodiments, this construct can optionally be co-expressed with mbIL15.

[00167] In several embodiments, chimeric receptors are provided wherein the extracellular domain comprises a fragment of NKG2D coupled IL15. Thus, in several embodiments, polynucleotides are provided encoding an IL15/NKG2D/CD8a/4-

1BB/CD3zeta chimeric receptor, which comprises an NKG2D fragment extracellular receptor domain that binds native ligands of NKG2D linked to IL-15, a CD8a hinge, a CD8a transmembrane domain, and intracellular effector domain comprising 4-1BB and CD3z. In some embodiments, the extracellular domain further comprises a GS3 linker. In some embodiments, the GS3 linker is positioned between IL15 and the NKG2D fragment extracellular receptor domain. In one embodiment, this chimeric receptor comprises the nucleic acid sequence of SEQ ID NO: 88. In yet another embodiment, this chimeric receptor is encoded by the amino acid sequence of SEQ ID NO: 89. In some embodiments, the sequence of the chimeric receptor may vary from SEQ ID NO. 88, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 88. In several embodiments, while the chimeric receptor may vary from SEQ ID NO. 88, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function.

[00168] In several embodiments, chimeric receptors are provided wherein the extracellular domain comprises a fragment of NKG2D coupled to a IgG4 short hinge. Thus, in several embodiments, polynucleotides are provided encoding a NKG2D/IgG4/CD8a/4-1BB/CD3zeta chimeric receptor, which comprises an NKG2D fragment extracellular receptor domain that binds native ligands of NKG2D, an IgG4 short hinge, a CD8a transmembrane domain, and intracellular effector domain comprising 4-1BB, and CD3zeta. In one embodiment, this chimeric receptor comprises the nucleic acid sequence of SEQ ID NO: 96. In yet another embodiment, this chimeric receptor is encoded by the amino acid sequence of SEQ ID NO: 97. In some embodiments, the sequence of the chimeric receptor may vary from SEQ ID NO. 96, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 96. In several embodiments, while the chimeric receptor may vary from SEQ ID NO. 96, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function. Additionally, in several embodiments, this construct can optionally be co-expressed with mbIL15.

[00169] In several embodiments, chimeric receptors are provided wherein the effector domain comprises OX40. Thus, in several embodiments, polynucleotides are provided encoding a NKG2D/CD8a/OX40/CD3z chimeric receptor, which comprises an NKG2D fragment extracellular receptor domain that binds native ligands of NKG2D, a

CD8a hinge, a CD8a transmembrane domain, and an intracellular effector domain comprising OX40, and CD3z. In one embodiment, this chimeric receptor comprises the nucleic acid sequence of SEQ ID NO: 90. In yet another embodiment, this chimeric receptor is encoded by the amino acid sequence of SEQ ID NO: 91. In some embodiments, the sequence of the chimeric receptor may vary from SEQ ID NO. 90, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 90. In several embodiments, while the chimeric receptor may vary from SEQ ID NO. 90, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function. Additionally, in several embodiments, this construct can optionally be co-expressed with mbIL15. In several embodiments, polynucleotides are provided encoding a NKG2D/IgG4/CD8a/OX40/CD3zeta chimeric receptor, which comprises an NKG2D fragment extracellular receptor domain that binds native ligands of NKG2D, an IgG4 hinge, a CD8a transmembrane domain, and intracellular effector domain comprising OX40 and CD3zeta. In one embodiment, this chimeric receptor comprises the nucleic acid sequence of SEQ ID NO: 100. In yet another embodiment, this chimeric receptor is encoded by the amino acid sequence of SEQ ID NO: 101. In some embodiments, the sequence of the chimeric receptor may vary from SEQ ID NO. 100, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 100. In several embodiments, while the chimeric receptor may vary from SEQ ID NO. 100, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function. Additionally, in several embodiments, this construct can optionally be co-expressed with mbIL15.

[00170] In several embodiments, chimeric receptors are provided comprising a CD28 peptide comprising both the transmembrane region and intracellular effector domain. Thus, in several embodiments, polynucleotides are provided encoding a NKG2D/CD28/CD3zeta chimeric receptor, which comprises an NKG2D fragment extracellular receptor domain that binds native ligands of NKG2D, a CD8a hinge, a CD28 transmembrane/intracellular domain, and CD3zeta. In one embodiment, this chimeric receptor comprises the nucleic acid sequence of SEQ ID NO: 92. In yet another embodiment, this chimeric receptor is encoded by the amino acid sequence of SEQ ID NO: 93. In some embodiments, the sequence of the chimeric receptor may vary from SEQ ID NO. 92, but remains, depending on the embodiment, at least 70%, at least 75%,

at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 92. In several embodiments, while the chimeric receptor may vary from SEQ ID NO. 92, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function. Additionally, in several embodiments, this construct can optionally be co-expressed with mbIL15. In further embodiments, polynucleotides are provided encoding a NKG2D/CD28/CD3zeta/4-1BB chimeric receptor, which comprises an NKG2D fragment extracellular receptor domain that binds native ligands of NKG2D, a CD8a hinge, a CD28 transmembrane/intracellular domain, and 4-1BB and CD3zeta. In one embodiment, this chimeric receptor comprises the nucleic acid sequence of SEQ ID NO: 94. In yet another embodiment, this chimeric receptor is encoded by the amino acid sequence of SEQ ID NO: 95. In some embodiments, the sequence of the chimeric receptor may vary from SEQ ID NO. 94, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 94. In several embodiments, while the chimeric receptor may vary from SEQ ID NO. 94, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function. Additionally, in several embodiments, this construct can optionally be co-expressed with mbIL15. In further embodiments, polynucleotides are provided encoding a NKG2D/IgG4/CD28/CD3zeta chimeric receptor, which comprises an NKG2D fragment extracellular receptor domain that binds native ligands of NKG2D, an IgG4 hinge, a CD28 transmembrane/intracellular domain, and CD3zeta. In one embodiment, this chimeric receptor comprises the nucleic acid sequence of SEQ ID NO: 98. In yet another embodiment, this chimeric receptor is encoded by the amino acid sequence of SEQ ID NO: 99. In some embodiments, the sequence of the chimeric receptor may vary from SEQ ID NO. 98, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 98. In several embodiments, while the chimeric receptor may vary from SEQ ID NO. 98, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function. Additionally, in several embodiments, this construct can optionally be co-expressed with mbIL15.

[00171] NCR1 (NKp46), NCR2 (NKp44) and NCR3 (NKp30) are receptors on NK cells that transduce activation signals upon ligand binding. Thus, in several embodiments, polynucleotides are provided encoding a NKG2D/NCR1 chimeric receptor, which comprises an NKG2D fragment extracellular receptor domain that binds native

ligands of NKG2D and a NCR1 peptide comprising both the transmembrane region and intracellular effector domain. In one embodiment, this chimeric receptor comprises the nucleic acid sequence of SEQ ID NO: 27. In yet another embodiment, this chimeric receptor is encoded by the amino acid sequence of SEQ ID NO: 28. In some embodiments, the sequence of the chimeric receptor may vary from SEQ ID NO. 30, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 27. In several embodiments, while the chimeric receptor may vary from SEQ ID NO. 27, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function. Additionally, in several embodiments, this construct can optionally be co-expressed with mbIL15.

[00172] In several additional embodiments, polynucleotides are provided encoding a NKG2D/NCR1/4-1BB chimeric receptor, wherein the signaling domain of 4-1BB acts as a second transducer of activating signals in the effector domain, leading to synergistically enhanced NK cell activation and cytotoxicity. In several additional embodiments, polynucleotides are provided encoding a NKG2D/NCR2 chimeric receptor, which comprises an NKG2D fragment extracellular receptor domain that binds native ligands of NKG2D and a NCR2 peptide comprising both the transmembrane region and intracellular effector domain. As with NCR1, in several embodiments these constructs are particularly amenable for use in creating NK cells expressing the chimeric receptor, due to their relatively small size and simplicity on sequence. However, they retain the ability, in several embodiments, to yield highly effective NK cells, despite the apparent simplicity of the construct. Additionally, in several embodiments, these constructs can optionally be co-expressed with mbIL15.

[00173] In several additional embodiments, polynucleotides are provided encoding a NKG2D/NCR3 chimeric receptor, which comprises an NKG2D fragment extracellular receptor domain that binds native ligands of NKG2D and a NCR3 peptide comprising both the transmembrane region and intracellular effector domain. As with NCR1 and or NCR2, in several embodiments these constructs are particularly amenable for use in creating NK cells expressing the chimeric receptor, due to their relatively small size and simplicity on sequence. However, they retain the ability, in several embodiments, to yield highly effective NK cells, despite the apparent simplicity of the construct. In one embodiment, this chimeric receptor comprises the nucleic acid sequence of SEQ ID NO: 29. In yet another embodiment, this chimeric receptor is

encoded by the amino acid sequence of SEQ ID NO: 30. In some embodiments, the sequence of the chimeric receptor may vary from SEQ ID NO. 29, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 29. In several embodiments, while the chimeric receptor may vary from SEQ ID NO. 29, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function. Additionally, in several embodiments, this construct can optionally be co-expressed with mbIL15.

[00174] In several additional embodiments, polynucleotides are provided encoding a NKG2D/NCR2/4-1BB chimeric receptor, wherein the signaling domain of 4-1BB acts as a second transducer of activating signals in the effector domain, thereby leading to a synergistic effect between the signaling domains, and unexpectedly effectively cytotoxic NK cells. Additionally, in several embodiments, this construct can optionally be co-expressed with mbIL15.

[00175] In several additional embodiments, polynucleotides are provided encoding a NKG2D/NCR3/4-1BB chimeric receptor, wherein the signaling domain of 4-1BB acts as a second transducer of activating signals in the effector domain, thereby leading to a synergistic effect between the signaling domains, and unexpectedly effectively cytotoxic NK cells. Additionally, in several embodiments, this construct can optionally be co-expressed with mbIL15.

[00176] In some embodiments the surface expression and efficacy of the chimeric receptors disclosed herein are enhanced by variations in a spacer region (hinge), which, in several embodiments, are located in the extracellular domain between the NKG2D fragment and the transmembrane domain. In some embodiments, the hinge regions can be included between other portions of the chimeric receptor (e.g., between intracellular and transmembrane domains, or between multiple intracellular domains). In some embodiments, domains that serve certain purposes as disclosed elsewhere herein, can serve additional functions. For example, in several embodiments, CD8a is repurposed to serve as a hinge region (encoded, in several embodiments, by the nucleic acid sequence of SEQ ID NO: 5). In yet another embodiment, the hinge region comprises an N-terminal truncated form of CD8a and/or a C-terminal truncated form of CD8a. Depending on the embodiment, these truncations can be at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% homologous to the hinge encoded by SEQ ID NO. 5. In several additional embodiments, the hinge comprises

spans of Glycine and Serine residues (herein termed “GS linkers”) where GS_n represents the sequence (Gly-Gly-Gly-Gly-Ser)_n (SEQ ID NO. 42). In one embodiment, the hinge comprises both CD8a and GS₃, and is encoded by the amino acid sequence of SEQ ID NO: 32, for example, where n=3. In additional embodiments, the value of n may be equal to 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or greater depending on the embodiment. In several embodiments, the hinge could also be structured as GS_n/CD8a. Alternatively, the GS linker can comprise the entire hinge region. In one such embodiment, the hinge region is encoded by the nucleic acid sequence of SEQ ID NO: 33. In another such embodiment, the hinge region is encoded by the nucleic acid sequence of SEQ ID NO: 34. In several embodiments, IgG4 is repurposed as a hinge region (encoded, in several embodiments, by the nucleic acid sequence of SEQ ID NO: 104). In yet another embodiment, the hinge region comprises an N-terminal truncated form of IgG4 and/or a C-terminal truncated form of IgG4. Depending on the embodiment, these truncations can be at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% homologous to the hinge encoded by SEQ ID NO. 104.

[00177] In several embodiments, the chimeric receptor constructs employ a 2B4 intracellular signaling domain. In several embodiments, this domain is encoded by the amino acid sequence of SEQ ID NO. 35. In some embodiments, the 2B4 domain is encoded by the nucleic acid sequence of SEQ ID NO. 36. In some embodiments, the sequence of the 2B4 intracellular domain used in a chimeric receptor may vary from SEQ ID NO. 36, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 36. In several embodiments, while the signaling domain of the chimeric receptor may vary from SEQ ID NO. 36, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function. Likewise, in several embodiments an NKp80 intracellular domain is used, in several embodiments. In some embodiments, the NKp80 domain is the sole intracellular signaling domain, while in some embodiments, that domain is used in conjunction with one or more additional domains. In several embodiments, the NKp80 is encoded by the amino acid sequence of SEQ ID NO. 37. In some embodiments, the NKp80 domain is encoded by the nucleic acid sequence of SEQ ID NO. 38. In some embodiments, the sequence of the NKp80 intracellular domain used in a chimeric receptor may vary from SEQ ID NO. 38, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 38. In several

embodiments, while the signaling domain of the chimeric receptor may vary from SEQ ID NO. 38, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function.

[00178] In several embodiments, the chimeric receptor uses a portion of a beta-adrenergic receptor as a transmembrane domain. In several embodiments, the portion comprises a portion of the beta-adrenergic extracellular domain. In several embodiments, the portion is a portion of the beta-adrenergic receptor transmembrane domain. In several embodiments, a combination of an extracellular domain and a transmembrane domain of the beta adrenergic receptor is used. Depending on the embodiment the portions are from the beta-1 and/or beta-2 adrenergic receptor. In several embodiments, a portion of the N-terminal extracellular region of the beta-2 adrenergic receptor is used. In several embodiments that portion has the amino acid sequence of SEQ ID NO. 39. In some embodiments, the extracellular beta-2 adrenergic domain is encoded by the nucleic acid sequence of SEQ ID NO. 40. In some embodiments, the sequence of the extracellular beta-2 adrenergic domain used in a chimeric receptor may vary from SEQ ID NO. 39, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 39. In several embodiments, the first transmembrane helix of the beta-2 adrenergic receptor is used, optionally in conjunction with the extracellular beta-2 adrenergic domain. In several embodiments, the first transmembrane helix of the beta-2 adrenergic receptor has the amino acid sequence of SEQ ID NO. 41. In some embodiments, the first transmembrane helix of the beta-2 adrenergic receptor is encoded by the nucleic acid sequence of SEQ ID NO. 42. In some embodiments, the sequence of the first transmembrane helix of the beta-2 adrenergic receptor used in a chimeric receptor may vary from SEQ ID NO. 41, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 41.

[00179] In one embodiment, the chimeric receptor comprises CD8, truncated NKG2D, CD8a, transmembrane domain, a CD16 intracellular domain, and 4-1BB as a costimulatory molecule. In several embodiments, such a construct is encoded by SEQ ID NO. 25. In some embodiments, the chimeric receptor may vary from SEQ ID NO. 25, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 25. In several embodiments, hinge regions surrounding CD8 are increased by way of addition of

GS linkers (disclosed herein), such as GS3, by way of non-limiting example. In such embodiments, the construct is encoded by the nucleic acid of SEQ ID NO. 43. In some embodiments, the chimeric receptor may vary from SEQ ID NO. 43, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 43. In several embodiments, hinge regions surrounding CD8 are increased by way of addition of longer GS linkers, such as GS12, or other linker. In several embodiments, hinge regions are decreased by way of truncating CD8. For example, in several embodiments, the N-terminal region of CD8a is truncated by at least 20%, at least 30%, at least 40%, or at least 50%. In several embodiments, the CD8 hinge is replaced with a GS linker. For example, in several embodiments, the hinge region comprises a GS3 linker, thereby the construct comprises NKG2D-GS3-CD16-4-1BB. In one embodiment, such a construct is encoded by the nucleic acid of SEQ ID NO. 44. In some embodiments, the chimeric receptor may vary from SEQ ID NO. 44, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 44. In several embodiments, neither CD8 nor GS_n are used. In one embodiment, such a construct is encoded by the nucleic acid of SEQ ID NO. 45. In some embodiments, the chimeric receptor may vary from SEQ ID NO. 45, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 45.

[00180] As discussed above, in several embodiments, codon optimized sequences are employed. For example in several embodiments, codon optimization (full or partial) is performed on the NKG2D domain of a chimeric receptor. In several embodiments, however, codon optimization is not performed. In several embodiments, a chimeric receptor construct is provided with an NKG2D extracellular domain that is not optimized, a CD8a hinge, and a 4-1BB signaling domain. In several embodiments, a chimeric receptor construct is provided with an NKG2D extracellular domain that is not optimized, a CD8a hinge and transmembrane domain, and a 4-1BB signaling domain. In several embodiments, a chimeric receptor construct is provided with an NKG2D extracellular domain that is not optimized, a CD8a hinge and transmembrane domain, a 4-1BB signaling domain and a 2B4 signaling domain. In several embodiments, such a construct has the nucleic acid sequence of SEQ ID NO. 46. In some embodiments, the chimeric receptor may vary from SEQ ID NO. 46, but remains, depending on the

embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 46.

[00181] In several embodiments, a chimeric receptor construct is provided with an NKG2D extracellular domain that is not optimized, a beta-adrenergic derived transmembrane domain, and a 4-1BB signaling domain. In several embodiments, a chimeric receptor construct is provided with an NKG2D extracellular domain that is not optimized, a beta-adrenergic derived transmembrane domain made up of the extracellular region of the beta-2 adrenergic receptor and the first transmembrane helix of the beta-2 adrenergic receptor, and a 4-1BB signaling domain. In several embodiments, a chimeric receptor construct is provided with an NKG2D extracellular domain that is not optimized, a beta-adrenergic derived transmembrane domain made up of the extracellular region of the beta-2 adrenergic receptor and the first transmembrane helix of the beta-2 adrenergic receptor, a 4-1BB signaling domain and a 2B4 signaling domain. In several embodiments, such a construct has the nucleic acid sequence of SEQ ID NO. 47. In some embodiments, the chimeric receptor may vary from SEQ ID NO. 47, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 47.

[00182] In several embodiments, a chimeric receptor construct is provided with an NKG2D extracellular domain that is not optimized, a CD8a hinge, and a 2B4 signaling domain. In several embodiments, a chimeric receptor construct is provided with an NKG2D extracellular domain that is not optimized, a CD8a hinge and transmembrane domain, and both a 2B4 and a 4-1BB signaling domain. In several embodiments, a chimeric receptor construct is provided with an NKG2D extracellular domain that is not optimized, a CD8a hinge and transmembrane domain, a 4-1BB signaling domain and a 2B4 signaling domain, as well as a NKp80 domain. In several embodiments, a GS linker, such as a GS3 linker joins the 2B4 and NKp80 domains. In several embodiments, such a construct has the nucleic acid sequence of SEQ ID NO. 48. In some embodiments, the chimeric receptor may vary from SEQ ID NO. 48, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 48.

[00183] In several embodiments, a chimeric receptor construct is provided with an NKG2D extracellular domain that is not optimized, a CD8a hinge, and a NKp80 signaling domain. In several embodiments, a chimeric receptor construct is provided with an NKG2D extracellular domain that is not optimized, a CD8a hinge and transmembrane

domain, and a NKp80 signaling domain. In several embodiments, a chimeric receptor construct is provided with an NKG2D extracellular domain that is not optimized, a CD8a hinge and transmembrane domain, a 4-1BB signaling domain and a NKp80 domain. In several embodiments, a GS linker, such as a GS3 linker joins the 4-1BB and NKp80 domains. In several embodiments, such a construct has the nucleic acid sequence of SEQ ID NO. 49. In some embodiments, the chimeric receptor may vary from SEQ ID NO. 49, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 49.

[00184] In several embodiments, a CD8 transmembrane domain is coupled with a 2B4 intracellular domain. In several embodiments, a CD8 transmembrane domain is replaced with a 2B4 domain that is transmembrane and intracellular. In several embodiments, the CD8 transmembrane domain is replaced with 2B4 and 4-1BB is expressed in a proximal configuration.

[00185] In several embodiments, a CD16 intracellular signaling domain is coupled with a CD3zeta or gamma subunit which are exogenously expressed in *trans* to the chimeric receptors described herein. As discussed above, such constructs can result in unexpectedly enhanced signal transduction, and thus an unexpected increase in cytotoxic effects of the NK cells.

[00186] In several embodiments, the chimeric receptors are configured to dimerize, as discussed in additional detail herein. In several embodiments a truncated NKG2D receptor according to several embodiments disclosed herein is optionally dimerized. Dimerization may comprise homodimers or heterodimers, depending on the embodiment. In several embodiments, dimerization results in a shift of avidity of the chimeric receptor (and hence the NK cells expressing the receptor) to better ligand recognition with a coordinate balance in reduced (or lack) of adverse toxic effects. In still further embodiments, the extracellular receptor domain further comprises a CD8a signal peptide. In several embodiments, the chimeric receptors employ internal dimers, or repeats of one or more component subunits. For example, in several embodiments, the chimeric receptor comprises a NKG2D extracellular domain coupled to a second NKG2D extracellular domain, and a transmembrane/signaling region (or a separate transmembrane region along with a separate signaling region). In several embodiments, one or more of the NKG2D extracellular domains are codon optimized. In several embodiments, the two NKG2D extracellular domains are separated by a linker, for example a GS_n linker. In one embodiment, a GS3 linker is used. In several embodiments, the transmembrane

domain comprises an extracellular region of the beta-adrenergic receptor. In several embodiments, the transmembrane domain transmembrane domain comprises an extracellular region of the beta-2 adrenergic receptor and further comprises the first transmembrane domain of the beta-2 adrenergic receptor. In several embodiments, the signaling region comprises 4-1BB. In several embodiments, the signaling region comprises NKp80. In several embodiments, the signaling region comprises a CD16 transmembrane-intracellular domain. In several embodiments, the signaling region comprises 4-1BB in conjunction with NKp80 or a CD16 transmembrane-intracellular domain. In several embodiments, the chimeric receptor has the nucleic acid sequence of SEQ ID NO. 50. In some embodiments, the chimeric receptor may vary from SEQ ID NO. 50, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 50. In several embodiments, the chimeric receptor has the nucleic acid sequence of SEQ ID NO. 51. In some embodiments, the chimeric receptor may vary from SEQ ID NO. 51, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 51. In several embodiments, the chimeric receptor has the nucleic acid sequence of SEQ ID NO. 52. In some embodiments, the chimeric receptor may vary from SEQ ID NO. 52, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 52. In several embodiments, the chimeric receptor comprises a hinge region. In several embodiments, CD8a is repurposed to serve as a hinge region (encoded, in several embodiments, by the nucleic acid sequence of SEQ ID NO: 5). In several embodiments, the chimeric receptor comprises a CD8a transmembrane domain. In several embodiments, the signaling region comprises 4-1BB in conjunction with 2B4 and CD3zeta. In some embodiments, the chimeric receptor comprises the fragment of NKG2D that is codon optimized coupled to a GS3 linker, an additional NKG2D fragment, a CD8a hinge, a CD8a transmembrane domain, and an effector domain comprising 4-1BB and CD3zeta. In several embodiments, the chimeric receptor has the nucleic acid sequence of SEQ ID NO. 66. In some embodiments, the chimeric receptor may vary from SEQ ID NO. 66, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 50. In several embodiments, the chimeric receptor chimeric receptor comprises the amino acid sequence of SEQ ID NO: 67. In some embodiments, the chimeric receptor may vary from SEQ ID NO. 66, but

remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 50.

[00187] In several embodiments, the chimeric receptors are configured to be bispecific, as discussed in additional detail herein. In several embodiments, a truncated NKG2D receptor according to several embodiments disclosed herein is bispecific due to a second peptide that binds, for example, non-NKG2D ligands. In several embodiments, bi-specificity results in a shift of the targeting of the chimeric receptor (and hence the NK cells expressing the receptor) to better target cell recognition with a coordinate balance in reduced (or lack) of adverse toxic effects. In still further embodiments, the extracellular receptor domain further comprises a CD8a signal peptide. For example, in several embodiments, the chimeric receptor comprises a NKG2D extracellular domain coupled to a second extracellular domain that binds other (non-NKG2D) ligands, and a transmembrane/signaling region (or a separate transmembrane region along with a separate signaling region). In several embodiments, the two extracellular domains are separated by a linker, for example a GS_n linker. In one embodiment, a GS3 linker is used.

[00188] According to several embodiments disclosed herein, additional chimeric receptors employing codon optimized NKG2D domains are provided for (optionally, these constructs can also be replicated with non-optimized or partially optimized domains). For example, in several embodiments, a codon optimized extracellular domain is coupled with a hinge and at least two transmembrane/signaling domains. In several embodiments, the multiple signaling domains provide enhanced cytotoxic efficacy of the NK cells because multiple, non-redundant signal cascades are set in motion. While in some embodiments these multiple pathways may converge on a single signaling molecule (e.g., IFN γ), the overall cytotoxic effect is unexpectedly increased because of the overall magnitude of signaling molecules driving a cytotoxic endpoint. As a non-limiting example, in several embodiments an NKG2D is coupled to a CD8a hinge followed by a CD16 transmembrane-intracellular signaling domain and a 4-1BB signaling domain. In several embodiments, this construct further comprises a 2B4 signaling domains. In several embodiments, such a chimeric receptor has the nucleic acid sequence of SEQ ID NO. 53. In some embodiments, the chimeric receptor may vary from SEQ ID NO. 53, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 53. In additional embodiments, the NKG2D-CD8a-CD16IC/TM construct further

comprises a NKp80 signaling domain. In several embodiments, such a construct further comprises a GS3 linker between the 4-1BB and NKp80 domains. In several embodiments, such a chimeric receptor has the nucleic acid sequence of SEQ ID NO. 54. In some embodiments, the chimeric receptor may vary from SEQ ID NO. 54, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 54.

[00189] In still additional embodiments, certain components of a chimeric receptor can be replaced with one or more additional subunits that lead to enhanced efficacy (e.g., activation or cytotoxicity of NK cells). For example, in one embodiment, a CD16 intracellular signaling domain can be replaced with a quad-repeat of DAP10 (e.g., 4xDAP10). In an additional embodiment, a CD16 intracellular signaling domain can be replaced with a Zap70 subunit. Certain such embodiments lead to unexpectedly enhanced NK cell cytotoxicity.

[00190] In several additional embodiments, the effector domain comprises one or more consensus hemi-ITAM sequences to enhance the transduction of activation signaling upon ligand binding. In additional embodiments, the inclusion of a GS linker between the signaling domains of 4-1BB, CD16, NCR1, NCR2 and/or NCR3 enhances signal transduction. Moreover, in several embodiments one or both of CD3 ζ and FcR γ are additionally expressed along with the chimeric receptors described herein (either on the same or a separate construct), which results in unexpectedly enhanced signal transduction, and thus an unexpected increase in cytotoxic effects of the NK cells. Depending on the embodiment, the engineered expression of one or more of CD3 ζ and FcR γ supplements endogenous expression of these molecules by NK cells, thereby further enhancing the signaling and ultimate cytotoxic potency of the NK cells.

[00191] Optionally, depending on the embodiment, any of the polynucleotides disclosed herein may also encode truncations and/or variants of one or more of the constituent subunits of a chimeric receptor, yet retain their ability to direct NK cells to target cells and in several embodiments unexpectedly enhance cytotoxicity upon binding. In addition, any of the polynucleotides disclosed herein may also optionally include codon-optimized nucleotide sequences encoding the various constituent subunits of a chimeric receptor. As used herein, the terms “fragment” and “truncated” shall be given their ordinary meaning and shall also include N- and C-terminal deletion variants of proteins.

[00192] The polynucleotides encoding the chimeric receptors described herein may be inserted into vectors to achieve recombinant protein expression in NK cells. In one embodiment, the polynucleotide is operably linked to at least one regulatory element for the expression of the chimeric receptor. In specific embodiments, transcriptional regulatory elements heterologous, such as, for example an internal ribosome entry site (IRES) or enhancer element, to the peptides disclosed herein are employed to direct the transcription of the chimeric receptor. In some embodiments, the polynucleotide comprises one or more cytosolic protease cleavage sites. In some embodiments, the cleavage site is recognized and cleaved by a cytosolic protease. In some embodiments, this cleavage site is selected from the group comprising a T2A cleavage site, a P2A cleavage site, an E2A cleavage site, and an F2A cleavage site. Depending on the embodiment, the various constituent parts of a chimeric receptor can be delivered to an NK cell in a single vector, or alternatively in multiple vectors. In some embodiments, a chimeric receptor construct is delivered in a single vector, while another factor that enhances efficacy of the chimeric receptor, such as mbIL15, is delivered in a separate vector. In several embodiments, a chimeric receptor and a factor that enhances efficacy of the chimeric receptor (e.g., mbIL15), is delivered in a single vector. Regardless of the number of vectors used, any polynucleotide may optionally include a tag sequence, allowing identification of the presence of NK cells expressing the construct. For example, in several embodiments a FLAG tag (DYKDDDDK, SEQ ID NO. 55) is used. Also available are other tag sequences, such as a polyhistidine tag (His-tag) (HHHHHH, SEQ ID NO. 56), HA-tag or myc-tag (EQKLISEEDL; SEQ ID NO: 57). Alternatively, green fluorescent protein, or other fluorescent moiety, is used. Combinations of tag types can also be used, to individually recognize sub-components of a chimeric receptor.

[00193] In several embodiments, the polynucleotide encoding the chimeric receptor is an mRNA that may be introduced into NK cells by electroporation. In another embodiment, the vector is a virus, preferably a retrovirus, which may be introduced into NK cells by transduction. In several embodiments, the vector is a Murine Stem Cell Virus (MSCV). In additional embodiments, other vectors may be used, for example lentivirus, adenovirus, adeno-associated virus, and the like may be used. In several embodiments, non-HIV-derived retroviruses are used. The vector chosen will depend upon a variety of factors, including, without limitation, the strength of the transcriptional regulatory elements and the cell to be used to express a protein. The vector can be a

plasmid, phagemid, cosmid, viral vector, phage, artificial chromosome, and the like. In additional embodiments, the vectors can be episomal, non-homologously, or homologously integrating vectors, which can be introduced into the appropriate cells by any suitable means (transformation, transfection, conjugation, protoplast fusion, electroporation, calcium phosphate-precipitation, direct microinjection, etc.) to transform them. Other approaches to induce expression of chimeric receptors in NK cells are used in several embodiments, including for example, the SV40 early promoter region, the promoter contained in the 3' long terminal repeat of Rous sarcoma virus, the herpes thymidine kinase promoter, the regulatory sequences of the metallothionein gene, an adenovirus (ADV) promoter, a cytomegalovirus (CMV) promoter, the bovine papilloma virus (BPV) promoter, the parovirus B19p6 promoter, the beta-lactamase promoter, the tac promoter, the nopaline synthetase promoter region or the cauliflower mosaic virus 35S RNA promoter, the promoter of ribulose biphosphate carboxylase, the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, the PGK (phosphoglycerol kinase) promoter, the synthetic MND promoter containing the U3 region of a modified MoMuLV LTR with the myeloproliferative sarcoma virus enhancer, and the alkaline phosphatase promoter.

[00194] Natural killer cells may be engineered to express the chimeric receptors disclosed herein. Chimeric receptor expression constructs may be introduced into NK cells using any of the techniques known to one of skill in the art. In one embodiment, the chimeric receptors are transiently expressed in the NK cells. In another embodiment, the chimeric receptors are stably expressed in NK cells. In an additional embodiment, the NK cells are autologous cells. In yet another embodiment, the NK cells are donor-derived (allogeneic) cells.

[00195] Further provided herein are methods of treating a subject having cancer or an infectious disease comprising administering to the subject a composition comprising NK cells engineered to express a chimeric receptor as disclosed herein, the chimeric receptor designed to target a marker or ligand expressed differentially on the damaged or diseased cells or tissue (e.g., expressed to a different degree as compared to a normal cell or tissue). As used herein, the terms “express”, “expressed” and “expression” be given their ordinary meaning and shall refer to allowing or causing the information in a gene or polynucleotide sequence to become manifest, for example producing a protein by activating the cellular functions involved in transcription and translation of a corresponding gene or DNA sequence. The expression product itself, e.g., the resulting

protein, may also be said to be “expressed” by the cell. An expression product may be characterized as intracellular, extracellular or transmembrane. The term “intracellular” shall be given its ordinary meaning and shall refer to inside a cell. The term “extracellular” shall be given its ordinary meaning and shall refer to outside a cell. The term “transmembrane” shall be given its ordinary meaning and shall refer to at least a portion of a polypeptide is embedded in a cell membrane. The term “cytoplasmic” shall be given its ordinary meaning and shall refer to residing within the cell membrane, outside the nucleus. As used herein, the terms “treat,” “treating,” and “treatment” in the context of the administration of a therapy to a subject shall be given their ordinary meaning and shall refer to the beneficial effects that a subject derives from a therapy. In certain embodiments, treatment of a subject with a genetically engineered cell(s) described herein achieves one, two, three, four, or more of the following effects, including, for example: (i) reduction or amelioration the severity of disease or symptom associated therewith; (ii) reduction in the duration of a symptom associated with a disease; (iii) protection against the progression of a disease or symptom associated therewith; (iv) regression of a disease or symptom associated therewith; (v) protection against the development or onset of a symptom associated with a disease; (vi) protection against the recurrence of a symptom associated with a disease; (vii) reduction in the hospitalization of a subject; (viii) reduction in the hospitalization length; (ix) an increase in the survival of a subject with a disease; (x) a reduction in the number of symptoms associated with a disease; (xi) an enhancement, improvement, supplementation, complementation, or augmentation of the prophylactic or therapeutic effect(s) of another therapy. Administration can be by a variety of routes, including, without limitation, intravenous, intra-arterial, subcutaneous, intramuscular, intrahepatic, intraperitoneal and/or local delivery to an affected tissue. Doses of NK cells can be readily determined for a given subject based on their body mass, disease type and state, and desired aggressiveness of treatment, but range, depending on the embodiments, from about 10^5 cells per kg to about 10^{12} cells per kg (e.g., $10^5 - 10^7$, $10^7 - 10^{10}$, $10^{10} - 10^{12}$ and overlapping ranges therein). In one embodiment, a dose escalation regimen is used. In several embodiments, a range of NK cells is administered, for example between about 1×10^6 cells/kg to about 1×10^8 cells/kg. Depending on the embodiment, various types of cancer or infection disease can be treated. Various embodiments provided for herein include treatment or prevention of the following non-limiting examples of cancers including, but not limited to, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML),

adrenocortical carcinoma, Kaposi sarcoma, lymphoma, gastrointestinal cancer, appendix cancer, central nervous system cancer, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain tumors (including but not limited to astrocytomas, spinal cord tumors, brain stem glioma, craniopharyngioma, ependymoblastoma, ependymoma, medulloblastoma, medulloepithelioma), breast cancer, bronchial tumors, Burkitt lymphoma, cervical cancer, colon cancer, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), chronic myeloproliferative disorders, ductal carcinoma, endometrial cancer, esophageal cancer, gastric cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, hairy cell leukemia, renal cell cancer, leukemia, oral cancer, nasopharyngeal cancer, liver cancer, lung cancer (including but not limited to, non-small cell lung cancer, (NSCLC) and small cell lung cancer), pancreatic cancer, bowel cancer, lymphoma, melanoma, ocular cancer, ovarian cancer, pancreatic cancer, prostate cancer, pituitary cancer, uterine cancer, and vaginal cancer.

[00196] Further, various embodiments provided for herein include treatment or prevention of the following non-limiting examples of infectious diseases including, but not limited to, infections of bacterial origin may include, for example, infections with bacteria from one or more of the following genera: *Bordetella*, *Borrelia*, *Brucella*, *Campylobacter*, *Chlamydia* and *Chlamydophila*, *Clostridium*, *Corynebacterium*, *Enterococcus*, *Escherichia*, *Francisella*, *Haemophilus*, *Helicobacter*, *Legionella*, *Leptospira*, *Listeria*, *Mycobacterium*, *Mycoplasma*, *Neisseria*, *Pseudomonas*, *Rickettsia*, *Salmonella*, *Shigella*, *Staphylococcus*, *Streptococcus*, *Treponema*, *Vibrio*, and *Yersinia*, and mutants or combinations thereof. In several embodiments, methods are provided to treat a variety to treat viral infections, such as those caused by one or more viruses, such as adenovirus, Coxsackievirus, Epstein-Barr virus, hepatitis a virus, hepatitis b virus, hepatitis c virus, herpes simplex virus, type 1, herpes simplex virus, type 2, cytomegalovirus, ebola virus, human herpesvirus, type 8, HIV, influenza virus, measles virus, mumps virus, human papillomavirus, parainfluenza virus, poliovirus, rabies virus, respiratory syncytial virus, rubella virus, and varicella-zoster virus.

[00197] In some embodiments, also provided herein are nucleic acid and amino acid sequences that have homology of at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% (and ranges therein) as compared with the respective nucleic acid or amino acid sequences of SEQ ID NOS. 1-68 and that also exhibit one or more of the functions as compared with the respective SEQ ID NOS. 1-68: including but not limited to, (i) enhanced proliferation, (ii) enhanced activation, (iii) enhanced cytotoxic activity against

cells presenting ligands to which NK cells harboring receptors encoded by the nucleic acid and amino acid sequences bind, (iv) enhanced homing to tumor or infected sites, (v) reduced off target cytotoxic effects, (vi) enhanced secretion of immunostimulatory cytokines and chemokines (including, but not limited to IFN γ , TNF α , IL-22, CCL3, CCL4, and CCL5), (vii) enhanced ability to stimulate further innate and adaptive immune responses, and (viii) combinations thereof.

[00198] Additionally, in several embodiments, there are provided amino acid sequences that correspond to any of the nucleic acids disclosed herein, while accounting for degeneracy of the nucleic acid code. Furthermore, those sequences (whether nucleic acid or amino acid) that vary from those expressly disclosed herein, but have functional similarity or equivalency are also contemplated within the scope of the present disclosure. The foregoing includes mutants, truncations, substitutions, or other types of modifications.

[00199] There are provided for herein, according to several embodiments, polynucleotides encoding chimeric receptors, comprising an extracellular receptor domain, wherein the extracellular receptor domain comprises a peptide that binds native ligands of Natural Killer Group 2 member D (NKG2D), wherein the peptide that binds native ligands of NKG2D is a fragment of NKG2D, an effector domain comprising a transmembrane region and an intracellular signaling domain. In several embodiments, the fragment of NKG2D is encoded by a polynucleotide comprising the sequence of SEQ ID NO. 2 or 3 or 68, or functional equivalent thereof. In several embodiments, the polynucleotide encodes an effector domain comprising CD16. In several embodiments, the polynucleotide encodes an effector domain comprising NCR1. In several embodiments, the polynucleotide encodes an effector domain comprising NCR2. In several embodiments, the polynucleotide encodes an effector domain comprising NCR3. In some embodiments, the polynucleotide encodes an additional effector domain portion comprising 4-1BB. In several embodiments, the polynucleotide encodes a chimeric receptor made up of NKG2D and CD16. In several embodiments, the polynucleotide encodes a chimeric receptor made up of NKG2D and NCR1. In several embodiments, the polynucleotide encodes a chimeric receptor made up of NKG2D and NCR2. In additional embodiments, the polynucleotide encodes a chimeric receptor made up of NKG2D coupled to CD16 and optionally 4-1BB. In several embodiments, CD16 is replaced by NCR1, and in some embodiments, by NCR2, or even NCR3, depending on the

embodiment. In several embodiments, the effector domain further comprises a GS linker between, for example, 4-1BB and one of CD16, NCR1, NCR2, or NCR3.

[00200] In several embodiments, the extracellular receptor domain further comprises a hinge region. In several embodiments, the hinge region comprises CD8a. However, in additional embodiments, the hinge region further comprises one or more linkers, which in some embodiments, comprise GS9, CD8a/GS3, truncated CD8a, GS3, and the like.

[00201] In several embodiments, the extracellular receptor domain further comprises a CD8a signal peptide. In several embodiments, the effector domain comprises one or more hemi-ITAM sequences. In several embodiments, the chimeric receptor does not comprise DNAX-activating protein 10 (DAP10). In several embodiments, the chimeric receptor does not comprise an ITAM motif, but rather employs an alternative signaling region, such as an ITSM, hemi-tam or other co-stimulatory region.

[00202] In one embodiment, there is provided a polynucleotide encoding a chimeric receptor comprising an extracellular receptor domain, wherein the extracellular receptor domain comprises a peptide that binds native ligands of Natural Killer Group 2 member D (NKG2D), wherein the peptide that binds native ligands of NKG2D is a fragment of NKG2D, a transmembrane region, wherein the transmembrane region comprises CD8a, and an effector domain, wherein the effector domain comprises 4-1BB and CD3 zeta, wherein the polynucleotide is co-expressed with an additional construct encoding membrane-bound interleukin 15 (mbIL15).

[00203] There is also provided in several embodiments, a polynucleotide encoding a chimeric receptor comprising an extracellular receptor domain, wherein the extracellular receptor domain comprises a peptide that binds native ligands of Natural Killer Group 2 member D (NKG2D), wherein the peptide that binds native ligands of NKG2D is a fragment of NKG2D, a transmembrane region, wherein the transmembrane region comprises CD8a, and an effector domain, wherein the effector domain comprises 4-1BB and the intracellular domain of 2B4 or DAP10. The polynucleotide encoding a chimeric receptor as described herein comprises a second peptide that binds native ligands of NKG2D. In several embodiments, the native ligands of NKG2D include, but are not limited to, MICA, MICB, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5 or ULBP6. In several embodiments, the portion of the chimeric receptor that binds native ligands of NKG2D has at least 80% homology to SEQ ID NO: 1, 2, 3, or 68.

[00204] In several embodiments, the provided polynucleotide is an mRNA. In some embodiments, the polynucleotide is operably linked to at least one regulatory element for the expression of the chimeric receptor. As used herein, the terms “nucleic acid,” “nucleotide,” and “polynucleotide” shall be given their ordinary meanings and shall include deoxyribonucleotides, deoxyribonucleic acids, ribonucleotides, and ribonucleic acids, and polymeric forms thereof, and includes either single- or double-stranded forms. Nucleic acids include naturally occurring nucleic acids, such as deoxyribonucleic acid (“DNA”) and ribonucleic acid (“RNA”) as well as nucleic acid analogs. Nucleic acid analogs include those which include non-naturally occurring bases, nucleotides that engage in linkages with other nucleotides other than the naturally occurring phosphodiester bond or which include bases attached through linkages other than phosphodiester bonds. Thus, nucleic acid analogs include, for example and without limitation, phosphorothioates, phosphorodithioates, phosphorotriesters, phosphoramidates, boranophosphates, methylphosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs), locked-nucleic acids (LNAs), and the like. As used herein, the term “operably linked,” for example in the context of a regulatory nucleic acid sequence being “operably linked” to a heterologous nucleic acid sequence, shall be given its ordinary meaning and shall mean that the regulatory nucleic acid sequence is placed into a functional relationship with the heterologous nucleic acid sequence. In the context of an IRES, “operably linked to” refers to a functional linkage between a nucleic acid sequence containing an internal ribosome entry site and a heterologous coding sequence initiation in the middle of an mRNA sequence resulting in translation of the heterologous coding sequence. As used herein, the term “vector” shall be given its ordinary meaning and shall refer to a vehicle by which a DNA or RNA sequence (e.g., a foreign gene) can be introduced into a genetically engineered cell, so as to transform the genetically engineered cell and promote expression (e.g., transcription and/or translation) of the introduced sequence. Vectors include viruses, plasmids, phages, etc. The term “chimeric receptor” as used herein shall be given its ordinary meaning and shall refer to a cell-surface receptor comprising at least two polypeptide domains not naturally found together on a single protein. The term “chimeric receptor complex” as used herein refers to a first polypeptide, which may comprise at least two polypeptide domains in a combination that are not naturally found together on a single protein, which first polypeptide is associated with a second polypeptide, for example, an adaptor polypeptide, a signaling molecule, or a stimulatory molecule. Additional terms relating to

generation and use of chimeric receptors as disclosed here are readily understood by one of ordinary skill in the art and can also be found in International Publication WO 2014/117121 and US Patent No. 7,994,298, each of which are incorporated by reference in their entirety herein.

[00205] Additionally provided, according to several embodiments, is a vector comprising the polynucleotide encoding any of the polynucleotides provided for herein, wherein the polynucleotides are optionally operatively linked to at least one regulatory element for expression of a chimeric receptor. In several embodiments, the vector is a retrovirus.

[00206] Further provided herein are engineered natural killer cells comprising the polynucleotide, vector, or chimeric receptors as disclosed herein. In several embodiments, these NK cells are suitable for use in the treatment of prevention of disease, such as, for example, cancer and/or infectious disease.

EXAMPLES

Methods

[00207] The following experimental methods and materials were used in the non-limiting experimental examples disclosed below.

Cell Lines and Culture Conditions

[00208] The human acute lymphoblastic leukemia cell line REH, human osteosarcoma cell line U-2 OS and human embryonic kidney fibroblast 293T (HEK 293T) cells were obtained from the American Type Culture Collection (ATCC; Manassas, Virginia). REH cells were maintained and grown in Roswell Park Memorial Institute series 1640 (RPMI-1640; Gibco, Carlsbad, California) supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, Utah) and 1% penicillin-streptomycin. Both HEK 293T and U-2 OS cells were maintained and grown in Dulbecco's modified Eagles Medium (DMEM; Hyclone) supplemented with 10% FBS and 1% penicillin-streptomycin. All mammalian cells were incubated at 37 °C with 5% CO₂.

DNA Plasmids

[00209] A DNA plasmid containing the chimeric receptor NKG2D-DAP10-CD3 ζ was made as previously described (see Chang et al. Cancer Research, Vol. 73(6):

2013). Splicing by overlapping extension polymerase chain reaction (SOE-PCR) was used to fuse the individual domains forming the NKG2D-41BB-CD3 ζ construct. That construct was then inserted into the Murine Stem Cell Virus (MSCV) retroviral vector (Figure 3A). The constructs for NKG2D-CD16 and NKG2D-CD16-41BB were codon optimized and inserted into the MSCV vector (Figure 3B) by GenScript (Nanjing, China). The sequences of the constructs were verified by DNA sequencing.

Expansion of Human NK Cells

[00210] Human peripheral blood mononuclear cells (PBMCs) were obtained by Ficoll density centrifugation of blood samples from healthy adult donors. To expand the NK cells, PBMCs were cultured with K562 genetically modified with membrane bound IL-15 and 4-1BB ligand (K562-mb15-41BBL). Cells were cultured in Stem Cell Growth Medium (SCGM; Cell Genix, Freiburg, Germany) supplemented with 40IU of IL-2/ml every two days.

[00211] After 7 days of culture, NK cells were T-cell depleted using anti-CD3 Dynabeads (Invitrogen, Carlsbad, California). NK cells were then cultured in SCGM supplemented with 40-200 IU of IL-2/ml every two days.

Production of Retrovirus and Transduction of NK Cells

[00212] Production of retrovirus was carried out by transiently transfecting HEK 293T cells with retroviral packaging plasmids. HEK 293T cells were first seeded to a concentration of 2.5×10^6 cells in 12 ml of DMEM 18 hours before the transfection. The cells were then transfected with 3.5 μ g of MSCV vector containing the respective NKG2D chimeric receptors (non-limiting constructs are illustrated schematically in Figures 1B-1C and 2A-2B), 3.5 μ g of pEQ-PAM3, and 3.0 μ g of pRDF. For control, empty MSCV vector containing GFP was used. X-tremeGENE 9 DNA Transfection Reagent (Roche, Basel, Switzerland) was used for the transfection. DMEM was replaced with conditioned RPMI-1640 24 hours after the transfection.

[00213] Transduction of NKG2D chimeric receptor transgene into NK cells was done 18 hours after the changing of media. NK cells were first suspended at a concentration of 0.25×10^6 cells in 2 ml of conditioned RPMI-1640. Cells were subsequently seeded into RetroNectin (TaKaRa, Otsu, Japan) coated tubes. RPMI-1640 containing the retrovirus (virus supernatant) was harvested from the HEK 293T cell cultures and fresh conditioned medium was added back to the cultures. The viral supernatant was supplemented with 200 IU of IL-2/ml and 3 ml of the viral supernatant

was dispensed into each RetroNectin coated tubes (containing the seeded NK cells). In accordance with certain embodiments of producing NK cells, seeded NK cells were transduced six times, once every 12 hours with fresh viral media. Transduced NK cells were then harvested 48 hours after the last transduction, and cultured in SCGM with the addition of 200 IU of IL-2/ml every two days. The transduced NK cells were used for experiments 14 to 28 days after expansion.

Detection of Chimeric Receptor Expression by Flow Cytometry

[00214] Transduced NK cells were washed once with phosphate-buffered saline containing albumin, and 2 μ l of rabbit serum was added. The cells were then stained with peridinin chlorophyll (PerCP)-conjugated anti-human NKG2D antibody (clone 149810; R&D Systems, Minneapolis, USA) for 10 minutes in the dark. For controls, the transduced NK cells were stained with the respective PerCP-conjugated IgG isotype antibody. All NK cells were washed again and fixed with 300 μ l 0.5% formaldehyde before analysis using Accuri C6 flow cytometer (BD, Franklin Lakes, New Jersey). Data was analyzed using a paired t-test.

Cytotoxicity Assays

[00215] REH cells were stained with calcein AM red-orange (Thermo Fisher Scientific, Waltham, Massachusetts). REH cells were seeded into a 96-well round bottom plate (CoStar, Corning, New York). Transduced NK cells were then added at various effector: target (E:T) ratio. The cell cultures were incubated for four hours at 37 $^{\circ}$ C and 5% CO₂. Stained viable target cells were counted using the Accuri C6 flow cytometer. U-2 OS cells were seeded into 96-well flat bottom white plate (Costar) and incubated for four hours. Transduced NK cells was then added according to different E:T ratios. Cell cultures were then incubated for another four hours. Prior to analysis, Bright-Glo substrate (Promega, Madison, Wisconsin) was added to the cells. Intensity of luminescence from viable target cells was measured using FLx800 Fluorescence Reader (Bio Tek, Winooski, Vermont). Differences between intensity of luminescence and control were converted to percentage cytotoxicity.

Interferon gamma (IFN γ) Production Assay

[00216] To determine the amount of IFN γ produced by the NK cells, effector and target cells were first cultured with (E:T of 1:1) or without REH in a 96-well round bottom plate. Cells were incubated for one hour before the addition of GolgiPlug (brefeldin A; BD Biosciences). After another 5 hours of culture, cells were labeled with phycoerythrin (PE)-conjugated anti-human CD56 antibody (clone MY31, BD Biosciences). Cells were permeabilized using a proprietary permeabilization reagent and incubated for 40 minutes in the dark. The cells were then washed with a proprietary wash buffer. Intracellular IFN γ was detected with allophycocyanin (APC)-conjugated IFN γ

antibody (clone 25723.11; BD Biosciences) for 45 minutes. The cells were then fixed and analyzed using Accuri C6 flow cytometer.

Example 1 – CD3-zeta Containing NKG2D Constructs

[00217] As disclosed herein, various constructs comprising NKG2D and/or NKG2D variants coupled with various transmembrane and/or signaling domains are provided. The present experiment was conducted to evaluate the expression and cytotoxic activity of constructs comprising CD3-zeta signaling domains. Two CD3-zeta constructs were prepared and tested according to the methods and materials described above. Depending on the construct, the methods used can be readily adjusted to account for variations required for generating, expressing and testing a construct. The two constructs were NKG2D-DAP10-CD3 ζ and NKG2D-41BB-CD3 ζ . For reference Figure 1A schematically depicts an endogenous NKG2D. In NK cells, ionic interactions between the transmembrane region of NKG2D allow association with its adaptor protein DAP10 (Wu et al., 1999). Upon ligand binding, NKG2D signals are transduced through the signaling motif, YxNM, found on DAP10. CD3 ζ transduce signals through its immunoreceptor tyrosine-based activation motif (ITAM; Lanier, 2008). The two experimental constructs are illustrated schematically in Figure 1B and 1C, respectively. Figure 1B shows NKG2D-DAP10-CD3 ζ , with signaling occurring through both the YxNM and ITAM motifs. Figure 1C shows the NKG2D-41BB-CD3 ζ construct, which employs a CD8a hinge region as a transmembrane domain and 4-1BB and CD3 ζ as signaling domains.

[00218] The ability of NK cells to effectively express these constructs was first assessed. NK cells expanded from PBMC of healthy adult donors were transduced with one of the two chimeric receptors. Mock-transduced NK cells were used as control (transduced with empty MSCV vector containing GFP only). The presence and relative abundance of the chimeric receptors were determined through staining the NK cells with a Per-CP conjugated anti-NKG2D antibody. Figure 4A depicts representative flow cytometry data related to the percentage of NKG2D-positive NK cells after transduction with Mock (left panel), NKG2D-DAP10-CD3 ζ (center panel) or NKG2D-41BB-CD3 ζ (right panel) constructs. Mock transduced NK cell showed no NKG2D expression with the antibody used (which does not showing staining above an isotype-matched non-reactive antibody, despite the naturally high NKG2D expression on activated NK cells), while just under 60% of cells transduced with the NKG2D-DAP10-CD3 ζ construct

exhibited NKG2D expression above the isotype-matched non-reactive antibody control, and over 80% of NK cells transduced with the NKG2D-41BB-CD3 ζ . Pooled data for the percentage of NKG2D positive NK cells from all donors is shown in Figure 4B. Both engineered NKG2D constructs result in substantial gain in NKG2D expression compared to Mock, though there is not a significant difference between the percent expression of the two constructs. Figure 4C depicts expression data based on Mean Fluorescence Intensity (MFI), which represents, within the population expressing the NKG2D construct, the degree to which that cell expresses the construct (e.g., multiple copies of the construct per cell would yield a greater MFI). By this measure, the expression of the NKG2D-41BB-CD3 ζ is significantly greater than that of the NKG2D-DAP10-CD3 ζ construct.

[00219] Collectively, these data demonstrate that, in accordance with several embodiments disclosed herein, engineered constructs can successfully be expressed on NK cells. In several embodiments, enhanced expression of the construct can be achieved by repeated transduction of the NK cells with a particular construct. In several embodiments, the components of the constructs can be delivered to a cell in a single vector, or alternatively using multiple vectors. Depending on the embodiment, the construct itself may lead to enhanced expression, for example a linear or head to tail construct may yield increased expression because of a lesser degree of in-cell assembly that a multiple subunit construct requires.

[00220] Further to successfully expressing NKG2D constructs on NK cells, effective signaling of the NK cells is required to act on target cells. To evaluate the potency of the two populations of transduced NK cells, cytotoxicity assays were performed using cell lines that are sensitive to NK cell activity, REH (suspension cells) and U-2 OS (adherent cells). Data summarizing the percentage cytotoxicity of the different groups of NK cells against REH cells and across independent donors at two E:T ratios are shown in Figures 5A-5C (error bars represent standard deviation; all experiments are done in triplicates; $n = 3$ ($P < 0.001$)). As depicted in Figures 5A-5C, NK cells expressing either NKG2D chimeric receptor (NKG2D-DAP10-CD3 ζ shown with an arrow labeled (a) and NKG2D-41BB-CD3 ζ shown with an arrow labeled (b)) had a significantly higher cytotoxicity against REH for all three donors as compared to mock NK cells (shown with an arrow labeled (c)). The mean percentage cytotoxicity of NKG2D-DAP10-CD3 ζ -expressing NK cells was $91.8\% \pm 5.8\%$ (1:1 E:T ratio) and $83.9\% \pm 5.6\%$ (1:2 E:T ratio). Those NK cells transduced with NKG2D-41BB-CD3 ζ showed

similar potencies - $87.4\% \pm 6.1\%$ at a 1:1 E:T ratio and $76.2\% \pm 4.8\%$ at a 1:2 E:T ratio. Chimeric receptor-expressing NK cells also showed elevated cytotoxicity against U-2 OS when compared to mock-transduced NK cells (See Figures 6A-6C, Figure 6A depicts NKG2D-DAP10-CD3 ζ shown with an arrow labeled (a), Figure 6B depicts NKG2D-41BB-CD3 ζ shown with an arrow labeled (b) and Figure 6C depicts mock NK cells shown with an arrow labeled (c)).

[00221] These data provide evidence that NK cells can not only be engineered to express chimeric receptor constructs, but those cells that express the chimeric receptors are able to be activated and successfully generate enhanced cytotoxic effects against target cells. Importantly, these data also show that there is only a slight decrease in the potency of the cells when in the presence of a greater number of target cells (doubled in this experiment). This suggests that the desired cytotoxic effects of the engineered NK cells can still be realized, even when the NK cells are present in smaller numbers vis-à-vis target cells, as would likely be the case in clinical use. Moreover, these data indicate that, according to some embodiments, a lesser density or degree of chimeric receptor expression on a given NK cell does not necessarily result in coordinately reduced cytotoxic effects, and can be associated with an unexpected efficacy of the NK cells in view of their lesser construct expression. Additionally, these data embody the unexpectedly enhanced cytotoxicity that is achieved according to several embodiments. While non-engineered NK cells are cytotoxic, and express a significant amount of NKG2D upon activation, it is unexpected that the engineered cells disclosed herein can push the cytotoxic effects significantly beyond what can be considered an already elevated ceiling (e.g., native NK cell cytotoxicity).

[00222] Further to the cytotoxicity data, the mechanism by which the NK cells are exerting these effects was examined, by evaluating the production of interferon-gamma (IFN γ) by the NK cells expressing the various NKG2D constructs. IFN γ is a key cytokine produced and released by NK cells (typically during an innate immune response) that recruits macrophages and has immunostimulatory effects. Figure 7A shows the relative amount of IFN γ production (measured by MFI) in Mock (left panel), NKG2D-DAP10-CD3 ζ -expressing NK cells (center panel), and NKG2D-41BB-CD3 ζ -expressing NK cells (right panel) with or without stimulation by REH cells. NK cells were stained by APC-conjugated anti-IFN γ antibody for intracellular IFN γ . Data was analyzed by paired t test. These data show that each of the three groups of NK cells were observed to have a similar level of IFN γ production without stimulation, with an increase observed after

stimulation by REH cells. As provided for in several embodiments, engineered NK cells expressing NKG2D constructs can lead to robust cytokine production. The presence of a target cell (here, REH cells) to which the engineered NK cells responds sets into motion the biochemical cascade which leads to IFN γ production and ultimately cytotoxic effects. As shown in Figure 7A, the NKG2D-41BB-CD3 ζ -expressing NK cells show a robust production of IFN γ in the presence of stimulatory REH cells. Interestingly, the NKG2D-DAP10-CD3 ζ -expressing NK cells failed to show a similar degree of response. This is further demonstrated in Figure 7B, where levels of IFN γ between different groups of NK cells after stimulation with REH cells (median values were represented; data was analyzed by unpaired t test) are evaluated. All IFN γ experiments were conducted in triplicates, with three independent donors, n = 9. Figure 7B shows that IFN γ production by NKG2D-DAP10-CD3 ζ -expressing NK cells was not significantly different from mock-transduced NK cells. In contrast, the NKG2D-41BB-CD3 ζ -expressing NK cells show a significant increase in IFN γ production as compared to mock-transduced NK cells. These data are interesting because they demonstrate that, as discussed herein, signaling by a chimeric receptor in response to ligand binding is an essential step in generating cytotoxic effects against a target cell of interest. However, there is not a singular pathway through which the various constructs signal, as NK cells transduced with two different chimeric receptors both exhibit relatively similar cytotoxicity, but without mirroring levels of IFN γ production. Thus, according to some embodiments, constructs are provided that achieve cytotoxic effects through an elevated production of IFN γ , or other immunostimulatory cytokine, as compared to normal NK cells. However, in several embodiments, increased production of IFN γ is not necessarily achieved or detected, rather another immunostimulatory pathway can be exploited by a given chimeric construct to achieve elevated cytotoxic effects.

Example 2 – CD16 and CD16-4-1BB Containing NKG2D Constructs

[00223] Additional constructs were generated to evaluate expression, cytotoxicity and cytokine production. As provided for herein, several embodiments relate to constructs comprising a truncated NKG2D (in some embodiments codon optimized), that employ a CD16 transmembrane and/or signaling domain. The constructs generated for evaluation in this experiment are schematically shown in Figures 2A-2B, which show the structure of A) NKG2D-CD16 and B) NKG2D-CD16-41BB chimeric receptors. Both chimeric receptors rely on the transmembrane region of CD16 to associate with either

CD3 ζ or FcR γ . The plasmids used to generate these constructs are shown in Figure 3B. As discussed above, in several embodiments, the constructs employed rely on endogenous expression of CD3 ζ or FcR γ , however, in several embodiments the plasmid encoding the chimeric receptor (or a separate plasmid) is configured to elevate expression of CD3 ζ and/or FcR γ by the NK cell, thereby enhancing the potency of the cells.

[00224] As above, expression levels of the constructs were evaluated. Figure 8A depicts representative flow cytometry data for mock (left panel), NKG2D-DAP10-CD3 ζ -expressing NK cells (center panel), and NKG2D-CD16-expressing NK cells (Experiments were conducted using cells from three independent donors represented by different symbols. Data was analyzed by paired t test). Figure 8B shows summary data relating to the percentage of cells that that express NKG2D (and hence the constructs). As expected, mock-transfected NK cells show low levels of NKG2D expression with the antibody used. In contrast, both of the engineered constructs exhibited significantly enhanced expression, with NKG2D-CD16-transduced NK cells expressing $35.8\% \pm 6.9\%$ greater expression as compared to mock-transduced NK cells. Additionally, as evaluated by MFI (Figure 8C), NKG2D-CD16-transduced NK cells also exhibited increased expression of the construct. These data are important to demonstrate that the constructs can effectively be introduced into NK cells and are expressed.

[00225] Having established expression of the constructs, their ability to exhibit cytotoxic effects was evaluated. As discussed above, NK cells from three donors were tested for cytotoxic effects against REH cells and U-2 OS cells, each at three E:T ratios (all experiments were done in triplicate, n=3). Interestingly, the enhanced expression of the NKG2D-CD16 construct as compared to mock NK cells did not result in increased cytotoxicity (see Figure 9A-9C, error bars represent standard deviations). As with the prior example, NKG2D-DAP10-CD3 ζ -expressing NK cells (shown with an arrow labeled (a)) did exhibit an increased cytotoxicity. With respect to cytotoxicity against U-2 OS cells, the NKG2D-CD16 (shown with an arrow labeled (b)) did exhibit an increased cytotoxicity as compared to mock NK cells (shown with an arrow labeled (c)) (see Figures 10A-10C). These data indicate that the degree of cytotoxic impact on a particular given target cell type may vary with the NK construct used. In some embodiments, a particular construct may not be as effective, however, in several embodiments, combinations of populations of NK cells can be used and exhibit synergistic effects. In other words, a population of NK cells, with a portion expressing NKG2D-CD16 and a portion expressing NKG2D-DAP10-CD3 ζ (or other combination of

any of the constructs disclosed herein), may exhibit unexpectedly enhanced cytotoxicity as compared to either sub-population alone.

[00226] Interferon- γ production was measured next, in order to confirm the mechanism of action of the transfected NK cells. The NK cells expressing the various constructs were either stimulated by REH cells, or not, and the production of IFN γ was measured. These data are shown in Figure 11 (data was analyzed by paired t test). All groups of NK cells had similar level of IFN γ without stimulation, and an increase after incubation with REH cells. The NKG2D-CD16-expressing NK cells exhibited an increase in IFN γ production of 634 ± 211 MFI, which was greater than the increase exhibited by the mock-transduced NK cells (423 ± 70 MFI). However, the increase was lower than that observed for NKG2D-DAP10-CD3 ζ -expressing NK cells, which increased 2041 ± 411 MFI. In line with data, according to several embodiments the production of IFN γ is correlated with the cytotoxic effects that NK cells expressing certain constructs exhibit.

[00227] In accordance with several embodiments disclosed herein, multiple signaling regions may be used. Additional experiments were conducted to evaluate the expression of a NKG2D-CD16-41BB in expanded NK cells (experiments were conducted using cells from one donor). The expression data is shown in Figures 12A-12B. Figure 12A shows raw flow cytometry data that demonstrate that the addition of the 4-1BB signaling region does not significantly impair the expression of the construct by NK cells, as compared to the NKG2D-CD16 construct. This is also reflected in the summary histogram of Figure 12B that shows the relative amount of NKG2D receptors on the surface of each of the NK cell groups tested. The NKG2D-CD16-41BB shows slightly reduced MFI as compared to NKG2D-CD16, but both constructs show elevated expression versus mock.

[00228] Cytotoxic effects were evaluated as described above, using both REH and U-2 OS cells as targets. Figures 13A-13B depict the resultant data (error bars represent standard deviations; all experiments were conducted in triplicates, $n = 3$). Figure 13A shows the cytotoxic effects of the constructs against REH cells. Similar to the experiment above, the NKG2D-CD16-expressing cells shown with an arrow labeled (b) did not show significantly elevated cytotoxic effects as compared to mock NK cells shown with an arrow labeled (a). In contrast, NK cells expressing NKG2D-CD16-41BB (shown with an arrow labeled (c)) showed enhanced cytotoxicity against REH cells. With respect to efficacy against U-2 OS cells, both the NKG2D-CD16 and NKG2D-

CD16-41BB expressing cells showed enhanced cytotoxicity, with the NKG2D-CD16-41BB expressing cells exhibiting a more robust cytotoxic effect. This demonstrates that, in accordance with several embodiments, use of a combination of signaling domains can result in unexpected enhancements in the efficacy of a transduced NK cell. Thus, as described above, several embodiments employ two or more transmembrane/signaling domains that work synergistically together to yield enhanced cytotoxicity against target cells.

Example 3 – Additional NKG2D Constructs

[00229] Additional constructs with varying extracellular domains, transmembrane domains, and intracellular effector domains were generated to evaluate their expression and cytotoxicity. The 12 constructs generated for evaluation in this experiment are schematically shown in Figure 14. Some of these variant chimeric receptors rely on a CD16 transmembrane region to associate with either CD3 ζ or FcR γ . As discussed above, in several embodiments, the constructs employed rely on endogenous expression of CD3 ζ or FcR γ , however, in several embodiments the plasmid encoding the chimeric receptor (or a separate plasmid) is configured to elevate expression of CD3 ζ and/or FcR γ by the NK cell, thereby enhancing the potency of the cells. As above, expression levels of the constructs were evaluated. Mock-transfected NK cells show low levels of NKG2D expression as evaluated by MFI (Figure 16A). In contrast, NK cells transduced with the variant NKG2D constructs described above showed varying levels of NKG2D expression, with engineered variant constructs 4 and 9 exhibiting significantly enhanced expression in NK cells. Figure 16B depicts representative flow cytometry data for variant NKG2D constructs 1, 4, 8, 9 after transduction into the NK cells of two donors. Relative to mock-transduced NK cells, Variant 8- and 9-transduced NK cells showed particularly strong expression of the chimeric receptor. Variant construct expression persisted in the NK cells of two donors 7 days following transduction, with Variants 8 and 9 showing particularly elevated levels as evaluated by MFI (Figure 16C). These data are important to demonstrate that the constructs can effectively be introduced into NK cells and are expressed. Having established expression of the constructs, their ability to deliver cytotoxic effects in transduced NK cells was also evaluated. The cytotoxicity of the NKG2D variant constructs 4, 8, and 9 were evaluated 14 days post-transduction into NK cells at a 1:1 E:T ratio (Figure 17).

[00230] Further variant constructs were generated and are schematically shown in Figure 15, which show the structure of chimeric receptors comprising various extracellular domains, transmembrane domains, and intracellular effector domains. Some of these variant chimeric receptors rely on an effector domain comprising CD3zeta and/or another signaling domain to transduce signaling upon ligand binding, while other variant chimeric receptors comprise a CD3zeta transmembrane domain that recruits full-length CD3zeta molecule to the synapse via dimerization. As above, expression levels of the constructs were evaluated. As evaluated by MFI (Figures 18A-B), NK cells transduced with engineered constructs exhibited increased expression of the chimeric receptor relative to mock transduced cells. Cytotoxic effects were evaluated as described above using an effector: target ratio of 1:1. As depicted in Figures 19A-B, NK cells transduced with engineered constructs (particularly variant 18) have enhanced cytotoxicity relative to the mock control.

[00231] As variant 18 exhibited robust expression in NK cells that was accompanied by enhanced cytotoxic effects, a series of variant NKG2D constructs comprising a CD3zeta transmembrane domain were generated. These variants are termed “NK39” and are schematically shown in Figure 15. Fourteen days following transfection into donor NK cells (with 4 days of culturing in low IL-2 conditions), the cytotoxicity of the transduced NK cells were evaluated. Figure 21 shows the cytotoxic effects of the constructs against cultured REH cells at 1:1 and 1:2 E:T ratios. All the of the NK cells expressing engineered NK39 constructs showed significantly elevated cytotoxic effects as compared to control NK cells at a 1:1 E:T ratio. When evaluated at a 1:2 E:T ratio, chimeric constructs 16-7, 39-1, 39-2, 39-3, and 39-5 each enhanced the cytotoxic effects of their respective transduced NK cells relative to the mock control. As exogenous expression of activating receptors can lead to NK cell anergy and cell death, the engineered constructs were transduced into two donor NK cells and survival was evaluated after 21 days. As depicted in Figures 23A-B, NK39-5 and NK39-10 transduced cells show better survival than NK16 in two tested donors.

Example 4 – Evaluation of NK45 NKG2D Constructs

[00232] Additional constructs with varying extracellular domains, hinges, transmembrane domains, and intracellular effector domains according to embodiments disclosed herein are schematically shown in Figure 22. The expression, cytotoxicity, persistence, and cytokine production mediated by these 7 constructs were evaluated in this Example relative to three of the NK39 constructs described in Example 3 (NK39-5,

NK39-6, NK39-10) as well as a version of NK16 that bicistronically expresses membrane-bound interleukin 15 (NK26-8). In accordance with several embodiments disclosed herein, multiple signaling regions may be used. Some of these variant chimeric receptors rely on an effector domain comprising CD3zeta and/or another signaling domain (e.g., OX40, CD28, and/or 4-1BB costimulatory domains) to transduce signaling upon ligand binding, while other variant chimeric receptors comprise a CD3zeta transmembrane domain that recruits full-length CD3zeta molecule to the synapse via dimerization. As disclosed herein, these constructs are further configured to co-express membrane-bound IL15.

[00233] As above, the ability of NK cells to effectively express these constructs was first assessed. NK cells expanded from the PBMC of four donors were transduced with the variant constructs (or an empty MSCV control vector containing GFP only) and NKG2D expression was evaluated by MFI after 3 days. As depicted in FIG. 24, mock-transfected NK cells show relatively low levels of NKG2D expression. In contrast, the engineered variant constructs exhibited significantly enhanced expression, with NK45-4 (NKG2D-OX40-CD3 ζ) showing surprisingly robust expression in all donors. OX40 is expressed in activated NK cells, but its role has not been well-established. A variant chimeric receptor with an effector domain containing a CD28 costimulatory domain (NK45-2; NKG2D-CD28-CD3 ζ) also demonstrated robust expression 3 days post-transduction.

[00234] Having established expression of the variant constructs, their ability to exert cytotoxic effects was evaluated as above using REH and HL60 cells as targets. The potency of NK cells from four donors were examined against REH cells (FIG. 25A) and HL60 cells (FIG. 25B) at 1:1 E:T ratios 14 days post-transduction. As depicted in FIGs. 25A-B, the engineered constructs exerted an enhanced cytotoxicity against both REH and HL60 cells in all four donors as compared to mock NK cells. In addition to its pronounced expression profile, cells expressing NK45-4 (NKG2D-OX40-CD3 ζ) also exhibited surprisingly elevated cytotoxicity relative to the mock control and the other constructs tested. NK cells expressing NK45-1 and NK45-2 also demonstrated pronounced cytotoxicity in these assays. These data demonstrate that, in accordance with several embodiments, use of a combination of signaling domains (particularly an OX40 costimulatory domain) can result in unexpected enhancements in the efficacy of a transduced NK cell. FIGs. 28A-B depict the cytotoxic activity against U2OS cells of the NK cells transduced with several of the variant constructs at various E:T ratios (1:2 and

1:4) and assessed over a more extended period of time. Surprisingly, NK cells transduced with the 45-4 construct appear to maintain cytotoxic activity through the time course. Advantageously, these experiments indicate that, according to several embodiments disclosed herein, the NKG2D variant constructs provide unexpectedly enhanced cytotoxicity over an extended period of time, which, depending on the embodiment, can range from 2-3 days, 3-5 days, 5-7, days, 7-8 days, 8-10 days, 10-14 days, 14-21 days, or 21-50 days (and any range in between those listed, including endpoints). In several embodiments, even longer durations of cytotoxic effects are achieved.

[00235] Further to the cytotoxicity data, the mechanism by which the NK cells are exerting these effects was examined by evaluating their production of IFN γ , TNF α , and GM-CSF following stimulation with REH cells. As depicted in FIGs. 26A-C, expression of each of the variant constructs yielded enhanced cytokine secretion relative to the production of IFN γ , TNF α , and GM-CSF exhibited by the GFP-expressing control NK cells. The chimeric receptor NK45-1 consistently mediated high cytokine production, which is surprising because this construct expresses at substantially lower levels than NK26-8 (from which it differs only with regards to the hinge region). Thus, these data demonstrate the unexpected importance of the hinge regions disclosed herein to mediating robust cytokine production in response to stimulation. Additionally, NKG2D-OX40-CD3 ζ -expressing NK cells also showed an elevated production of IFN γ , TNF α , and GM-CSF.

[00236] As exogenous expression of activating receptors can lead to NK cell anergy and cell death, the engineered constructs were transduced into two donor NK cells and the total cell count was evaluated 7, 14, and 21 days post-transduction. Surprisingly, the unexpectedly robust expression of NK45-4 does not come at the cost of reduced NK cell persistence in culture, as the total cell count remained at levels comparable to the GFP-expressing control cells (FIGs. 27A and 27B). Likewise, other NK cells expressing variant constructs at high levels continued to proliferate in the 2 donors for at least 3 weeks post-transduction. Collectively, these data demonstrate that, in accordance with several embodiments disclosed herein, engineered constructs can successfully be expressed at high levels in NK cells and mediate cytotoxic effects, and further, that this enhanced expression does not come at the detriment of reduced NK cell proliferation and/or survival.

[00237] It is contemplated that various combinations or subcombinations of the specific features and aspects of the embodiments disclosed above may be made and

still fall within one or more of the inventions. Further, the disclosure herein of any particular feature, aspect, method, property, characteristic, quality, attribute, element, or the like in connection with an embodiment can be used in all other embodiments set forth herein. Accordingly, it should be understood that various features and aspects of the disclosed embodiments can be combined with or substituted for one another in order to form varying modes of the disclosed inventions. Thus, it is intended that the scope of the present inventions herein disclosed should not be limited by the particular disclosed embodiments described above. Moreover, while the invention is susceptible to various modifications, and alternative forms, specific examples thereof have been shown in the drawings and are herein described in detail. It should be understood, however, that the invention is not to be limited to the particular forms or methods disclosed, but to the contrary, the invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the various embodiments described and the appended claims. Any methods disclosed herein need not be performed in the order recited. The methods disclosed herein include certain actions taken by a practitioner; however, they can also include any third-party instruction of those actions, either expressly or by implication. For example, actions such as “administering a population of expanded NK cells” include “instructing the administration of a population of expanded NK cells.” In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group.

[00238] The ranges disclosed herein also encompass any and all overlap, sub-ranges, and combinations thereof. Language such as “up to,” “at least,” “greater than,” “less than,” “between,” and the like includes the number recited. Numbers preceded by a term such as “about” or “approximately” include the recited numbers. For example, “about 90%” includes “90%.” In some embodiments, at least 95% homologous includes 96%, 97%, 98%, 99%, and 100% homologous to the reference sequence. In addition, when a sequence is disclosed as “comprising” a nucleotide or amino acid sequence, such a reference shall also include, unless otherwise indicated, that the sequence “comprises”, “consists of” or “consists essentially of” the recited sequence.

[00239] The term “comprising” as used in this specification and claims means “consisting at least in part of”. When interpreting statements in this specification, and claims which include the term “comprising”, it is to be understood that other features that are additional to the features prefaced by this term in each statement or claim may also be

present. Related terms such as “comprise” and “comprised” are to be interpreted in similar manner.

WHAT IS CLAIMED IS:

1. A polynucleotide encoding a chimeric receptor expressed by a cell, the chimeric receptor comprising:
 - (a) an extracellular receptor domain,
 - wherein said extracellular receptor domain comprises a peptide that binds native ligands of Natural Killer Group 2 member D (NKG2D),
 - wherein the peptide that binds native ligands of NKG2D is encoded by a polynucleotide: (i) having at least 95% sequence identity to SEQ ID NO. 2, or (ii) having at least 95% sequence identity to SEQ ID NO. 3; and
 - (b) an effector domain comprising a transmembrane region and an intracellular signaling domain,
 - wherein the transmembrane region comprises a CD8a hinge region and a CD8a transmembrane domain,
 - wherein the intracellular signaling domain comprises CD3zeta and OX40,
 - wherein CD3zeta is encoded by a polynucleotide having at least 95% sequence identity to SEQ ID NO. 13 and
 - wherein the polynucleotide further encodes a membrane-bound interleukin 15 (mbIL15).
 2. The polynucleotide of Claim 1, wherein the CD8a hinge region is encoded by a polynucleotide having at least 95% sequence identity to SEQ ID NO. 5.
 3. The polynucleotide according to Claim 1 or Claim 2, wherein the mbIL15 is encoded by a polynucleotide having at least 95% sequence identity to SEQ ID NO. 16.
 4. The polynucleotide according to any one of Claims 1 to 3, wherein mbIL15 comprises the amino acid sequence of SEQ ID NO. 17.
 5. The polynucleotide according to any one of Claims 1 to 4, wherein the mbIL15 and the chimeric receptor are bicistronically expressed from the polynucleotide.

6. The polynucleotide of any one of Claims 1-5, wherein the chimeric receptor is encoded by a nucleic acid sequence having at least 95% sequence identity to SEQ ID NO. 90.

7. The polynucleotide according to any one of Claims 1 to 6, wherein the chimeric receptor comprises the amino acid sequence of SEQ ID NO. 109.

8. A vector comprising the polynucleotide of any one of Claims 1 to 7.

9. The vector of Claim 8, wherein the vector is a viral vector.

10. A chimeric receptor encoded by the polynucleotide of any one of Claims 1 to 9.

11. A chimeric receptor comprising:

(a) an extracellular receptor domain,

wherein said extracellular receptor domain comprises a peptide that binds native ligands of Natural Killer Group 2 member D (NKG2D),

wherein the peptide that binds native ligands of NKG2D comprises an amino acid sequence encoded by SEQ ID NO. 2, and

(b) an effector domain comprising a transmembrane region and an intracellular signaling domain,

wherein the transmembrane region comprises a CD8a hinge region and a CD8a transmembrane domain,

wherein the CD8a hinge region consists of the amino acid sequence encoded by SEQ ID NO. 5

wherein the intracellular signaling domain comprises CD3zeta and OX40, and

wherein CD3zeta comprises an amino acid sequence encoded by SEQ ID NO. 13.

12. The chimeric receptor of Claim 11, wherein the OX40 domain comprises the amino acid sequence of SEQ ID NO. 107.

13. The chimeric receptor of Claim 11 or Claim 12, wherein the chimeric receptor comprises the amino acid sequence of SEQ ID NO. 109.

14. An immune cell expressing the chimeric receptor of any one of Claims 11-13, wherein the cell expresses membrane-bound interleukin 15 (mbIL15).

15. The immune cell of Claim 14, wherein the mbIL15 is bicistronically expressed from the same polynucleotide as the chimeric receptor.

16. The immune cell of Claim 14 or Claim 15, wherein the immune cell is a Natural Killer (NK) cell.

17. A method of generating a population of immune cells expressing a chimeric receptor for the treatment of cancer, the method comprising:
delivering to a population of immune cells the vector of Claim 8 or Claim 9.

18. A method of treating a cancer using immunotherapy, the method comprising:
administering to a subject having a cancer expressing a ligand of Natural Killer Group 2 member D (NKG2D) a population of immune cells that express the chimeric receptor of any one of Claims 11-13.

19. The method of Claim 17 or Claim 18, wherein population of immune cells comprises natural killer (NK) cells.

20. The method of Claim 18 or Claim 19, wherein the immune cells are allogeneic with respect to the subject.

21. The method of any one of Claims 18-20, wherein the cancer is a leukemia.

22. The method of any one of Claims 18-21, wherein the leukemia is acute myelogenous leukemia.

23. Use of a population of immune cells that express the chimeric receptor of any one of Claims 11-13 in the manufacture of a medicament for the treatment of a subject having a cancer expressing a ligand of Natural Killer Group 2 member D (NKG2D).




FIG. 1C

FIG. 1B

FIG. 1A




FIG. 2B

FIG. 2A

2/42




FIG. 3A




FIG. 3B

3/42




FIG. 4A




FIG. 4C




FIG. 4B

5/42





FIG. 5A

FIG. 5B

FIG. 5C





FIG. 6A

FIG. 6B

FIG. 6C




FIG. 7A





FIG. 7B



9/42




FIG. 8A




FIG. 8C




FIG. 8B





FIG. 9C

FIG. 9B

FIG. 9A

12/42





FIG. 10A

FIG. 10B

FIG. 10C




FIG. 11

14/42




FIG. 12A




FIG. 12B




FIG. 13B

FIG. 13A

NK15	NKG2D EC (Codon Optimized)	CD8 α Hinge	CD16 TM/IC	4-1BB
Variant 1	NKG2D EC (Codon Optimized)	GS ₃ CD8 α Hinge	CD16 TM/IC	4-1BB
Variant 2	NKG2D EC (Codon Optimized)	GS ₃ CD16 TM/IC	4-1BB	
Variant 3	NKG2D EC (Codon Optimized)	CD16 TM/IC	4-1BB	
Variant 4	NKG2D EC	CD8 α Hinge	CD8 α TM	4-1BB 2B4
Variant 5	NKG2D EC	ADRB2 EC	ADRB2 TM	4-1BB 2B4
Variant 6	NKG2D EC	CD8 α Hinge	CD8 α TM	4-1BB 2B4 GS ₃ NKp80
Variant 7	NKG2D EC	CD8 α Hinge	CD8 α TM	4-1BB GS ₃ NKp80
Variant 8	NKG2D EC (Codon Optimized)	GS ₃ NKG2D EC	ADRB2 EC	ADRB2 TM 4-1BB GS ₃ NKp80
Variant 9	NKG2D EC (Codon Optimized)	GS ₃ NKG2D EC	CD8 α Hinge	CD8 α TM 4-1BB GS ₃ NKp80
Variant 10	NKG2D EC (Codon Optimized)	GS ₃ NKG2D EC	CD8 α Hinge	CD16 TM/IC 4-1BB
Variant 11	NKG2D EC (Codon Optimized)	CD8 α Hinge	CD16 TM/IC	4-1BB 2B4
Variant 12	NKG2D EC (Codon Optimized)	CD8 α Hinge	CD16 TM/IC	4-1BB GS ₃ NKp80

FIG. 14

NK16	NKG2D EC	CD8α Hinge	CD8α TM	4-1BB	CD3ζ	ITAM
Variant 13	NKG2D EC	CD8α Hinge	CD8α TM	4-1BB	2B4	CD3ζ ITAM
Variant 14	NKG2D EC	CD8α Hinge	CD8α TM	4-1BB	DAP10 IC	
Variant 15	NKG2D EC	CD8α Hinge	CD8α TM	4-1BB	DAP10 IC	2B4
Variant 16	NKG2D EC	CD8α Hinge	CD8α TM	4-1BB	2B4	DAP10 IC
Variant 17	NKG2D EC (Codon Optimized)	GS ₃ NKG2D EC	CD8α Hinge	CD8α TM	4-1BB	CD3ζ ITAM
Variant 18 (NK39)	NKG2D EC (Codon Optimized)	CD8α Hinge	CD3ζ TM	CD16 IC	4-1BB	
NK39_1	NKG2D EC (Codon Optimized)	GS ₃ NKG2D EC	CD8α Hinge	CD3ζ TM	CD16 IC	4-1BB 2A MIL-15
NK39_2	NKG2D EC	CD8α Hinge	CD3ζ TM	CD16 IC	4-1BB	GS ₃ NKp80 2A MIL-15

FIG. 15

NK39_3	NKG2D EC (Codon Optimized)	GS ₃	NKG2D EC	CD8 α Hinge	CD3 ζ TM	CD16 IC	4-1BB	GS ₃	NKp80	mIL-15
NK39_4	NKG2D EC (Codon Optimized)		CD8 α Hinge	CD3 ζ TM	4-1BB	2A	mIL-15			
NK39_5	NKG2D EC (Codon Optimized)		CD8 α Hinge	CD3 ζ TM	4-1BB	CD3Zeta	2A	mIL-15		
NK39_6	NKG2D EC (Codon Optimized)		CD8 α Hinge	CD3 ζ TM	4-1BB	GS ₃	NKp80	2A	mIL-15	
NK39_7	NKG2D EC (Codon Optimized)		CD8 α Hinge	CD3 ζ TM	4-1BB	GS ₃	CD16 IC	2A	mIL-15	
NK39_8			NKG2D EC	CD8 α Hinge	CD3 ζ TM	4-1BB	FC Gamma	2A	mIL-15	
NK39_9		IL-15	GS ₃	NKG2D EC	CD8 α Hinge	CD8 α TM	4-1BB	CD3 ζ ITAM		
NK39_10	NKG2D EC (Codon Optimized)		CD8 α Hinge	CD3 ζ TM	CD16 IC	4-1BB	2A	mIL-15		
NK16_7	NKG2D EC (Codon Optimized)	GS ₃	NKG2D EC	CD8 α Hinge	CD8 α TM	4-1BB	Cd3 ζ ITAM	2A	mIL-15	

FIG. 15
(Continued)




FIG. 16A

20/42




FIG. 16B




FIG. 16B
(Continued)




FIG. 16B
(Continued)




FIG. 16B
(Continued)




FIG. 16B
(Continued)

25/42




FIG. 16C

26/42




FIG. 17

27/42




FIG. 18A




FIG. 18B

28/42




FIG. 19A




FIG. 19B

29/42




FIG. 20

30/42





FIG. 21

NK45-1	NKG2D(Short Hinge) - 41BB - Cd3z IgG4 Hinge: ESKYGPPCPSCP)							
	NKG2D EC	Ig4 SH	CD8 α TM	4-1BB	Cd3 ζ ITAM	2A	mIL- 15	
NKG2D-CD28-CD3z								
NK45-2	NKG2D EC	CD8 α Hinge	CD28 TM	CD28	Cd3 ζ ITAM	2A	mIL- 15	
	NKG2D (SH)-CD28 - CD3z							
NK45-3	NKG2D EC	Ig4SH	CD28 TM	CD28	Cd3 ζ ITAM	2A	mIL- 15	
	NKG2D-OX40-CD3z							
NK45-4	NKG2D EC	CD8 α Hinge	CD8 α TM	OX40	Cd3 ζ ITAM	2A	mIL- 15	
	NKG2D (SH)-OX40-CD3z							
NK45-5	NKG2D EC	Ig4SH	CD8 α TM	OX40	Cd3 ζ ITAM	2A	mIL- 15	
	NKG2D-CD3TM-CD28-CD3z							
NK45-6	NKG2D EC	CD8 α Hinge	CD3 α TM	CD28	Cd3 ζ ITAM	2A	mIL- 15	
	NKG2D-CD28-41BB-CD3z							
NK45-7	NKG2D EC	CD8 α Hinge	CD28 TM	CD28	4-1BB	Cd3 ζ ITAM	2A	mIL- 15


FIG. 22

32/42



**Donor 61
FIG. 23A**

33/42



Donor 103

FIG. 23B

NKG2D Expression in 4 Donors 3 Days Post Transduction




FIG. 24

35/42




FIG. 25A

36/42




FIG. 25B




FIG. 26A




FIG. 26B




FIG. 26C




FIG. 27A





FIG. 27B






FIG. 28B

44591144002SequenceListing.txt
SEQUENCE LISTING

<110> National University of Singapore; Nkarta, Inc

<120> TRUNCATED NKG2D CHIMERIC RECEPTORS AND USES THEREOF IN NATURAL
KILLER CELL IMMUNOTHERAPY

<130> 4459.1144002

<150> 62/477335
<151> 2017-03-27

<150> 62/628774
<151> 2018-02-09

<160> 109

<170> PatentIn version 3.5

<210> 1
<211> 645
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Full length NKG2D

<400> 1
gggtggattc gtggtcggag gtctcgacac agctgggaga tgagtgaatt tcataattat 60
aacttggatc tgaagaagag tgatTTTTca acacgatggc aaaagcaaag atgtccagta 120
gtcaaaagca aatgtagaga aatgcatct ccattTTTT tctgctgctt catcgctgta 180
gccatgggaa tccgtttcat tattatggta acaatatgga gtgctgtatt cctaaactca 240
ttattcaacc aagaagttca aattcccttg accgaaagtt actgtggccc atgtcctaaa 300
aactggatat gttacaaaaa taactgctac caattTTTTg atgagagtaa aaactggat 360
gagagccagg cttcttgtat gtctcaaaat gccagccttc tgaaagtata cagcaaagag 420
gaccaggatt tacttaaact ggtgaagtca tatcattgga tgggactagt acacattcca 480
acaaatggat cttggcagtg ggaagatggc tccattctct cacccaacct actaacaata 540
attgaaatgc agaagggaga ctgtgcactc tatgcctcga gctttaaagg ctatatagaa 600
aactgttcaa ctccaatac gtacatctgc atgcaaagga ctgtg 645

44591144002SequenceListing.txt

<210> 2
 <211> 405
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Truncated NKG2D

<400> 2
 ttattcaacc aagaagttca aattcccttg accgaaagtt actgtggccc atgtcctaaa 60
 aactggatat gttacaaaaa taactgctac caatTTTTTg atgagagtaa aaactgggat 120
 gagagccagg cttcttTgat gtctcaaaat gccagccttc tGaaagtata cagcaaagag 180
 gaccaggatt tacttaaact ggtgaagtca tatcattgga tgggactagt acacattcca 240
 acaaatggat cttggcagtg ggaagatggc tccattctct cacccaacct actaacaata 300
 attgaaatgc agaagggaga ctgtgcactc tatgcctcga gctTTaaagg ctatatagaa 360
 aactgttcaa ctccaatac gtacatctgc atgcaaagga ctgtg 405

<210> 3
 <211> 405
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Codon Optimized Truncated NKG2D

<400> 3
 ctgttcaatc aggaagtcca gatccccctg acagagtctt actgCGGCC atgtccaag 60
 aactggatct gctacaagaa caattgTtat cagttctttg acgagagcaa gaactgggat 120
 gagtcccagg cctcttTgat gagccagaat gcctctctgc tGaaagtgta cagcaaggag 180
 gaccaggatc tgctgaagct ggtgaagtcc tatcactgga tgggcctggT gcacatccct 240
 acaaacggct cttggcagtg ggaggacggc tccatcctgt ctccaatct gctgaccatc 300
 atcgagatgc agaagggcga ttgcgcctg tacgccagct cttcaaggg ctatatcgag 360
 aactgctcca cacccaatac ctacatctgt atgcagagga ccgtg 405

44591144002SequenceListing.txt

<210> 4
 <211> 63
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> CD8 Signaling Sequence

<400> 4
 atggctctgc ccgtcaccgc actgctgctg cctctggctc tgctgctgca cgccgcacga 60
 cca 63

<210> 5
 <211> 135
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> CD8 alpha hinge

<400> 5
 accacaacc ctgcaccacg cccccctaca ccagcaccta ccatcgcaag ccagcctctg 60
 tcctgcggc cagaggcatg tagaccagca gcaggaggag cagtgcacac aagaggcctg 120
 gacttcgcct gcgat 135

<210> 6
 <211> 1722
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> CD8 beta

<220>
 <221> misc_feature
 <222> (674)..(773)
 <223> n is a, c, g, or t

<220>
 <221> misc_feature

44591144002SequenceListing.txt

<222> (859)..(958)

<223> n is a, c, g, or t

<400> 6

atctaggtct	tgctgcaccc	gcacaaccta	caaacagcgt	cggggccttc	tctgcacctc	60
cagttcccag	ctcacctccc	tcagtgtcac	agccggttac	ctttccttcc	tccctggggg	120
agggcaagac	ttggggcttg	ctgactccag	gcccagccca	gcccggggca	cccaggagcc	180
cctcaattgc	tactcaaaca	gacaagaagc	ggcccagagtt	agtggccagc	tccacatg	240
actacacatc	ctgacctctc	tgagcctcta	ctgtcactcg	gggtcacaac	cctttcctga	300
gcacctcccg	gggcaggggg	cgatgacaca	catgcagctg	cctgggggag	gccggcggtg	360
tcccctcctt	tctggaacgc	ggagggtcct	ggtgggctct	ggaaacgcag	cccagacctt	420
tgcaatgcta	ggaggatgag	ggcggagacc	tcgcggtccc	caacaccaga	ctcccgcagc	480
caccgcgcc	ggtcccgccc	tccccactgc	ccccccagct	ccccgacca	ggcgccccgc	540
ccggccagct	cctcaccac	cccagccgcg	actgtctccg	ccgagcccc	ggggccaggt	600
gtcccgggcg	cgccacgatg	cggccgcggc	tgtggctcct	cctggccgcg	cagctgacag	660
gtaaggcggc	ggcnnnnnn	nnnnnnnnn	nnnnnnnnn	nnnnnnnnn	nnnnnnnnn	720
nnnnnnnnn	nnnnnnnnn	nnnnnnnnn	nnnnnnnnn	nnnnnnnnn	nnnttgcttt	780
cctcttccag	gccggcggag	gagagcccgg	cttcgtttca	tgaaacagta	agtgtataac	840
ctgggtgtgg	ccttgggann	nnnnnnnnn	nnnnnnnnn	nnnnnnnnn	nnnnnnnnn	900
nnnnnnnnn	nnnnnnnnn	nnnnnnnnn	nnnnnnnnn	nnnnnnnnn	nnnnnnnct	960
tgctgttggt	ttcagatfff	acaaatgagc	agagaatacg	gttttggtgt	cctgctacaa	1020
aaagacatcg	gtcagtaacg	agcacgatgt	ggaaaaatga	gagaaggac	acattcaacc	1080
ctggagagtt	caatggctgc	tgaagctgcc	tgcttttcac	tgctgcaagg	cctttctgtg	1140
tgtgacgtgc	atgggagcaa	cttgttcgtg	ggtcatcggg	aatactaggg	agaaggtttc	1200
attgccccca	gggcacttca	cagagtgtgc	tggaggactg	agtaagaaat	gctgcccattg	1260
ccaccgcttc	cggctcctgt	gctttccctg	aactgggacc	tttagtggtg	gccatttagc	1320
caccatcttt	gcaggttgct	ttgccctggt	agggcagtaa	cattgggtcc	tgggtctttc	1380
atggggtgat	gctgggctgg	ctccctggtg	gtcttcccag	gctggggctg	accttcctcg	1440

44591144002SequenceListing.txt

cagagaggcc aggtgcaggt tgggaatgag gcttgctgag aggggctgtc cagttcccag 1500
aaggcatatc agtctctgag ggcttccttt ggggccggga acttgccgggt ttgaggatag 1560
gagttcactt catcttctca gctcccattt ctactcttaa gtttctcagc tcccatttct 1620
actctcccat ggcttaatgc ttctttcatt ttctgtttgt tttatacaaa tgtcttagtt 1680
gtaaaaataa agtcccaggt taaagataac aaacgggtcc tg 1722

<210> 7
<211> 2415
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> CD16 alpha

<400> 7
attcttggtg ctgggtggat ccaaatccag gagatggggc aagcatcctg ggatggctga 60
gggcacactc tggcagattc tgtgtgtgtc ctgagatgct cagccacaga cctttgaggg 120
agtaaagggg gcagaccac ccaccttgcc tccaggctct ttccttcctg gtcctgttct 180
atggtggggc tcccttgcca gacttcagac tgagaagtca gatgaagttt caagaaaagg 240
aaattggtgg gtgacagaga tgggtggagg ggctggggaa aggctgttta cttcctcctg 300
tctagtcggt ttggtccctt tagggctccg gatatctttg gtgacttgtc cactccagtg 360
tggcatcatg tggcagctgc tcctccaac tgctctgcta cttctagttt cagctggcat 420
gcggaactgaa gatctccaa aggctgtggt gttcctggag cctcaatggt acagggtgct 480
cgagaaggac agtgtgactc tgaagtgcca gggagcctac tcccctgagg acaattccac 540
acagtggttt cacaatgaga gcctcatctc aagccaggcc tcgagctact tcattgacgc 600
tgccacagtc gacgacagtg gagagtacag gtgccagaca aacctctcca ccctcagtga 660
cccgggtgcag ctagaagtcc atatcggctg gctgttgctc caggcccctc ggtgggtggt 720
caaggaggaa gaccctattc acctgaggtg tcacagctgg aagaacactg ctctgcataa 780
ggtcacatat ttacagaatg gcaaaggcag gaagtatctt catcataatt ctgacttcta 840
cattcaaaa gccacactca aagacagcgg ctctacttc tgcagggggc tttttgggag 900

44591144002SequenceListing.txt

taaaaatgtg tcttcagaga ctgtgaacat caccatcact caaggtttgg cagtgtcaac	960
catctcatca ttctttccac ctgggtacca agtctctttc tgcttggtga tggactcct	1020
ttttgcagtg gacacaggac tatatttctc tgtgaagaca aacattcgaa gctcaacaag	1080
agactggaag gaccataaat ttaaattggag aaaggaccct caagacaaat gacccccatc	1140
ccatgggggt aataagagca gtagcagcag catctctgaa catttctctg gatttgcaac	1200
cccatcatcc tcaggcctct ctacaagcag caggaaacat agaactcaga gccagatccc	1260
ttatccaact ctcgactttt ccttggtctc cagtggaagg gaaaagcca tgatcttcaa	1320
gcaggaagc cccagtgagt agctgcattc ctagaaattg aagtttcaga gctacacaaa	1380
cactttttct gtcccaaccg ttccctcaca gcaaagcaac aatacaggct agggatggta	1440
atcctttaa catacaaaaa ttgctcgtgt tataaattac ccagtttaga ggggaaaaaa	1500
aaacaattat tcctaaata atggataagt agaattaatg gttgaggcag gaccatacag	1560
agtgtgggaa ctgctgggga tctagggaat tcagtgggac caatgaaagc atggctgaga	1620
aatagcaggt agtccaggat agtctaaggg aggtgttccc atctgagccc agagataagg	1680
gtgtcttctc agaacattag ccgtagtgga attaacagga aatcatgagg gtgacgtaga	1740
attgagtctt ccaggggact ctatcagaac tggaccatct ccaagtatat aacgatgagt	1800
cctcttaatg ctaggagtag aaaatgggtc taggaagggg actgaggatt gcggtggggg	1860
gtggggtgga aaagaaagta cagaacaaac cctgtgtcac tgtcccaagt tgctaagtga	1920
acagaactat ctcagcatca gaatgagaaa gcctgagaag aaagaaccaa ccacaagcac	1980
acaggaagga aagcgcagga ggtgaaaatg ctttcttggc cagggtagta agaattagag	2040
gttaatgcag ggactgtaaa accacctttt ctgcttcaat atctaattcc tgtgtagctt	2100
tgttcattgc atttatataa caaatgttgt ataaccaata ctaaattgtac tactgagctt	2160
cgctgagtta agttatgaaa ctttcaaadc cttcatcatg tcagttcaa tgaggtgggg	2220
atggagaaga caattgttgc ttatgaaaga aagctttagc tgtctctgtt ttgtaagctt	2280
taagcgcaac atttcttggg tccaataaag cattttacaa gatcttgcac gctactctta	2340
gatagaagat gggaaaacca tggtataaaa atatgaatga taaaaaaaa aaaaaaaaaa	2400
aaaaaaaaaa aaaaa	2415

44591144002SequenceListing.txt

<210> 8
 <211> 2473
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> CD16 beta

<220>
 <221> misc_feature
 <222> (211)..(310)
 <223> n is a, c, g, or t

<220>
 <221> misc_feature
 <222> (537)..(636)
 <223> n is a, c, g, or t

<220>
 <221> misc_feature
 <222> (968)..(1067)
 <223> n is a, c, g, or t

<400> 8
 aaagatgggt ggagggactg gggaaaggct gtttactccc tcctgtctag tcggcttggt 60
 cccttaggg gtccggatat ctttggtgac ttgtccactc cagtgtggca tcatgtggca 120
 gctgctcctc ccaactgctc tgctacttct aggtaagtag gatctccctg gttgagggag 180
 aagtttgaga tgccttggtg tcagcagaga nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 240
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 300
 nnnnnnnnnn aagaggcatg aacagtggaa gaccagagag caggtagcaa ggtttccacc 360
 agaaacatcc tgattcttgg gaaaattggg ctcttggggc agaggagggc aggggagttt 420
 taaactcact ctatgttcta atcactctga tctctgcccc tactcaatat ttgatttact 480
 cttttttctt gcagtttcag ctggcatgcg gactggtgag tcagcttcat ggtcttnnnn 540
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 600
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnncact gagagctgag ctcccgggcc 660
 tgggggtgtct ctgtgtcttt caggctggct gttgctccag gccctcggt ggggtgtcaa 720
 ggaggaagac cctattcacc tgaggtgtca cagctggaag aacctgctc tgcataaggt 780

44591144002SequenceListing.txt

cacatattta cagaatggca aagacaggaa gtattttcat cataattctg acttccacat	840
tccaaaagcc aactcaaag atagcggctc ctacttctgc agggggcttg ttgggagtaa	900
aatgtgtct tcagagactg tgaacatcac catcactcaa ggtgagacat gtgccaccct	960
ggaatgcnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn	1020
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnttt ttcactctctc	1080
cacttctcct aataggtttg gcagtgtcaa ccatctcatc attctctcca cctgggtacc	1140
aagtctcttt ctgcttggtg atggtactcc tttttgcagt ggacacagga ctatatttct	1200
ctgtgaagac aaacatttga agctcaacaa gagactggaa ggaccataaa cttaaattgga	1260
gaaaggacc tcaagacaaa tgaccccat cccatgggag taataagagc agtggcagca	1320
gcatctctga acatttctct ggatttgcaa cccatcatc ctcaggcctc tctacaagca	1380
gcaggaaaca tagaactcag agccagatcc tttatccaac tctcgatttt tccttggctct	1440
ccagtggaag ggaaaagccc atgatcttca agcaggggag cccagtgag tagctgcatt	1500
cctagaaatt gaagtttcag agctacacaa acactttttc tgtcccaacc attccctcac	1560
agtaaaacaa caatacaggc tagggatggt aatcctttaa acatacaaaa attgctcgta	1620
ttataaatta cccagtttag accggaaaaa agaaaataat tattcctaaa caaatggata	1680
agtagaatta atgattgagg caggacccta cagagtgtgg gaactgctgg ggatctagag	1740
aattcagtgg gaccaatgaa agcatggctg agaaatagca gggtagtcca ggagagtcta	1800
agggaggtgt tcccatctga gccagagat aagggtgtct tcctagaaca ttagccgtag	1860
tggaattaac aggaaatcat gaggggtgacg tagaattgag tcttccaggg gactctatca	1920
gaactggacc atttccaagt atataacgat gagccctcta atgctaggag tagcaaatgg	1980
tcctaggaag gggactgagg attgggggtg ggggtggggtg gaaaagaaag tacagaacaa	2040
accctgtgtc actgtcccaa gttaagctaa gtgaacagaa ctatctcagc atcagaatga	2100
gaaagcctga gaagaaagaa ccaaccacaa gcacacagga aggaaagcgc aggaggtgaa	2160
aatgctttct tggccagggt agtaagaatt agaggttaat gcagggactg taaaaccacc	2220
ttttctgctt caatgtctag ttctgtata gctttgttca ttgcatttat taacaaatg	2280
ttgtataacc aatactaaat gtactactga gcttactga gttacgctgt gaaactttca	2340

44591144002SequenceListing.txt

aatccttctt catgtcagtt ccaatgaggt ggggatggag aagacaattg ttgcttatga 2400
 aaaaaagcct tagctgtctc tgttttgtaa gctttcagtg caacatttct tggttccaat 2460
 aaagcatttt aca 2473

<210> 9
 <211> 370
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> 2B4

<400> 9

Met Leu Gly Gln Val Val Thr Leu Ile Leu Leu Leu Leu Lys Val
 1 5 10 15

Tyr Gln Gly Lys Gly Cys Gln Gly Ser Ala Asp His Val Val Ser Ile
 20 25 30

Ser Gly Val Pro Leu Gln Leu Gln Pro Asn Ser Ile Gln Thr Lys Val
 35 40 45

Asp Ser Ile Ala Trp Lys Lys Leu Leu Pro Ser Gln Asn Gly Phe His
 50 55 60

His Ile Leu Lys Trp Glu Asn Gly Ser Leu Pro Ser Asn Thr Ser Asn
 65 70 75 80

Asp Arg Phe Ser Phe Ile Val Lys Asn Leu Ser Leu Leu Ile Lys Ala
 85 90 95

Ala Gln Gln Gln Asp Ser Gly Leu Tyr Cys Leu Glu Val Thr Ser Ile
 100 105 110

Ser Gly Lys Val Gln Thr Ala Thr Phe Gln Val Phe Val Phe Glu Ser
 115 120 125

44591144002SequenceListing.txt

Leu Leu Pro Asp Lys Val Glu Lys Pro Arg Leu Gln Gly Gln Gly Lys
 130 135 140

Ile Leu Asp Arg Gly Arg Cys Gln Val Ala Leu Ser Cys Leu Val Ser
 145 150 155 160

Arg Asp Gly Asn Val Ser Tyr Ala Trp Tyr Arg Gly Ser Lys Leu Ile
 165 170 175

Gln Thr Ala Gly Asn Leu Thr Tyr Leu Asp Glu Glu Val Asp Ile Asn
 180 185 190

Gly Thr His Thr Tyr Thr Cys Asn Val Ser Asn Pro Val Ser Trp Glu
 195 200 205

Ser His Thr Leu Asn Leu Thr Gln Asp Cys Gln Asn Ala His Gln Glu
 210 215 220

Phe Arg Phe Trp Pro Phe Leu Val Ile Ile Val Ile Leu Ser Ala Leu
 225 230 235 240

Phe Leu Gly Thr Leu Ala Cys Phe Cys Val Trp Arg Arg Lys Arg Lys
 245 250 255

Glu Lys Gln Ser Glu Thr Ser Pro Lys Glu Phe Leu Thr Ile Tyr Glu
 260 265 270

Asp Val Lys Asp Leu Lys Thr Arg Arg Asn His Glu Gln Glu Gln Thr
 275 280 285

Phe Pro Gly Gly Gly Ser Thr Ile Tyr Ser Met Ile Gln Ser Gln Ser
 290 295 300

Ser Ala Pro Thr Ser Gln Glu Pro Ala Tyr Thr Leu Tyr Ser Leu Ile
 305 310 315 320

Gln Pro Ser Arg Lys Ser Gly Ser Arg Lys Arg Asn His Ser Pro Ser
 325 330 335

44591144002SequenceListing.txt

Phe Asn Ser Thr Ile Tyr Glu Val Ile Gly Lys Ser Gln Pro Lys Ala
 340 345 350

Gln Asn Pro Ala Arg Leu Ser Arg Lys Glu Leu Glu Asn Phe Asp Val
 355 360 365

Tyr Ser
 370

<210> 10
 <211> 279
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> DAP10

<400> 10
 atgatccatc tgggtcacat cctcttctcg cttttgctcc cagtggtctgc agctcagacg 60
 actccaggag agagatcatc actccctgcc ttttaccctg gcacttcagg ctcttgttcc 120
 ggatgtgggt ccctctctct gccgctcctg gcaggcctcg tggctgctga tgcggtggca 180
 tcgctgctca tcgtgggggc ggtgttctcg tgcgcacgcc cacgccgag ccccgcccaa 240
 gatggcaaag tctacatcaa catgccaggc aggggctga 279

<210> 11
 <211> 575
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> DAP12

<400> 11
 agacttctc cttcacttgc ctggacgctg cgccacatcc caccggccct tacactgtgg 60
 tgtccagcag catccggctt catgggggga cttgaaccct gcagcaggct cctgctcctg 120
 cctctcctgc tggctgtaag tgattgcagt tgctctacgg tgagcccggg cgtgctggca 180
 gggatcgtga tgggagacct ggtgctgaca gtgctcattg ccctggccgt gtacttctcg 240

44591144002SequenceListing.txt

ggccggctgg tccctcgggg gcgaggggct gcgaggcag cgacccggaa acagcgtatc 300
 actgagaccg agtcgcctta tcaggagctc cagggtcaga ggtcggatgt ctacagcgac 360
 ctcaacacac agaggccgta ttacaaatga gcccgaaatca tgacagtcag caacatgata 420
 cctggatcca gccattcctg aagcccaccc tgcacctcat tccaactcct accgcgatac 480
 agaccacag agtgccatcc ctgagagacc agaccgctcc ccaatactct cctaaaataa 540
 acatgaagca caaaaacaaa aaaaaaaaaa aaaaa 575

<210> 12
 <211> 126
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> 4-1BB

<400> 12
 aaacggggca gaaagaaact cctgtatata ttcaaacaac catttatgag accagtacaa 60
 actactcaag aggaagatgg ctgtagctgc cgatttccag aagaagaaga aggaggatgt 120
 gaactg 126

<210> 13
 <211> 339
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> CD3-zeta

<400> 13
 agagtgaagt tcagcaggag cgcagacgcc cccgcgtacc agcaggcca gaaccagctc 60
 tataacgagc tcaatctagg acgaagagag gactacgatg ttttggacaa gagacgtggc 120
 cgggaccctg agatgggggg aaagccgaga aggaagaacc ctgaggaagg cctgtacaat 180
 gaactgcaga aagataagat ggcggaggcc tacagtgaga ttgggatgaa aggcgagcgc 240
 cggaggggca aggggcacga tggcctttac cagggtctca gtacagccac caaggacacc 300

tacgacgcc ttcacatgca ggccctgccc cctcgctaa

339

<210> 14
<211> 6
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> Canonical hemi-tam

<220>
<221> MISC_FEATURE
<222> (4)..(5)
<223> X = any amino acid

<400> 14

Asp Gly Tyr Xaa Xaa Leu
1 5

<210> 15
<211> 6
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> ITSM Motif

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> N = S or T

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> x = any amino acid

<220>
<221> MISC_FEATURE
<222> (4)..(5)
<223> x = any amino acid

<220>
<221> MISC_FEATURE

44591144002SequenceListing.txt

<222> (6)..(6)
 <223> N = L or I

<400> 15

Asn Xaa Tyr Xaa Xaa Asn
 1 5

<210> 16
 <211> 614
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Membrane-bound IL15

<400> 16
 atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg 60
 ccgaactggg tgaatgtaat aagtgatttg aaaaaaattg aagatcttat tcaatctatg 120
 catattgatg ctactttata tacggaaagt gatgttcacc ccagttgcaa agtaacagca 180
 atgaagtgct ttctcttgga gttacaagtt atttcacttg agtccggaga tgcaagtatt 240
 catgatacag tagaaaatct gatcatccta gcaaacaaca gtttgtcttc taatgggaat 300
 gtaacagaat ctggatgcaa agaatgtgag gaactggagg aaaaaaatat taaagaattt 360
 ttgcagagtt ttgtacatat tgtccaaatg ttcacaaaca cttctaccac gacgccagcg 420
 ccgcgaccac caacaccggc gccaccatc gcgtcgcagc ccctgtccct gcgcccagag 480
 gcgtgccggc cagcggcggg gggcgcagtg cacacgaggg ggctggactt cgcctgtgat 540
 atctacatct gggcgcctt ggccgggact tgtgggggtcc ttctcctgtc actggtatca 600
 ccctttactg ctaa 614

<210> 17
 <211> 204
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Membrane-bound IL15

44591144002SequenceListing.txt

<400> 17

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1 5 10 15

His Ala Ala Arg Pro Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys
 20 25 30

Ile Glu Asp Leu Ile Gln Ser Met His Ile Asp Ala Thr Leu Tyr Thr
 35 40 45

Glu Ser Asp Val His Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe
 50 55 60

Leu Leu Glu Leu Gln Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile
 65 70 75 80

His Asp Thr Val Glu Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu Ser
 85 90 95

Ser Asn Gly Asn Val Thr Glu Ser Gly Cys Lys Glu Cys Glu Glu Leu
 100 105 110

Glu Glu Lys Asn Ile Lys Glu Phe Leu Gln Ser Phe Val His Ile Val
 115 120 125

Gln Met Phe Ile Asn Thr Ser Thr Thr Thr Pro Ala Pro Arg Pro Pro
 130 135 140

Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu
 145 150 155 160

Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp
 165 170 175

Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly
 180 185 190

Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys

<210> 18
 <211> 1140
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> NKG2D/CD8a/4-1BB/CD3z

<220>
 <221> misc_feature
 <223> NKG2D/CD8a/4-1BB/CD3z (aka NK16)

<400> 18
 atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg 60
 ccgttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct 120
 aaaaactgga tatgttaca aaataactgc taccaatfff ttgatgagag taaaaactgg 180
 tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa 240
 gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt 300
 ccaacaaatg gatccttgca gtgggaagat ggctccattc tctcaccaa cctactaaca 360
 ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata 420
 gaaaactgtt caactccaaa tacatacatc tgcattgcaa ggactgtgac cacgacgcca 480
 gcgccgcgac caccaacacc ggcgcccacc atcgcgtcgc agcccctgtc cctgcgcca 540
 gaggcgtgcc ggccagcggc ggggggcgca gtgcacacga gggggctgga cttgcctgt 600
 gatatttaca tctgggcgcc cttggccggg acttgtgggg tccttctcct gtcactggtt 660
 atcacccttt actgcaaacg gggcagaaag aaactcctgt atatattcaa acaaccattt 720
 atgagaccag taaaactac tcaagaggaa gatggctgta gctgccgatt tccagaagaa 780
 gaagaaggag gatgtgaact gagagtgaag ttcagcagga gcgcagacgc ccccgcgtac 840
 cagcagggcc agaaccagct ctataacgag ctcaatctag gacgaagaga ggagtacgat 900
 gttttggaca agagacgtgg ccgggaccct gagatggggg gaaagccgag aaggaagaac 960
 cctcaggaag gcctgtacaa tgaactgcag aaagataaga tggcggaggc ctacagtgag 1020

44591144002SequenceListing.txt

attgggatga aaggcgagcg ccggaggggc aaggggcacg atggccttta ccagggtctc 1080

agtacagcca ccaaggacac ctacgacgcc cttcacatgc aggcctgcc ccctcgctaa 1140

<210> 19
 <211> 379
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Amino acid sequence of NKG2D/CD8a/4-1BB/CD3z

<220>
 <221> MISC_FEATURE
 <223> Amino acid sequence of NKG2D/CD8a/4-1BB/CD3z (aka NK16)

<400> 19

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1 5 10 15

His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr
 20 25 30

Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn
 35 40 45

Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln
 50 55 60

Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
 65 70 75 80

Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly
 85 90 95

Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
 100 105 110

Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp
 115 120 125

44591144002SequenceListing.txt

Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
130 135 140

Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro
145 150 155 160

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
165 170 175

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
180 185 190

Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu
195 200 205

Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr
210 215 220

Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe
225 230 235 240

Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg
245 250 255

Phe Pro Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser
260 265 270

Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr
275 280 285

Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys
290 295 300

Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn
305 310 315 320

Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu
325 330 335

44591144002SequenceListing.txt

Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly
340 345 350

His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr
355 360 365

Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
370 375

<210> 20
<211> 46
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> Amino acid for NCR1 TM/IC

<400> 20

Met Gly Leu Ala Phe Leu Val Leu Val Ala Leu Val Trp Phe Leu Val
1 5 10 15

Glu Asp Trp Leu Ser Arg Lys Arg Thr Arg Glu Arg Ala Ser Arg Ala
20 25 30

Ser Thr Trp Glu Gly Arg Arg Arg Leu Asn Thr Gln Thr Leu
35 40 45

<210> 21
<211> 276
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> Full length NCR2

<400> 21

Met Ala Trp Arg Ala Leu His Pro Leu Leu Leu Leu Leu Leu Phe
1 5 10 15

44591144002SequenceListing.txt

Pro Gly Ser Gln Ala Gln Ser Lys Ala Gln Val Leu Gln Ser Val Ala
 20 25 30

Gly Gln Thr Leu Thr Val Arg Cys Gln Tyr Pro Pro Thr Gly Ser Leu
 35 40 45

Tyr Glu Lys Lys Gly Trp Cys Lys Glu Ala Ser Ala Leu Val Cys Ile
 50 55 60

Arg Leu Val Thr Ser Ser Lys Pro Arg Thr Met Ala Trp Thr Ser Arg
 65 70 75 80

Phe Thr Ile Trp Asp Asp Pro Asp Ala Gly Phe Phe Thr Val Thr Met
 85 90 95

Thr Asp Leu Arg Glu Glu Asp Ser Gly His Tyr Trp Cys Arg Ile Tyr
 100 105 110

Arg Pro Ser Asp Asn Ser Val Ser Lys Ser Val Arg Phe Tyr Leu Val
 115 120 125

Val Ser Pro Ala Ser Ala Ser Thr Gln Thr Ser Trp Thr Pro Arg Asp
 130 135 140

Leu Val Ser Ser Gln Thr Gln Thr Gln Ser Cys Val Pro Pro Thr Ala
 145 150 155 160

Gly Ala Arg Gln Ala Pro Glu Ser Pro Ser Thr Ile Pro Val Pro Ser
 165 170 175

Gln Pro Gln Asn Ser Thr Leu Arg Pro Gly Pro Ala Ala Pro Ile Ala
 180 185 190

Leu Val Pro Val Phe Cys Gly Leu Leu Val Ala Lys Ser Leu Val Leu
 195 200 205

Ser Ala Leu Leu Val Trp Trp Gly Asp Ile Trp Trp Lys Thr Met Met
 210 215 220

44591144002SequenceListing.txt

Glu Leu Arg Ser Leu Asp Thr Gln Lys Ala Thr Cys His Leu Gln Gln
225 230 235 240

Val Thr Asp Leu Pro Trp Thr Ser Val Ser Ser Pro Val Glu Arg Glu
245 250 255

Ile Leu Tyr His Thr Val Ala Arg Thr Lys Ile Ser Asp Asp Asp Asp
260 265 270

Glu His Thr Leu
275

<210> 22
<211> 66
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> NCR3 TM/IC domains

<400> 22

Ala Gly Thr Val Leu Leu Leu Arg Ala Gly Phe Tyr Ala Val Ser Phe
1 5 10 15

Leu Ser Val Ala Val Gly Ser Thr Val Tyr Tyr Gln Gly Lys Cys Leu
20 25 30

Thr Trp Lys Gly Pro Arg Arg Gln Leu Pro Ala Val Val Pro Ala Pro
35 40 45

Leu Pro Pro Pro Cys Gly Ser Ser Ala His Leu Leu Pro Pro Val Pro
50 55 60

Gly Gly
65

<210> 23
<211> 741
<212> DNA

44591144002SequenceListing.txt

<213> Homo sapiens

<220>

<221> misc_feature

<223> NKG2D/CD16

<400> 23

```

atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgcccgc      60
cccctgttca accaggaagt gcagatcccc ctgaccgagt cctattgtgg cccttgcctt      120
aagaattgga tttgctataa aaacaactgc taccagttct ttgacgagtc taagaattgg      180
tatgagtccc aggcctcttg tatgagccag aacgcctctc tgctgaaggt gtacagcaag      240
gaggaccagg atctgctgaa gctgggtgaag tcctatcact ggatgggcct ggtgcacatc      300
cccacaaacg gctcttggca gtgggaggac ggctccatcc tgtctcctaa tctgctgacc      360
atcatcgaga tgcagaaggg cgattgcgcc ctgtacgcca gtccttcaa gggctatatac      420
gagaactgca gcacacccaa tacctacatc tgtatgcagc ggacagtgac cacaacccca      480
gcacccaggc ccctacacc tgcaccaacc atcgcaagcc agccactgtc cctgaggcct      540
gaggcatgta ggccagcagc aggaggagca gtgcacacac ggggcctgga cttgcctgctgc      600
gatgtgagct tttgtctggt catggtgctg ctgttcgccg tggataccgg cctgtatttt      660
tccgtgaaga caaatatccg gtctagcacc agagactgga aggatcacaa gttcaaattgg      720
aggaaggacc cacaggacaa g                                     741

```

<210> 24

<211> 247

<212> PRT

<213> Homo sapiens

<220>

<221> MISC_FEATURE

<223> NKG2D/CD16

<400> 24

```

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1           5           10           15

```

```

His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr

```

44591144002SequenceListing.txt

20

25

30

Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn
 35 40 45

Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln
 50 55 60

Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
 65 70 75 80

Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly
 85 90 95

Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
 100 105 110

Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp
 115 120 125

Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
 130 135 140

Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro
 145 150 155 160

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
 165 170 175

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
 180 185 190

Thr Arg Gly Leu Asp Phe Ala Cys Asp Val Ser Phe Cys Leu Val Met
 195 200 205

Val Leu Leu Phe Ala Val Asp Thr Gly Leu Tyr Phe Ser Val Lys Thr
 210 215 220

Asn Ile Arg Ser Ser Thr Arg Asp Trp Lys Asp His Lys Phe Lys Trp

225

230

235

240

Arg Lys Asp Pro Gln Asp Lys
245

<210> 25
<211> 870
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> CD8/NKG2DOpt/CD8a/CD16 TM/IC/4-1BB

<400> 25
atggctctgc ccgtcaccgc actgctgctg cctctggctc tgctgctgca cgccgcacga 60
ccactgttca atcaggaagt ccagatcccc ctgacagagt cttactgcgg cccatgtccc 120
aagaactgga tctgctacaa gaacaattgt tatcagttct ttgacgagag caagaactgg 180
tatgagtccc aggcctcttg catgagccag aatgcctctc tgctgaaggt gtacagcaag 240
gaggaccagg atctgctgaa gctggtgaag tcctatcact ggatgggcct ggtgcacatc 300
cctacaaacg gctcttggca gtgggaggac ggctccatcc tgtctcaaaa tctgctgacc 360
atcatcgaga tgcagaaggg cgattgcgcc ctgtacgcca gctccttcaa gggctatatc 420
gagaactgct ccacacccaa tacctacatc tgtatgcaga ggaccgtgac cacaaccctt 480
gcaccacgcc cccctacacc agcacctacc atcgcaagcc agcctctgtc cctgcggcca 540
gaggcatgta gaccagcagc aggaggagca gtgcacacaa gaggcctgga cttgcctgctg 600
gatgtgagct tttgtctggt catggtgctg ctgttcgccg tggataccgg cctgtacttt 660
tccgtgaaga caaatatcag gtctagcacc cgcgactgga aggatcacaa gtttaagtgg 720
cggaaggacc ctcaggataa gaagcggggc agaaagaagc tgctgtatat cttcaagcag 780
cccttcatgc ggcccgtgca gacaaccag gaggaagacg gctgctcatg tagatttcct 840
gaagaagaag aagggggctg tgaactgtaa 870

<210> 26
<211> 289
<212> PRT

44591144002SequenceListing.txt

<213> Homo sapiens

<220>

<221> MISC_FEATURE

<223> CD8/NKG2DOpt/CD8a/CD16 TM/IC/4-1BB

<400> 26

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1 5 10 15

His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr
 20 25 30

Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn
 35 40 45

Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln
 50 55 60

Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
 65 70 75 80

Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly
 85 90 95

Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
 100 105 110

Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp
 115 120 125

Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
 130 135 140

Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro
 145 150 155 160

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
 165 170 175

44591144002SequenceListing.txt

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
 180 185 190

Thr Arg Gly Leu Asp Phe Ala Cys Asp Val Ser Phe Cys Leu Val Met
 195 200 205

Val Leu Leu Phe Ala Val Asp Thr Gly Leu Tyr Phe Ser Val Lys Thr
 210 215 220

Asn Ile Arg Ser Ser Thr Arg Asp Trp Lys Asp His Lys Phe Lys Trp
 225 230 235 240

Arg Lys Asp Pro Gln Asp Lys Lys Arg Gly Arg Lys Lys Leu Leu Tyr
 245 250 255

Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu
 260 265 270

Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu
 275 280 285

Leu

<210> 27
 <211> 741
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> NKG2D/NCR1

<400> 27
 atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgcccgc 60
 cctctgttca accaggaagt gcagatcct ctgaccgaaa gctattgctg accttgcct 120
 aagaattgga tttgctataa aaacaactgc taccagttct ttgacgagtc taagaattgg 180
 tatgagtctc aggccagctg tatgtcccag aacgcctctc tgctgaaggt gtacagcaag 240

44591144002SequenceListing.txt

gaggaccagg atctgctgaa gctggtgaag tcctatcact ggatgggcct ggtgcacatc 300
cccacaaacg gctccttgga gtgggaggac ggctctatcc tgagccctaa tctgctgacc 360
atcatcgaga tgcagaaggg cgattgcgcc ctgtacgcca gtccttcaa gggctatatc 420
gagaactgca gcacacccaa tacctacatc tgtatgcaga ggacagtgac cacaacccca 480
gcaccccgcc cccctacacc tgcaccaacc atcgaagcc agccactgtc cctgcggcct 540
gaggcctgca gaccagcagc aggaggagca gtgcacaccc ggggcctgga cttgcctgt 600
gatatgggcc tggcctttct ggtgctggtg gccctggtgt ggtttctggt ggaggattgg 660
ctgtcccgga agagaacaag ggagagggcc tcccgggcct ctacctggga aggaagaagg 720
agactgaaca cccagacact g 741

<210> 28
<211> 247
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> NKG2D/NCR1

<400> 28

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr
20 25 30

Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn
35 40 45

Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln
50 55 60

Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
65 70 75 80

Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly

44591144002SequenceListing.txt

85

90

95

Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
 100 105 110

Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp
 115 120 125

Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
 130 135 140

Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro
 145 150 155 160

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
 165 170 175

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
 180 185 190

Thr Arg Gly Leu Asp Phe Ala Cys Asp Met Gly Leu Ala Phe Leu Val
 195 200 205

Leu Val Ala Leu Val Trp Phe Leu Val Glu Asp Trp Leu Ser Arg Lys
 210 215 220

Arg Thr Arg Glu Arg Ala Ser Arg Ala Ser Thr Trp Glu Gly Arg Arg
 225 230 235 240

Arg Leu Asn Thr Gln Thr Leu
 245

<210> 29
 <211> 801
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> NKG2D/NCR3

44591144002SequenceListing.txt

<400> 29
atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccaga 60
cccctgttca accaggaggt gcagattccc ctgacagaaa gctattgtgg cccttgcctt 120
aaaaattgga tttgctataa aaacaactgc taccagttct ttgacgagtc taagaattgg 180
tatgagtctc aggccagctg tatgtcccag aacgcctctc tgctgaaggt gtacagcaag 240
gaggaccagg atctgctgaa gctggtgaag tcctatcact ggatgggcct ggtgcacatc 300
cctacaaacg gctcttggca gtgggaggac ggctctatcc tgagcccaaa tctgctgacc 360
atcatcgaga tgcagaaggg cgattgcgcc ctgtacgcca gctccttcaa gggctatatc 420
gagaactgca gcacacccaa tacctacatc tgtatgcagc ggacagtgc cacaacccca 480
gcaccagac cccctacacc tgcaccaacc atcgccagcc agccactgtc cctgaggccc 540
gaggcatgca ggcctgcagc aggaggcgcc gtgcacacaa ggggcctgga ctttgcctgt 600
gatgcaggaa ccgtgctgct gctgagagca ggcttctatg ccgtgtcctt tctgtctgtg 660
gccgtgggct ccacagtgta ctatcagggc aagtgccctga cctggaaggg cccacggaga 720
cagctgcccg ccgtggtgcc cgcccctctg ccaccccctt gtggcagtag cgcccacctg 780
ctgccaccgg tgcccggagg a 801

<210> 30
<211> 267
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> NKG2D/NCR3

<400> 30

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr
20 25 30

Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn

44591144002SequenceListing.txt

35

40

45

Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln
 50 55 60

Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
 65 70 75 80

Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly
 85 90 95

Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
 100 105 110

Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp
 115 120 125

Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
 130 135 140

Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro
 145 150 155 160

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
 165 170 175

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
 180 185 190

Thr Arg Gly Leu Asp Phe Ala Cys Asp Ala Gly Thr Val Leu Leu Leu
 195 200 205

Arg Ala Gly Phe Tyr Ala Val Ser Phe Leu Ser Val Ala Val Gly Ser
 210 215 220

Thr Val Tyr Tyr Gln Gly Lys Cys Leu Thr Trp Lys Gly Pro Arg Arg
 225 230 235 240

Gln Leu Pro Ala Val Val Pro Ala Pro Leu Pro Pro Pro Cys Gly Ser

245

250

255

Ser Ala His Leu Leu Pro Pro Val Pro Gly Gly
 260 265

<210> 31
 <211> 6
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <222> (6)..(6)
 <223> N is an integer indicating the number of GGGGS repeated

<400> 31

Gly Gly Gly Gly Ser Asn
 1 5

<210> 32
 <211> 60
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> GS3/CD8a

<400> 32

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Thr
 1 5 10 15

Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser
 20 25 30

Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly
 35 40 45

Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp
 50 55 60

44591144002SequenceListing.txt

<210> 33
<211> 45
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> GS9

<400> 33

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1 5 10 15

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
20 25 30

Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
35 40 45

<210> 34
<211> 15
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> GS3

<400> 34

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10 15

<210> 35
<211> 120
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> 2B4 ICR

<400> 35

44591144002SequenceListing.txt

Trp Arg Arg Lys Arg Lys Glu Lys Gln Ser Glu Thr Ser Pro Lys Glu
 1 5 10 15

Phe Leu Thr Ile Tyr Glu Asp Val Lys Asp Leu Lys Thr Arg Arg Asn
 20 25 30

His Glu Gln Glu Gln Thr Phe Pro Gly Gly Gly Ser Thr Ile Tyr Ser
 35 40 45

Met Ile Gln Ser Gln Ser Ser Ala Pro Thr Ser Gln Glu Pro Ala Tyr
 50 55 60

Thr Leu Tyr Ser Leu Ile Gln Pro Ser Arg Lys Ser Gly Ser Arg Lys
 65 70 75 80

Arg Asn His Ser Pro Ser Phe Asn Ser Thr Ile Tyr Glu Val Ile Gly
 85 90 95

Lys Ser Gln Pro Lys Ala Gln Asn Pro Ala Arg Leu Ser Arg Lys Glu
 100 105 110

Leu Glu Asn Phe Asp Val Tyr Ser
 115 120

<210> 36
 <211> 360
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> 2B4 ICR

<400> 36
 tggaggagga aaaggaagga gaaacagagc gagacctccc ctaaggagtt cctgaccatc 60
 tacgaggacg tgaaggacct gaagaccagg aggaaccacg agcaggaaca gacctttcct 120
 ggctggaggca gcaccatcta cagcatgatc cagagccaga gcagcgcccc taccagccaa 180
 gagcctgcct acaccctgta cagcctgatc cagcccagca ggaaaagcgg ctccaggaag 240
 aggaaccaca gccccagctt caacagcacc atctatgagg tgatcggcaa gagccagccc 300

44591144002SequenceListing.txt

aaggcccaga accctgccag gctgtccagg aaggagctgg agaacttcga cgtgtacagc 360

<210> 37
 <211> 38
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> NKp80 ICR

<400> 37

Met Gln Asp Glu Asp Gly Tyr Met Thr Leu Asn Val Gln Ser Lys Lys
 1 5 10 15

Arg Ser Ser Ala Gln Thr Ser Gln Leu Thr Phe Lys Asp Tyr Ser Val
 20 25 30

Thr Leu His Trp Tyr Lys
 35

<210> 38
 <211> 114
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> NKp80 ICR

<400> 38

atgcaggatg aggacggcta tatgaccctg aacgtccagt ccaagaagag gtccagcgct 60

cagaccagcc agctgacctt caaggactac tccgtgaccc tgcactggta caag 114

<210> 39
 <211> 30
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE

44591144002SequenceListing.txt

<223> B2Ad N-term ECD

<400> 39

Met Gly Gln Pro Gly Asn Gly Ser Ala Phe Leu Leu Ala Pro Asn Arg
 1 5 10 15

Ser His Ala Pro Asp His Asp Val Thr Gln Gln Arg Asp Glu
 20 25 30

<210> 40
 <211> 90
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> B2 AdR N-term ECD

<400> 40
 atggggcaac cgggaacgg cagcgccttc ttgctggcac ccaatagaag ccatgcgccg 60
 gaccacgacg tcacgcagca aaggacgag 90

<210> 41
 <211> 33
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> B2 AdR TM helix

<400> 41

Val Trp Val Val Gly Met Gly Ile Val Met Ser Leu Ile Val Leu Ala
 1 5 10 15

Ile Val Phe Gly Asn Val Leu Val Ile Thr Ala Ile Ala Lys Phe Glu
 20 25 30

Arg

44591144002SequenceListing.txt

<210> 42
 <211> 99
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> B2AdR TM helix

<400> 42
 gtgtgggtgg tgggcatggg catcgtcatg tctctcatcg tcctggccat cgtgtttggc 60
 aatgtgctgg tcatcacagc cattgccaag ttcgagcgt 99

<210> 43
 <211> 924
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> NK15_1

<400> 43
 gccgccacca tggctctgcc cgtcaccgca ctgctgctgc ctctggctct gctgctgcac 60
 gccgcacgac cactgttcaa tcaggaagtc cagatcccc tgacagagtc ttactgcggc 120
 ccatgtccca agaactggat ctgctacaag aacaattggt atcagttctt tgacgagagc 180
 aagaactggt atgagtccca ggctcttgc atgagccaga atgcctctct gctgaagggt 240
 tacagcaagg aggaccagga tctgctgaag ctggtgaagt cctatcactg gatgggcctg 300
 gtgcacatcc ctacaaacgg ctcttggcag tgggaggacg gctccatcct gtctccaaat 360
 ctgctgacca tcatcgagat gcagaagggc gattgcgccc tgtacgccag ctcttcaag 420
 ggctatatcg agaactgctc cacaccaat acctacatct gtatgcagag gaccgtgggt 480
 ggcggtggct cgggcggtgg tgggtcgggt ggcggcggat ctaccacaac ccctgcacca 540
 cgcccccta caccagcacc taccatcgca agccagcctc tgtccctgcg gccagaggca 600
 tntagaccag cagcaggagg agcagtgcac acaagaggcc tggacttcgc ctgcatgtg 660
 agcttttgtc tggatcatggt gctgctgttc gccgtggata ccggcctgta cttttccgtg 720
 aagacaaata tcaggtctag caccgcgac tggaaggatc acaagtttaa gtggcggaag 780

44591144002SequenceListing.txt

gaccctcagg ataagaagcg gggcagaaag aagctgctgt atatcttcaa gcagcccttc 840
atgcggcccc tgacagacaac ccaggaggaa gacggctgct catgtagatt tcctgaagaa 900
gaagaagggg gctgtgaact gtaa 924

<210> 44
<211> 789
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> NK15_2

<400> 44
gccgccacca tggctctgcc cgtcaccgca ctgctgctgc ctctggctct gctgctgcac 60
gccgcacgac cactgttcaa tcaggaagtc cagatcccc tgacagagtc ttactgcggc 120
ccatgtccca agaactggat ctgctacaag aacaattggt atcagttctt tgacgagagc 180
aagaactggt atgagtccca ggcctcttgc atgagccaga atgcctctct gctgaaggtg 240
tacagcaagg aggaccagga tctgctgaag ctggtgaagt cctatcactg gatgggctctg 300
gtgcacatcc ctacaaacgg ctcttggcag tgggaggacg gctccatcct gtctccaaat 360
ctgctgacca tcatcgagat gcagaagggc gattgcgccc tgtacgccag ctccttcaag 420
ggctatatcg agaactgctc cacaccaat acctacatct gtatgcagag gaccgtgggt 480
ggcgggtggct cgggcggtgg tgggtcgggt ggcggcggat ctgtgagctt ttgtctggtc 540
atggtgctgc tgttcgccgt ggataccggc ctgtactttt ccgtgaagac aaatatcagg 600
tctagcacc gcgactggaa ggatcacaag ttttaagtggc ggaaggaccc tcaggataag 660
aagcggggca gaaagaagct gctgtatata ttcaagcagc cttcatgcg gcccgctgcag 720
acaaccaggg aggaagacgg ctgctcatgt agatttcctg aagaagaaga agggggctgt 780
gaactgtaa 789

<210> 45
<211> 744
<212> DNA
<213> Homo sapiens

44591144002SequenceListing.txt

<220>

<221> misc_feature

<223> NK15_3

<400> 45

```
gccgccacca tggctctgcc cgtcaccgca ctgctgctgc ctctggctct gctgctgcac      60
gccgcacgac cactgttcaa tcaggaagtc cagatcccc tgacagagtc ttactgcggc      120
ccatgtccca agaactggat ctgctacaag aacaattggt atcagttctt tgacgagagc      180
aagaactggg atgagtccca ggctcttgc atgagccaga atgcctctct gctgaagggt      240
tacagcaagg aggaccagga tctgctgaag ctggtgaagt cctatcactg gatgggcctg      300
gtgcacatcc ctacaaacgg ctcttggcag tgggaggacg gctccatcct gtctccaaat      360
ctgctgacca tcatcgagat gcagaagggc gattgcgccc tgtacgccag ctcttcaag      420
ggctatatcg agaactgctc cacaccaat acctacatct gtatgcagag gaccgtggtg      480
agcttttgtc tggatcatggg gctgctgttc gccgtggata ccggcctgta cttttccgtg      540
aagacaaata tcaggtctag caccgcgac tggaaggatc acaagtttaa gtggcgggaag      600
gaccctcagg ataagaagcg gggcagaaag aagctgctgt atatcttcaa gcagcccttc      660
atgcgggccc tgagagacaac ccaggaggaa gacggctgct catgtagatt tcctgaagaa      720
gaagaagggg gctgtgaact gtaa                                             744
```

<210> 46

<211> 1164

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> NK15_4

<400> 46

```
gccgccacca tggccctgcc tgtgacagcc ctgctgctgc ctctggctct gctgctgcac      60
gctgccagac cttattcaa ccaagaagtt caaattccct tgaccgaaag ttactgtggc      120
ccatgtccta aaaactggat atgttacaaa aataactgct accaattttt tgatgagagt      180
aaaaactggg atgagagcca ggcttcttgt atgtctcaaa atgccagcct tctgaaagta      240
```

44591144002SequenceListing.txt

tacagcaaag aggaccagga tttacttaaa ctggtgaagt catatcattg gatgggacta	300
gtacacattc caacaaatgg atcttggcag tgggaagatg gctccattct ctacccaac	360
ctactaacia taattgaaat gcagaaggga gactgtgcac tctatgcctc gagctttaa	420
ggctatatag aaaactgttc aactccaaat acgtacatct gcatgcaaag gactgtgacc	480
acaacccccg ctcccagacc tcctaccct gccctacaa tcgccagcca gccctgagc	540
ctgagacccg aagcctgtag acctgctgcc ggaggcgctg tgcacacaag aggcctggac	600
ttgcctgcg atatctatat ctgggccct ctggctggaa cctgtggcgt gctgctgctg	660
agcctggtga ttaccaagag gggcaggaag aagctgctgt acatcttcaa gcagccttc	720
atgaggcccg tgcaaaccac ccaggaggag gacggctgca gctgcagatt ccctgaggag	780
gaggagggcg gatgcgagct gtggaggagg aaaaggaagg agaaacagag cgagacctc	840
cctaaggagt tcctgacat ctacgaggac gtgaaggacc tgaagaccag gaggaaccac	900
gagcaggaac agaccttcc tggcggaggc agcaccatct acagcatgat ccagagccag	960
agcagcgccc ctaccagcca agagcctgcc tacaccctgt acagcctgat ccagcccagc	1020
aggaaaagcg gctccaggaa gaggaaccac agccccagct tcaacagcac catctatgag	1080
gtgatcggca agagccagcc caaggcccag aaccctgcc ggctgtccag gaaggagctg	1140
gagaacttcg acgtgtacag ctga	1164

<210> 47
 <211> 1155
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> NK15_5

<400> 47	
gccgccacca tggccctgcc tgtgacagcc ctgctgctgc ctctggctct gctgctgcac	60
gctgccagac cttattcaa ccaagaagtt caaattccct tgaccgaaag ttactgtggc	120
ccatgtccta aaaactggat atgttacaaa aataactgct accaattttt tgatgagagt	180
aaaaactggat atgagagcca ggcttcttgt atgtctcaaa atgccagcct tctgaaagta	240

44591144002SequenceListing.txt

tacagcaaag aggaccagga tttacttaaa ctggtgaagt catatcattg gatgggacta	300
gtacacattc caacaaatgg atcttggcag tgggaagatg gctccattct ctcacccaac	360
ctactaacia taattgaaat gcagaaggga gactgtgcac tctatgcctc gagctttaa	420
ggctatatag aaaactgttc aactccaaat acgtacatct gcatgcaaag gactgtgatg	480
ggacagcctg gaaacggcag cgccttctg ctggccccta acagaagcca cgccccgat	540
cacgatgtga cccagcagag ggacgaggtg tgggtggtgg gcatgggcat cgtgatgagc	600
ctgatcgtgc tggctatcgt gttcggcaac gtgctggtga tcaccgcat cgccaagttc	660
gagaggaaga ggggcaggaa aaagctgctc tacatcttca agcagccctt catgaggccc	720
gtgcagacca cccaggaaga ggatggctgc tcctgtaggt ttcccagga ggaggagggc	780
ggctgtgagc tgtggaggag aaaaaggaag gagaagcaga gcgagaccag cccaaggag	840
ttcctgacca tctacgagga cgtgaaggac ctgaagacca ggaggaacca cgagcaggaa	900
cagaccttc ccggcggagg cagcaccatc tacagcatga tccagagcca gtccagcgcc	960
cccacaagcc aggaaccgc ctacacactg tatagcctga tccagccctc caggaagagc	1020
ggcagcagga agaggaacca cagccccagc ttcaacagca ccatttacga ggtgatcgga	1080
aagagccagc ccaaggctca gaaccccgcc aggctgagca ggaaggagct cgaaaacttc	1140
gacgtgtaca gctga	1155

<210> 48
 <211> 1349
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> NK15_6

<400> 48	
ggatccgaat tcgccgccac catggccctg cctgtgacag ccctgctgct gcctctggct	60
ctgctgctgc acgctgccag acccttattc aaccaagaag ttcaaattcc cttgaccgaa	120
agttactgtg gcccatgtcc taaaaactgg atatgttaca aaaataactg ctaccaattt	180
tttgatgaga gtaaaaactg gtatgagagc caggcttctt gtatgtctca aaatgccagc	240

44591144002SequenceListing.txt

cttctgaaag tatacagcaa agaggaccag gatttactta aactggtgaa gtcatatcat 300
tggatgggac tagtacacat tccaacaaat ggatcttggc agtgggaaga tggctccatt 360
ctctcaccca acctactaac aataattgaa atgcagaagg gagactgtgc actctatgcc 420
tcgagcttta aaggctatat agaaaactgt tcaactccaa atacgtacat ctgcatgcaa 480
aggactgtga ccacaacccc tgctcccaga cctcccacac ccgcccctac aatcgcctcc 540
cagcctctga gcctgagacc cgaagcctgt agacctgccg ccggcggagc tgtgcataca 600
agaggcctgg acttcgcctg cgacatctac atctgggccc ctctggctgg cacatgcgga 660
gtcctgctgc tgagcctggt gatcaccaag aggggcagga agaagctgct gtacatcttc 720
aagcagccct tcatgaggcc tgtgcagacc acacaggagg aggacggctg ctctgcagg 780
ttccctgagg aggaggaggg aggctgcgag ctgtggagga ggaagagaaa ggagaagcag 840
tccgagacct cccccaagga gttcctcacc atttacgagg acgtgaagga cctgaagacc 900
aggagaaacc acgagcagga acaaaccttc cccggcggcg gcagcaccat ctacagcatg 960
atccagagcc agtcctccgc ccctacaagc caggagcctg cctacaccct gtacagcctg 1020
atccagccta gcaggaagag cggctccagg aagaggaacc actccccag cttcaacagc 1080
accatttatg aggtgatcgg caagtcccag cccaaggccc agaaccctgc cagactgtcc 1140
aggaaggagc tggagaactt cgacgtctac tccggcggcg gcggcagcgg cggaggaggc 1200
tccggaggag gcggcagcat gcaggatgag gacggctata tgaccctgaa cgtccagtcc 1260
aagaagaggt ccagcgtca gaccagccag ctgaccttca aggactactc cgtgaccctg 1320
cactggtaca agtgagcggc cgcgtcgac 1349

<210> 49
<211> 989
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> NK15_7

<400> 49
ggatccgaat tcgccgccac catggccctg cctgtgacag ccctgctgct gcctctggct 60

44591144002SequenceListing.txt

ctgctgctgc atgccgccag acccttattc aaccaagaag ttcaaattcc cttgaccgaa 120
agttactgtg gcccatgtcc taaaaactgg atatgttaca aaaataactg ctaccaattt 180
tttgatgaga gtaaaaactg gtatgagagc caggcttctt gtatgtctca aatgccagc 240
cttctgaaag tatacagcaa agaggaccag gatttactta aactggtgaa gtcatatcat 300
tggatgggac tagtacacat tccaacaaat ggatcttggc agtgggaaga tggctccatt 360
ctctcaccca acctactaac aataattgaa atgcagaagg gagactgtgc actctatgcc 420
tcgagcttta aaggctatat agaaaactgt tcaactccaa atacgtacat ctgcatgcaa 480
aggactgtga ccaccacccc tgctcccaga cccctacac ctgcccctac aatgccagc 540
cagcccctga gcctgagacc tgaggcctgc agacctgctg ctggaggcgc tgtgcacaca 600
aggggcctcg acttcgcctg cgacatctac atctgggccc ctctggccgg cacatgtgga 660
gtgctgctgc tgtccctggt gatcaccaag aggggcagga agaagctgct gtacatcttc 720
aagcagccct tcatgaggcc cgtgcagacc acccaggagg aggacggctg ctcctgcaga 780
ttccccgagg aggaggaggg cggatgtgaa ctgggcggag gaggcagcgg cggcggcggc 840
agcggcggcg gcggcagcat gcaggatgag gacggctaca tgaccctgaa cgtgcagagc 900
aagaagagga gcagcgcca gaccagccag ctgaccttca aggactacag cgtgaccctg 960
cactggtaca agtgagcggc cgcgtcgac 989

<210> 50
<211> 1430
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> NK15_8

<400> 50
ggatccgaat tcgccgccac catggccctg cccgtgacag ctctgctgct gcctctggcc 60
ctgctgctgc atgccgctag acccctgttc aaccaggagg tgcagatccc cctgaccgaa 120
agctactgcg gccctgccc caagaactgg atctgttaca agaacaactg ctatcagttc 180
ttcgacgaga gcaagaactg gtacgagagc caggccagct gtatgagcca gaacgccagc 240

44591144002SequenceListing.txt

ctgctgaaag tgtatagcaa ggaggaccag gacctgctga agctggtgaa gagctaccac 300
tggatgggcc tggatgacat cccaccaaac ggaagctggc agtgggagga cggcagcatc 360
ctgagcccca acctgctgac catcatcgag atgcagaagg gcgactgctc cctgtatgcc 420
agcagcttca agggctacat cgagaactgt agcaccacca acacctacat ctgcatgcag 480
aggaccgtgg gcggcggcgg cagcggcggg ggcggctccg gcggcggcgg cagcttattc 540
aaccaagaag ttcaaattcc cttgaccgaa agttactgtg gcccatgtcc taaaaactgg 600
atatgttaca aaaataactg ctaccaattt tttgatgaga gtaaaaactg gtatgagagc 660
caggcttctt gtatgtctca aaatgccagc cttctgaaag tatacagcaa agaggaccag 720
gatttactta aactggtgaa gtcatatcat tggatgggac tagtacacat tccaacaaat 780
ggatcttggc agtgggaaga tggctccatt ctctcaccca acctactaac aataattgaa 840
atgcagaagg gagactgtgc actctatgcc tcgagcttta aaggctatat agaaaactgt 900
tcaactcaa atacgtacat ctgcatgcaa aggactgtga tgggccagcc tggcaacggc 960
agcgcctttc tgctggcccc caacaggagc catgcccctg accacgacgt gaccagcag 1020
agggacgagg tgtgggtggt gggcatgggc atcgtgatga gcctgatcgt gctggccatc 1080
gtgttcggca acgtgctggt gatcaccgcc atcgccaagt tcgagaggaa gaggggcagg 1140
aagaagctgc tgtacatctt caagcagccc ttcatgagac ccgtgcaaac caccagagg 1200
gaggacggct gcagctgcag gtttcccgag gaggaggagg gcggatgcga actgggaggc 1260
ggaggaagcg gaggaggagg atccggagga ggcggaagca tgcaggacga ggacggctac 1320
atgaccctga acgtccagag caagaagagg agcagcggcc agacctcca gctgaccttc 1380
aaggactact ccgtgaccct gcactggtac aagtgagcgg ccgctcgcac 1430

<210> 51
<211> 1439
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> NK15_9

44591144002SequenceListing.txt

<400> 51
ggatccgaat tcgccgccac catggccctg cccgtgacag ctctgctgct gcctctggcc 60
ctgctgctgc atgccgctag acccctgttc aaccaggagg tgcagatccc cctgaccgaa 120
agctactgcg gccctgccc caagaactgg atctgttaca agaacaactg ctatcagttc 180
ttcgacgaga gcaagaactg gtacgagagc caggccagct gtatgagcca gaacgccagc 240
ctgctgaaag tgtatagcaa ggaggaccag gacctgctga agctggtgaa gagctaccac 300
tggatgggcc tggtgacat cccaccaac ggaagctggc agtgggagga cggcagcatc 360
ctgagcccca acctgctgac catcatcgag atgcagaagg gcgactgcgc cctgtatgcc 420
agcagcttca agggctacat cgagaactgt agcaccccca acacctacat ctgcatgcag 480
aggaccgtgg gcggcggcgg cagcggcggg ggcggctccg gcggcggcgg cagcttattc 540
aaccaagaag ttcaaattcc cttgaccgaa agttactgtg gcccatgtcc taaaaactgg 600
atatgttaca aaaataactg ctaccaattt tttgatgaga gtaaaaactg gtatgagagc 660
caggcttctt gtatgtctca aaatgccagc cttctgaaag tatacagcaa agaggaccag 720
gatttactta aactggtgaa gtcatatcat tggatgggac tagtacacat tccaacaaat 780
ggatcttggc agtgggaaga tggctccatt ctctaccca acctactaac aataattgaa 840
atgcagaagg gagactgtgc actctatgcc tcgagcttta aaggctatat agaaaactgt 900
tcaactcaa atacgtacat ctgcatgcaa aggactgtga ccaccacccc tgctcccaga 960
ccccctacac ctgcccctac aatcgccagc cagcccctga gcctgagacc tgaggcctgc 1020
agacctgctg ctggaggcgc tgtgcacaca aggggcctcg acttcgcctg cgacatctac 1080
atctgggccc ctctggccgg cacatgtgga gtgctgctgc tgtccctggt gatcaccaag 1140
aggggcagga agaagctgct gtacatcttc aagcagccct tcatgaggcc cgtgcagacc 1200
accaggagg aggacggctg ctctgcaga ttccccgagg aggaggaggg cggatgtgaa 1260
ctgggcggag gaggcagcgg cggcggcggc agcggcggcg gcggcagcat gcaggatgag 1320
gacggctaca tgaccctgaa cgtgcagagc aagaagagga gcagcgcca gaccagccag 1380
ctgaccttca aggactacag cgtgaccctg cactggtaca agtgagcggc cgcgtcgac 1439

<210> 52
<211> 1329

44591144002SequenceListing.txt

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> NK15_10

<400> 52

```
gccgccacaa tggccctgcc tgtgacagcc ctgctgctgc ctctggccct gctgctgcat      60
gctgccaggc ctctgttcaa ccaggagggtg cagatccctc tgaccgagag ctactgcggc      120
ccctgccccca agaactggat ctgctacaag aacaactgct accagttctt cgacgagagc      180
aagaactggt acgagagcca ggccagctgc atgtcccaga acgctagcct gctgaagggtg      240
tatagcaagg aggaccagga cctgctgaag ctggtgaaga gctaccactg gatgggacctg      300
gtgcacatcc ccaccaacgg ctctggcag tgggaggacg gcagcatcct gagccctaac      360
ctgctgacca tcatcgagat gcagaaggga gactgcgccc tgtacgccag ctcctttaag      420
ggctacatcg agaactgcag ccccccaac acctacatct gtatgcagag gaccgtggga      480
ggcggcggca gcggcggcgg cggcagcggc ggcggcggca gcttattcaa ccaagaagtt      540
caaattcctt tgaccgaaag ttactgtggc ccatgtccta aaaactggat atgttataaa      600
aataactgct accaattttt tgatgagagt aaaaactggt atgagagcca ggcttcttgt      660
atgtctcaaa atgccagcct tctgaaagta tacagcaaag aggaccagga ttactttaa      720
ctggtgaagt catatcattg gatgggacta gtacacattc caacaaatgg atcttggcag      780
tgggaagatg gctccattct ctcaccaac ctactaaca taattgaaat gcagaaggga      840
gactgtgcac tctatgcctc gagctttaa ggctatatag aaaactgttc aactccaaat      900
acgtacatct gcatgcaaag gactgtgacc accaccctg cccctagacc ccctacacct      960
gcccctacca tcgccagcca gcctctgagc ctgagacccg aggcctgtag acctgctgcc     1020
ggaggagccg tgcacacaag aggcctggac ttcgcctgcg acgtgagctt ctgcctggtg     1080
atggtgctgc tgttcgccgt ggacaccggc ctgtacttca gcgtgaagac caacatcagg     1140
agcagcacca gggactggaa ggaccacaaa ttcaagtgga ggaaggaccc ccaggacaag     1200
aagaggggca ggaagaagct gctgtacatc ttcaagcagc cttcatgag gcctgtgcag     1260
accaccaggg aggaggacgg ctgcagctgc aggttcctg aggaggaaga gggcggctgc     1320
```

44591144002SequenceListing.txt

gagctgtga 1329

<210> 53
 <211> 1239
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> NK15_11

<400> 53
 gccgccacca tggctctgcc cgtcaccgca ctgctgctgc ctctggctct gctgctgcac 60
 gccgcacgac cactgttcaa tcaggaagtc cagatcccc tgacagagtc ttactgcggc 120
 ccatgtcca agaactggat ctgctacaag aacaattggt atcagttctt tgacgagagc 180
 aagaactggg atgagtccca ggcctcttgc atgagccaga atgcctctct gctgaagggtg 240
 tacagcaagg aggaccagga tctgctgaag ctgggtgaagt cctatcactg gatgggctctg 300
 gtgcacatcc ctacaaacgg ctcttggcag tgggaggacg gctccatcct gtctccaaat 360
 ctgctgacca tcatcgagat gcagaagggc gattgcgccc tgtacgccag ctcttcaag 420
 ggctatatcg agaactgctc cacaccaat acctacatct gtatgcagag gaccgtgacc 480
 acaaccctg caccacgccc ccctacacca gcacctacca tcgcaagcca gcctctgtcc 540
 ctgctggccag aggcatgtag accagcagca ggaggagcag tgcacacaag aggcctggac 600
 ttgcctgcg atgtgagctt ttgtctggtc atgggtgctgc tgttcgccgt ggataccggc 660
 ctgtactttt ccgtgaagac aaatatcagg tctagcacc gcgactggaa ggatcacaag 720
 ttaagtggc ggaaggacc tcaggataag aagcggggca gaaagaagct gctgtatatc 780
 ttcaagcagc cttcatgcg gcccgctcag acaaccagc aggaagacgg ctgctcatgt 840
 agatttcctg aagaagaaga agggggctgt gaactgtgga ggaggaaaag gaaggagaaa 900
 cagagcgaga cttcccctaa ggagttcctg accatctacg aggacgtgaa ggacctgaag 960
 accaggagga accacgagca ggaacagacc tttcctggcg gaggcagcac catctacagc 1020
 atgatccaga gccagagcag cggccctacc agccaagagc ctgcctacac cctgtacagc 1080
 ctgatccagc ccagcaggaa aagcggctcc aggaagagga accacagccc cagcttcaac 1140

44591144002SequenceListing.txt

agcaccatct atgaggtgat cggcaagagc cagcccaagg cccagaaccc tgccaggctg 1200
tccaggaagg agctggagaa cttcgacgtg tacagctga 1239

<210> 54
<211> 1064
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> NK15_12

<400> 54
ggatccgaat tcgccgccac catggctctg cccgtcaccg cactgctgct gcctctggct 60
ctgctgctgc acgccgcacg accactgttc aatcaggaag tccagatccc cctgacagag 120
tcttactgcg gcccatgtcc caagaactgg atctgctaca agaacaattg ttatcagttc 180
tttgacgaga gcaagaactg gtatgagtcc caggcctctt gcatgagcca gaatgcctct 240
ctgctgaagg tgtacagcaa ggaggaccag gatctgctga agctggtgaa gtcctatcac 300
tggatgggcc tggtgacat ccctacaaac ggctcttggc agtgggagga cggctccatc 360
ctgtctcaa atctgctgac catcatcgag atgcagaagg gcgattgctc cctgtacgcc 420
agctccttca agggctatat cgagaactgc tccacacca atacctacat ctgtatgcag 480
aggaccgtga ccacaacccc tgcaccacgc cccctacac cagcacctac catcgcaagc 540
cagcctctgt ccctgcggcc agaggcatgt agaccagcag caggaggagc agtgcacaca 600
agaggcctgg acttcgcctg cgatgtgagc ttttgtctgg tcatggtgct gctgttcgcc 660
gtggataccg gcctgtactt ttccgtgaag acaaatatca ggtctagcac ccgcgactgg 720
aaggatcaca agtttaagtg gcggaaggac cctcaggata agaagcgggg cagaaagaag 780
ctgctgtata tcttcaagca gcccttcatg cggcccgtgc agacaacca ggaggaagac 840
ggctgctcat gtagatttcc tgaagaagaa gaagggggct gtgaactggg cggaggaggc 900
agcggcggcg gcggcagcgg cggcggcggc agcatgcagg atgaggacgg ctacatgacc 960
ctgaacgtgc agagcaagaa gaggagcagc gccagacca gccagctgac cttcaaggac 1020
tacagcgtga ccctgcactg gtacaagtga gcggccgcgt cgac 1064

44591144002SequenceListing.txt

<210> 55
<211> 8
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> FLAG tag

<400> 55

Asp Tyr Lys Asp Asp Asp Asp Lys
1 5

<210> 56
<211> 6
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> His tag

<400> 56

His His His His His His
1 5

<210> 57
<211> 10
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> Myc tag

<400> 57

Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu
1 5 10

<210> 58
<211> 1499

44591144002SequenceListing.txt

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> DNA Sequence for Variant 13

<400> 58

```
atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg      60
ccgttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct      120
aaaaactgga tatgttacia aaataactgc taccaatttt ttgatgagag taaaaactgg      180
tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa      240
gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt      300
ccaacaaatg gatcttggca gtgggaagat ggctccattc tctcaccaa cctactaaca      360
ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata      420
gaaaactggt caactccaaa tacgtacatc tgcatgcaaa ggactgtgac cacgacgcca      480
gcgccgcgac caccaacacc ggcgcccacc atcgcgtcgc agcccctgtc cctgcgcca      540
gaggcgtgcc ggccagcggc ggggggcgca gtgcacacga gggggctgga cttgcctgt      600
gatatctaca tctgggcgcc cttggccggg acttgtgggg tccttctcct gtcactggtt      660
atcacccttt actgcaaacg gggcagaaaag aaactcctgt atatattcaa acaaccattt      720
atgagaccag taaaactac tcaagaggaa gatggctgta gctgccgatt tccagaagaa      780
gaagaaggag gatgtgaact gtggaggagg aaaaggaagg agaaacagag cgagacctcc      840
cctaaggagt tcctgaccat ctacgaggac gtgaaggacc tgaagaccag gaggaaccac      900
gagcaggaac agacctttcc tggcggaggc agcaccatct acagcatgat ccagagccag      960
agcagcgccc ctaccagcca agagcctgcc tacaccctgt acagcctgat ccagcccagc     1020
aggaaaagcg gctccaggaa gaggaaccac agccccagct tcaacagcac catctatgag     1080
gtgatcggca agagccagcc caaggcccag aaccctgcca ggctgtccag gaaggagctg     1140
gagaacttcg acgtgtacag cagagtgaag ttcagcagga gcgcagacgc ccccgctac     1200
cagcagggcc agaaccagct ctataacgag ctcaatctag gacgaagaga ggagtacgat     1260
gttttggaca agagacgtgg ccgggaccct gagatggggg gaaagccgag aaggaagaac     1320
```

44591144002SequenceListing.txt

cctcaggaag gcctgtacaa tgaactgcag aaagataaga tggcggaggc ctacagtgag 1380
 attgggatga aaggcgagcg ccggaggggc aaggggcacg atggccttta ccagggtctc 1440
 agtacagcca ccaaggacac ctacgacgcc cttcacatgc aggccctgcc ccctcgcta 1499

<210> 59
 <211> 499
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Amino Acid Sequence for Variant 13

<400> 59

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1 5 10 15

His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr
 20 25 30

Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn
 35 40 45

Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln
 50 55 60

Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
 65 70 75 80

Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly
 85 90 95

Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
 100 105 110

Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp
 115 120 125

44591144002SequenceListing.txt

Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
 130 135 140

Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro
 145 150 155 160

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
 165 170 175

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
 180 185 190

Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu
 195 200 205

Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr
 210 215 220

Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe
 225 230 235 240

Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg
 245 250 255

Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Trp Arg Arg Lys Arg
 260 265 270

Lys Glu Lys Gln Ser Glu Thr Ser Pro Lys Glu Phe Leu Thr Ile Tyr
 275 280 285

Glu Asp Val Lys Asp Leu Lys Thr Arg Arg Asn His Glu Gln Glu Gln
 290 295 300

Thr Phe Pro Gly Gly Gly Ser Thr Ile Tyr Ser Met Ile Gln Ser Gln
 305 310 315 320

Ser Ser Ala Pro Thr Ser Gln Glu Pro Ala Tyr Thr Leu Tyr Ser Leu
 325 330 335

44591144002SequenceListing.txt

Ile Gln Pro Ser Arg Lys Ser Gly Ser Arg Lys Arg Asn His Ser Pro
 340 345 350

Ser Phe Asn Ser Thr Ile Tyr Glu Val Ile Gly Lys Ser Gln Pro Lys
 355 360 365

Ala Gln Asn Pro Ala Arg Leu Ser Arg Lys Glu Leu Glu Asn Phe Asp
 370 375 380

Val Tyr Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
 385 390 395 400

Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
 405 410 415

Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
 420 425 430

Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
 435 440 445

Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
 450 455 460

Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
 465 470 475 480

Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
 485 490 495

Pro Pro Arg

<210> 60
 <211> 870
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature

44591144002SequenceListing.txt

<223> DNA Sequence Variant 14

<400> 60

```

atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg      60
ccgttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct      120
aaaaactgga tatgttacia aaataactgc taccaatttt ttgatgagag taaaaactgg      180
tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa      240
gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt      300
ccaacaaatg gatccttgga gtgggaagat ggctccattc tctcaccaa cctactaaca      360
ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata      420
gaaaactggt caactccaaa tacgtacatc tgcatgcaaa ggactgtgac cacgacgcca      480
gcgccgcgac caccaacacc ggcgcccacc atcgcgtcgc agcccctgtc cctgcgccca      540
gaggcgtgcc ggccagcggc ggggggcgca gtgcacacga gggggctgga cttgcctgt      600
gatatctaca tctgggcgcc cttggccggg acttgtgggg tccttctcct gtcactggtt      660
atcaccttt actgcaaacg gggcagaaag aaactcctgt atatattcaa acaaccattt      720
atgagaccag taaaactac tcaagaggaa gatggctgta gctgccgatt tccagaagaa      780
gaagaaggag gatgtgaact gctgtgcgca cgcccacgcc gcagccccgc ccaagatggc      840
aaagtctaca tcaacatgcc aggcaggggc      870
    
```

<210> 61

<211> 290

<212> PRT

<213> Homo sapiens

<220>

<221> MISC_FEATURE

<223> Amino Acid Sequence Variant 14

<400> 61

```

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1           5           10           15
    
```

```

His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr
           20           25           30
    
```

44591144002SequenceListing.txt

Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn
35 40 45

Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln
50 55 60

Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
65 70 75 80

Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly
85 90 95

Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
100 105 110

Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp
115 120 125

Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
130 135 140

Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro
145 150 155 160

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
165 170 175

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
180 185 190

Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu
195 200 205

Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr
210 215 220

Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe
225 230 235 240

44591144002SequenceListing.txt

Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg
 245 250 255

Phe Pro Glu Glu Glu Gly Gly Cys Glu Leu Leu Cys Ala Arg Pro
 260 265 270

Arg Arg Ser Pro Ala Gln Asp Gly Lys Val Tyr Ile Asn Met Pro Gly
 275 280 285

Arg Gly
 290

<210> 62
 <211> 1230
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> DNA Sequence Variant 15

<400> 62
 atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg 60
 ccgttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct 120
 aaaaactgga tatgttacia aaataactgc taccaatttt ttgatgagag taaaaactgg 180
 tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa 240
 gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt 300
 ccaacaaatg gatccttgga gtgggaagat ggctccattc tctcacccaa cctactaaca 360
 ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata 420
 gaaaactggt caactccaaa tacgtacatc tgcattgcaa ggactgtgac cacgacgcca 480
 gcgcccgcac caccaacacc ggcgcccacc atcgcgtcgc agcccctgtc cctgcgcccc 540
 gaggcgtgcc ggccagcggc ggggggcgca gtgcacacga gggggctgga cttcgcctgt 600
 gatatctaca tctgggcgcc cttggccggg acttgtgggg tccttctcct gtcactgggt 660
 atcacccttt actgcaaacg gggcagaaaag aaactcctgt atatattcaa acaaccattt 720

44591144002SequenceListing.txt

```

atgagaccag tacaaactac tcaagaggaa gatggctgta gctgccgatt tccagaagaa      780
gaagaaggag gatgtgaact gctgtgcgca cgcccacgcc gcagccccgc ccaagatggc      840
aaagtctaca tcaacatgcc aggcaggggc tggaggagga aaaggaagga gaaacagagc      900
gagacctccc ctaaggagtt cctgaccatc tacgaggacg tgaaggacct gaagaccagg      960
aggaaccacg agcaggaaca gacctttcct ggcggaggca gcaccatcta cagcatgatc     1020
cagagccaga gcagcgcccc taccagccaa gagcctgcct acaccctgta cagcctgatc     1080
cagcccagca ggaaaagcgg ctccaggaag aggaaccaca gccccagctt caacagcacc     1140
atctatgagg tgatcggcaa gagccagccc aaggcccaga accctgccag gctgtccagg     1200
aaggagctgg agaacttcga cgtgtacagc                                     1230

```

```

<210> 63
<211> 410
<212> PRT
<213> Homo sapiens

```

```

<220>
<221> MISC_FEATURE
<223> Amino Acid Sequence Variant 15

```

```

<400> 63

```

```

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1             5             10             15

```

```

His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr
      20             25             30

```

```

Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn
      35             40             45

```

```

Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln
      50             55             60

```

```

Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
      65             70             75             80

```

44591144002SequenceListing.txt

Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly
85 90 95

Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
100 105 110

Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp
115 120 125

Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
130 135 140

Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro
145 150 155 160

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
165 170 175

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
180 185 190

Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu
195 200 205

Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr
210 215 220

Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe
225 230 235 240

Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg
245 250 255

Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Leu Cys Ala Arg Pro
260 265 270

Arg Arg Ser Pro Ala Gln Asp Gly Lys Val Tyr Ile Asn Met Pro Gly
275 280 285

44591144002SequenceListing.txt

Arg Gly Trp Arg Arg Lys Arg Lys Glu Lys Gln Ser Glu Thr Ser Pro
 290 295 300

Lys Glu Phe Leu Thr Ile Tyr Glu Asp Val Lys Asp Leu Lys Thr Arg
 305 310 315 320

Arg Asn His Glu Gln Glu Gln Thr Phe Pro Gly Gly Gly Ser Thr Ile
 325 330 335

Tyr Ser Met Ile Gln Ser Gln Ser Ser Ala Pro Thr Ser Gln Glu Pro
 340 345 350

Ala Tyr Thr Leu Tyr Ser Leu Ile Gln Pro Ser Arg Lys Ser Gly Ser
 355 360 365

Arg Lys Arg Asn His Ser Pro Ser Phe Asn Ser Thr Ile Tyr Glu Val
 370 375 380

Ile Gly Lys Ser Gln Pro Lys Ala Gln Asn Pro Ala Arg Leu Ser Arg
 385 390 395 400

Lys Glu Leu Glu Asn Phe Asp Val Tyr Ser
 405 410

- <210> 64
- <211> 1232
- <212> DNA
- <213> Homo sapiens

- <220>
- <221> misc_feature
- <223> DNA Sequence Variant 16

<400> 64
 atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg 60
 ccgttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct 120
 aaaaactgga tatgttaca aaataactgc taccaatttt ttgatgagag taaaaactgg 180
 tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa 240
 gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt 300

44591144002SequenceListing.txt

ccaacaaatg gatcttggca gtgggaagat ggctccattc tctcacccaa cctactaaca 360
 ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata 420
 gaaaactggt caactccaaa tacgtacatc tgcatgcaaa ggactgtgac cacgacgcca 480
 gcgccgagac caccaacacc ggcgcccacc atcgcgtcgc agcccctgtc cctgcgcca 540
 gaggcgtgcc ggccagcggc ggggggagca gtgcacacga gggggctgga cttgcctgt 600
 gatattaca tctgggagcc cttggccggg acttgtgggg tccttctcct gtcactggtt 660
 atcaccttt actgcaaagc gggcagaaag aaactcctgt atatattcaa acaaccattt 720
 atgagaccag taaaactac tcaagaggaa gatggctgta gctgccgatt tccagaagaa 780
 gaagaaggag gatgtgaact gtggaggagg aaaaggaagg agaaacagag cgagacctcc 840
 cctaaggagt tcctgacat ctacgaggac gtgaaggacc tgaagaccag gaggaaccac 900
 gagcaggaac agacctttcc tggcggaggc agcaccatct acagcatgat ccagagccag 960
 agcagcggcc ctaccagcca agagcctgcc tacaccctgt acagcctgat ccagcccagc 1020
 aggaaaagcg gctccaggaa gaggaaccac agccccagct tcaacagcac catctatgag 1080
 gtgatcggca agagccagcc caaggcccag aaccctgccca ggctgtccag gaaggagctg 1140
 gagaacttcg acgtgtacag cctgtgagca cggccacgcc gcagccccgc ccaagatggc 1200
 aaagtctaca tcaacatgcc aggcaggggc tg 1232

<210> 65
 <211> 410
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Amino Acid Sequence Variant 16

<400> 65

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1 5 10 15

His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr
 20 25 30

44591144002SequenceListing.txt

Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn
 35 40 45

Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln
 50 55 60

Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
 65 70 75 80

Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly
 85 90 95

Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
 100 105 110

Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp
 115 120 125

Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
 130 135 140

Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro
 145 150 155 160

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
 165 170 175

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
 180 185 190

Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu
 195 200 205

Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr
 210 215 220

Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe
 225 230 235 240

44591144002SequenceListing.txt

Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg
 245 250 255

Phe Pro Glu Glu Glu Gly Gly Cys Glu Leu Trp Arg Arg Lys Arg
 260 265 270

Lys Glu Lys Gln Ser Glu Thr Ser Pro Lys Glu Phe Leu Thr Ile Tyr
 275 280 285

Glu Asp Val Lys Asp Leu Lys Thr Arg Arg Asn His Glu Gln Glu Gln
 290 295 300

Thr Phe Pro Gly Gly Gly Ser Thr Ile Tyr Ser Met Ile Gln Ser Gln
 305 310 315 320

Ser Ser Ala Pro Thr Ser Gln Glu Pro Ala Tyr Thr Leu Tyr Ser Leu
 325 330 335

Ile Gln Pro Ser Arg Lys Ser Gly Ser Arg Lys Arg Asn His Ser Pro
 340 345 350

Ser Phe Asn Ser Thr Ile Tyr Glu Val Ile Gly Lys Ser Gln Pro Lys
 355 360 365

Ala Gln Asn Pro Ala Arg Leu Ser Arg Lys Glu Leu Glu Asn Phe Asp
 370 375 380

Val Tyr Ser Leu Cys Ala Arg Pro Arg Arg Ser Pro Ala Gln Asp Gly
 385 390 395 400

Lys Val Tyr Ile Asn Met Pro Gly Arg Gly
 405 410

- <210> 66
- <211> 1587
- <212> DNA
- <213> Homo sapiens

44591144002SequenceListing.txt

<220>

<221> misc_feature

<223> DNA Sequence Variant 17

<400> 66

atggccctgc ccgtgacagc tctgctgctg cctctggccc tgctgctgca tgccgctaga	60
cccctgttca accaggaggt gcagatcccc ctgaccgaaa gctactgcgg cccctgcccc	120
aagaactgga tctgttaca gaacaactgc tatcagttct tcgacgagag caagaactgg	180
tacgagagcc aggccagctg tatgagccag aacgccagcc tgctgaaagt gtatagcaag	240
gaggaccagg acctgctgaa gctggtgaag agctaccact ggatgggcct ggtgcacatc	300
cccaccaacg gaagctggca gtgggaggac ggcagcatcc tgagcccaa cctgctgacc	360
atcatcgaga tgcagaaggg cgactgcgcc ctgtatgcca gcagcttcaa gggctacatc	420
gagaactgta gcaccccaa cacctacatc tgcatgcaga ggaccgtggg cggcggcggc	480
agcggcggag gcggctccgg cggcggcggc agcttattca accaagaagt tcaaattccc	540
ttgaccgaaa gttactgtgg cccatgtcct aaaaactgga tatgttaca aaataactgc	600
taccaatfff ttgatgagag taaaaactgg tatgagagcc aggcttcttg tatgtctcaa	660
aatgccagcc ttctgaaagt atacagcaa gaggaccagg atttacttaa actggtgaag	720
tcatatcatt ggatgggact agtacacatt ccaacaaatg gatcttggca gtgggaagat	780
ggctccattc tctcaccaa cctactaaca ataattgaaa tgcagaaggg agactgtgca	840
ctctatgcct cgagctttaa aggctatata gaaaactgtt caactccaaa tacgtacatc	900
tgcatgcaaa ggactgtgac cacgacgcca gcgccgcgac caccaacacc ggcgcccacc	960
atcgcgtcgc agcccctgtc cctgcgcca gaggcgtgcc ggccagcggc ggggggcgca	1020
gtgcacacga gggggctgga cttgcctgt gatatctaca tctgggcgcc cttggccggg	1080
acttgtgggg tccttctcct gtcactggtt atcacccttt actgcaaacg gggcagaaag	1140
aaactcctgt atatattcaa acaaccattt atgagaccag tacaactac tcaagaggaa	1200
gatggctgta gctgccgatt tccagaagaa gaagaaggag gatgtgaact gagagtgaag	1260
ttcagcagga gcgcagacgc ccccgcttac cagcagggcc agaaccagct ctataacgag	1320
ctcaatctag gacgaagaga ggagtacgat gttttggaca agagacgtgg ccgggaccct	1380
gagatggggg gaaagccgag aaggaagaac cctcaggaag gcctgtacaa tgaactgcag	1440

44591144002SequenceListing.txt

aaagataaga tggcggaggc ctacagtgag attgggatga aaggcgagcg ccggaggggc 1500
aaggggcacg atggccttta ccagggtctc agtacagcca ccaaggacac ctacgacgcc 1560
cttcacatgc aggccctgcc ccctcgc 1587

<210> 67
<211> 529
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> Amino Acid Sequence Variant 17

<400> 67

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr
20 25 30

Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn
35 40 45

Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln
50 55 60

Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
65 70 75 80

Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly
85 90 95

Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
100 105 110

Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp
115 120 125

44591144002SequenceListing.txt

Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
 130 135 140

Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Gly Gly Gly Gly
 145 150 155 160

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Leu Phe Asn Gln Glu
 165 170 175

Val Gln Ile Pro Leu Thr Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn
 180 185 190

Trp Ile Cys Tyr Lys Asn Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys
 195 200 205

Asn Trp Tyr Glu Ser Gln Ala Ser Cys Met Ser Gln Asn Ala Ser Leu
 210 215 220

Leu Lys Val Tyr Ser Lys Glu Asp Gln Asp Leu Leu Lys Leu Val Lys
 225 230 235 240

Ser Tyr His Trp Met Gly Leu Val His Ile Pro Thr Asn Gly Ser Trp
 245 250 255

Gln Trp Glu Asp Gly Ser Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile
 260 265 270

Glu Met Gln Lys Gly Asp Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly
 275 280 285

Tyr Ile Glu Asn Cys Ser Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg
 290 295 300

Thr Val Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr
 305 310 315 320

Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala
 325 330 335

44591144002SequenceListing.txt

Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile
 340 345 350

Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser
 355 360 365

Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr
 370 375 380

Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu
 385 390 395 400

Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu
 405 410 415

Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln
 420 425 430

Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu
 435 440 445

Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly
 450 455 460

Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln
 465 470 475 480

Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu
 485 490 495

Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr
 500 505 510

Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro
 515 520 525

Arg

44591144002SequenceListing.txt

<210> 68
 <211> 405
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> DNA Sequence for alternative NKG2D codon-optimized extracellular domain

<400> 68
 ctgttcaacc aggaggtgca gatccccctg accgaaagct actgcggccc ctgcccccaag 60
 aactggatct gttacaagaa caactgctat cagttcttcg acgagagcaa gaactggtag 120
 gagagccagg ccagctgtat gagccagaac gccagcctgc tgaaagtgta tagcaaggag 180
 gaccaggacc tgctgaagct ggtgaagagc taccactgga tgggcctggt gcacatcccc 240
 accaacggaa gctggcagtg ggaggacggc agcatcctga gcccacaacct gctgaccatc 300
 atcgagatgc agaagggcga ctgcgccctg tatgccagca gcttcaaggg ctacatcgag 360
 aactgtagca cccccaacac ctacatctgc atgcagagga cctgtg 405

<210> 69
 <211> 21
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Amino Acid Sequence CD3zeta transmembrane

<400> 69

Leu Cys Tyr Leu Leu Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Leu
 1 5 10 15

Thr Ala Leu Phe Leu
 20

<210> 70
 <211> 876
 <212> DNA
 <213> Homo sapiens

44591144002SequenceListing.txt

<220>

<221> misc_feature

<223> DNA Sequence Variant 18 (NK39)

<400> 70

```

atggctctgc ccgtcaccgc actgctgctg cctctggctc tgctgctgca cgccgcacga      60
ccactgttca atcaggaagt ccagatcccc ctgacagagt cttactgcgg cccatgtccc      120
aagaactgga tctgctacaa gaacaattgt tatcagttct ttgacgagag caagaactgg      180
tatgagtccc aggcctcttg catgagccag aatgcctctc tgctgaaggt gtacagcaag      240
gaggaccagg atctgctgaa gctggtgaag tcctatcact ggatgggcct ggtgcacatc      300
cctacaaacg gctcttggca gtgggaggac ggctccatcc tgtctcaaaa tctgctgacc      360
atcatcgaga tgcagaaggg cgattgcgcc ctgtacgcca gctccttcaa gggctatatc      420
gagaactgct ccacacccaa tacctacatc tgtatgcaga ggaccgtgac cacaaccctc      480
gcaccacgcc cccctacacc agcacctacc atcgcaagcc agcctctgtc cctgcggcca      540
gaggcatgta gaccagcagc aggaggagca gtgcacacaa gaggcctgga cttgcctgctc      600
gatcccaaac tctgctacct gctggatgga atcctcttca tctatgggtg cattctcact      660
gccttgttcc tgaagacaaa tadcaggtct agcaccgcg actggaagga tcacaagttt      720
aagtggcgga aggaccctca ggataagaag cggggcagaa agaagctgct gtatatcttc      780
aagcagccct tcatgcggcc cgtgcagaca acccaggagg aagacggctg ctcatgtaga      840
tttctgaag aagaagaagg gggctgtgaa ctgtaa      876

```

<210> 71

<211> 291

<212> PRT

<213> Homo sapiens

<220>

<221> MISC_FEATURE

<223> Amino Acid Sequence Variant 18 (NK39)

<400> 71

```

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1           5           10          15

```

44591144002SequenceListing.txt

His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr
 20 25 30

Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn
 35 40 45

Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln
 50 55 60

Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
 65 70 75 80

Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly
 85 90 95

Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
 100 105 110

Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp
 115 120 125

Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
 130 135 140

Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro
 145 150 155 160

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
 165 170 175

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
 180 185 190

Thr Arg Gly Leu Asp Phe Ala Cys Asp Pro Lys Leu Cys Tyr Leu Leu
 195 200 205

Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Leu Thr Ala Leu Phe Leu
 210 215 220

44591144002SequenceListing.txt

taccaatttt ttgatgagag taaaaactgg tatgagagcc aggcttcttg tatgtctcaa 660
aatgccagcc ttctgaaagt atacagcaaa gaggaccagg atttacttaa actggtgaag 720
tcatatcatt ggatgggact agtacacatt ccaacaaatg gatcttggca gtgggaagat 780
ggctccattc tctcaccaa cctactaaca ataattgaaa tgcagaaggg agactgtgca 840
ctctatgcct cgagctttaa aggctatata gaaaactggt caactccaaa tacgtacatc 900
tgcattgcaaa ggactgtgac caccaccct gctcccagac cccctacacc tgcccctaca 960
atgccagcc agcccctgag cctgagacct gaggcctgca gacctgctgc tggaggcgt 1020
gtgcacacaa ggggcctcga cttgcctgc gaccccaaac tctgctacct gctggatgga 1080
atcctcttca tctatggtgt cattctcact gccttgttcc tgaagacaaa tatcaggtct 1140
agcaccgcg actggaagga tcacaagttt aagtggcgga aggaccctca ggataagaag 1200
cggggcagaa agaagctgct gtatatcttc aagcagccct tcatgcggcc cgtgcagaca 1260
accaggagg aagacggctg ctcatgtaga tttcctgaag aagaagaagg gggctgtgaa 1320
ctg 1323

<210> 73
<211> 441
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> Amino Acid Sequence NK39_1

<400> 73

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr
20 25 30

Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn
35 40 45

Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln

44591144002SequenceListing.txt

50

55

60

Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
65 70 75 80

Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly
85 90 95

Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
100 105 110

Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp
115 120 125

Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
130 135 140

Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Gly Gly Gly Gly
145 150 155 160

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Leu Phe Asn Gln Glu
165 170 175

Val Gln Ile Pro Leu Thr Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn
180 185 190

Trp Ile Cys Tyr Lys Asn Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys
195 200 205

Asn Trp Tyr Glu Ser Gln Ala Ser Cys Met Ser Gln Asn Ala Ser Leu
210 215 220

Leu Lys Val Tyr Ser Lys Glu Asp Gln Asp Leu Leu Lys Leu Val Lys
225 230 235 240

Ser Tyr His Trp Met Gly Leu Val His Ile Pro Thr Asn Gly Ser Trp
245 250 255

Gln Trp Glu Asp Gly Ser Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile

44591144002SequenceListing.txt

260

265

270

Glu Met Gln Lys Gly Asp Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly
 275 280 285

Tyr Ile Glu Asn Cys Ser Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg
 290 295 300

Thr Val Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr
 305 310 315 320

Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala
 325 330 335

Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Pro
 340 345 350

Lys Leu Cys Tyr Leu Leu Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile
 355 360 365

Leu Thr Ala Leu Phe Leu Lys Thr Asn Ile Arg Ser Ser Thr Arg Asp
 370 375 380

Trp Lys Asp His Lys Phe Lys Trp Arg Lys Asp Pro Gln Asp Lys Lys
 385 390 395 400

Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg
 405 410 415

Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro
 420 425 430

Glu Glu Glu Glu Gly Gly Cys Glu Leu
 435 440

<210> 74
 <211> 1032
 <212> DNA
 <213> Homo sapiens

44591144002SequenceListing.txt

<220>

<221> misc_feature

<223> DNA Sequence NK39_2

<400> 74

atggccctgc ccgtgacagc tctgctgctg cctctggccc tgctgctgca tgccgctaga	60
cccttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct	120
aaaaactgga tatgttaca aaataactgc taccaatfff ttgatgagag taaaaactgg	180
tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa	240
gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt	300
ccaacaaatg gatccttgga gtgggaagat ggctccattc tctcaccaa cctactaaca	360
ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata	420
gaaaactgtt caactccaaa tacgtacatc tgcattgcaa ggactgtgac caccaccct	480
gctcccagac cccctacacc tgcccctaca atgccagcc agcccctgag cctgagacct	540
gaggcctgca gacctgctgc tggaggcgct gtgcacacaa ggggcctcga cttgcctgc	600
gaccccaaac tctgctacct gctggatgga atcctcttca tctatggtgt cattctcact	660
gccttgttcc tgaagacaaa tatcaggtct agcaccgcg actggaagga tcacaagttt	720
aagtggcggga aggaccctca ggataagaag cggggcagaa agaagctgct gtatatcttc	780
aagcagccct tcatgcggcc cgtgcagaca acccaggagg aagacggctg ctcattgtaga	840
tttctgaag aagaagaagg gggctgtgaa ctgggcggag gaggcagcgg cggcggcggc	900
agcggcggcg gcggcagcat gcaggatgag gacggctaca tgaccctgaa cgtgcagagc	960
aagaagagga gcagcgccca gaccagccag ctgaccttca aggactacag cgtgaccctg	1020
cactggtaca ag	1032

<210> 75

<211> 344

<212> PRT

<213> Homo sapiens

<220>

<221> MISC_FEATURE

<223> Amino Acid Sequence NK39_2

44591144002SequenceListing.txt

<400> 75

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1 5 10 15

His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr
 20 25 30

Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn
 35 40 45

Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln
 50 55 60

Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
 65 70 75 80

Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly
 85 90 95

Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
 100 105 110

Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp
 115 120 125

Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
 130 135 140

Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro
 145 150 155 160

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
 165 170 175

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
 180 185 190

Thr Arg Gly Leu Asp Phe Ala Cys Asp Pro Lys Leu Cys Tyr Leu Leu

44591144002SequenceListing.txt

195

200

205

Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Leu Thr Ala Leu Phe Leu
 210 215 220

Lys Thr Asn Ile Arg Ser Ser Thr Arg Asp Trp Lys Asp His Lys Phe
 225 230 235 240

Lys Trp Arg Lys Asp Pro Gln Asp Lys Lys Arg Gly Arg Lys Lys Leu
 245 250 255

Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln
 260 265 270

Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly
 275 280 285

Cys Glu Leu Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
 290 295 300

Gly Ser Met Gln Asp Glu Asp Gly Tyr Met Thr Leu Asn Val Gln Ser
 305 310 315 320

Lys Lys Arg Ser Ser Ala Gln Thr Ser Gln Leu Thr Phe Lys Asp Tyr
 325 330 335

Ser Val Thr Leu His Trp Tyr Lys
 340

<210> 76
 <211> 1416
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> DNA Sequence NK39_3

<400> 76
 atggccctgc ccgtgacagc tctgctgctg cctctggccc tgctgctgca tgccgctaga

60

44591144002SequenceListing.txt

cccctgttca accaggaggt gcagatcccc ctgaccgaaa gctactgcgg cccctgcccc 120
aagaactgga tctgttaca gaacaactgc tatcagttct tcgacgagag caagaactgg 180
tacgagagcc aggccagctg tatgagccag aacgccagcc tgctgaaagt gtatagcaag 240
gaggaccagg acctgctgaa gctggtgaag agctaccact ggatgggcct ggtgcacatc 300
cccaccaacg gaagctggca gtgggaggac ggcagcatcc tgagcccaa cctgctgacc 360
atcatcgaga tgcagaagg cgactgcgcc ctgtatgcca gcagcttcaa gggctacatc 420
gagaactgta gcaccccaa cacctacatc tgcattcaga ggaccgtggg cggcggcggc 480
agcggcggag gcggctccgg cggcggcggc agcttattca accaagaagt tcaaattccc 540
ttgaccgaaa gttactgtgg cccatgtcct aaaaactgga tatgttaca aaataactgc 600
taccaatfff ttgatgagag taaaaactgg tatgagagcc aggcttcttg tatgtctcaa 660
aatgccagcc ttctgaaagt atacagcaa gaggaccagg atttacttaa actggtgaag 720
tcatatcatt ggatgggact agtacacatt ccaacaaatg gatcctggca gtgggaagat 780
ggctccattc tctcaccaa cctactaaca ataattgaaa tgcagaagg agactgtgca 840
ctctatgcct cgagctttaa aggctatata gaaaactggt caactccaaa tacgtacatc 900
tgcattgaaa ggactgtgac caccaccct gctcccagac cccctacacc tgcccctaca 960
atgccagcc agcccctgag cctgagacct gaggcctgca gacctgctgc tggaggcgct 1020
gtgcacaaa gggcctcga cttgcctgc gaccccaaac tctgctacct gctggatgga 1080
atcctctca tctatggtgt cattctcact gccttgttcc tgctttactg caagcggggc 1140
agaaagaagc tgctgtatat cttcaagcag cccttcatgc ggcccgtgca gacaaccag 1200
gaggaagacg gctgctcatg tagatttcct gaagaagaag aagggggctg tgaactgggc 1260
ggaggaggca gcggcggcgg cggcagcggc ggcggcggca gcatgcagga tgaggacggc 1320
tacatgacc tgaacgtgca gagcaagaag aggagcagcg cccagaccag ccagctgacc 1380
ttcaaggact acagcgtgac cctgcactgg tacaag 1416

<210> 77
<211> 472
<212> PRT
<213> Homo sapiens

44591144002SequenceListing.txt

<220>

<221> MISC_FEATURE

<223> Amino Acid Sequence NK39_3

<400> 77

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr
20 25 30

Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn
35 40 45

Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln
50 55 60

Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
65 70 75 80

Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly
85 90 95

Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
100 105 110

Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp
115 120 125

Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
130 135 140

Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Gly Gly Gly Gly
145 150 155 160

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Leu Phe Asn Gln Glu
165 170 175

Val Gln Ile Pro Leu Thr Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn

44591144002SequenceListing.txt

180

185

190

Trp Ile Cys Tyr Lys Asn Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys
 195 200 205

Asn Trp Tyr Glu Ser Gln Ala Ser Cys Met Ser Gln Asn Ala Ser Leu
 210 215 220

Leu Lys Val Tyr Ser Lys Glu Asp Gln Asp Leu Leu Lys Leu Val Lys
 225 230 235 240

Ser Tyr His Trp Met Gly Leu Val His Ile Pro Thr Asn Gly Ser Trp
 245 250 255

Gln Trp Glu Asp Gly Ser Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile
 260 265 270

Glu Met Gln Lys Gly Asp Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly
 275 280 285

Tyr Ile Glu Asn Cys Ser Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg
 290 295 300

Thr Val Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr
 305 310 315 320

Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala
 325 330 335

Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Pro
 340 345 350

Lys Leu Cys Tyr Leu Leu Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile
 355 360 365

Leu Thr Ala Leu Phe Leu Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu
 370 375 380

Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln

44591144002SequenceListing.txt

gaggcatgta gaccagcagc aggaggagca gtgcacacaa gaggcctgga cttgcctgc 600
 gatcccaaac tctgctacct gctggatgga atcctcttca tctatgggtgt cattctcact 660
 gccttgttcc tgctttactg caagcggggc agaaagaagc tgctgtatat cttcaagcag 720
 cccttcatgc ggcccgtgca gacaaccag gaggaagacg gctgctcatg tagatttcct 780
 gaagaagaag aagggggctg tgaactg 807

<210> 79
 <211> 269
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Amino Acid Sequence NK39_4

<400> 79

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1 5 10 15

His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr
 20 25 30

Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn
 35 40 45

Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln
 50 55 60

Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
 65 70 75 80

Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly
 85 90 95

Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
 100 105 110

Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp

44591144002SequenceListing.txt

115

120

125

Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
 130 135 140

Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro
 145 150 155 160

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
 165 170 175

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
 180 185 190

Thr Arg Gly Leu Asp Phe Ala Cys Asp Pro Lys Leu Cys Tyr Leu Leu
 195 200 205

Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Leu Thr Ala Leu Phe Leu
 210 215 220

Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln
 225 230 235 240

Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser
 245 250 255

Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu
 260 265

<210> 80
 <211> 1143
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> DNA Sequence NK39_5

<400> 80
 atggctctgc ccgtcaccgc actgctgctg cctctggctc tgctgctgca cgccgcacga

60

44591144002SequenceListing.txt

ccactgttca atcaggaagt ccagatcccc ctgacagagt cttactgcgg cccatgtccc	120
aagaactgga tctgctacaa gaacaattgt tatcagttct ttgacgagag caagaactgg	180
tatgagtccc aggccctctg catgagccag aatgcctctc tgctgaaggt gtacagcaag	240
gaggaccagg atctgctgaa gctggtgaag tcctatcact ggatgggcct ggtgcacatc	300
cctacaaacg gctcttggca gtgggaggac ggctccatcc tgtctccaaa tctgctgacc	360
atcatcgaga tgcagaaggg cgattgcgcc ctgtacgcca gtccttcaa gggctatatc	420
gagaactgct ccacacccaa tacctacatc tgtatgcaga ggaccgtgac cacaaccctt	480
gcaccacgcc cccctacacc agcacctacc atcgcaagcc agcctctgtc cctgcggcca	540
gaggcatgta gaccagcagc aggaggagca gtgcacacaa gaggcctgga cttcgcctgc	600
gatcccaaac tctgctacct gctggatgga atcctcttca tctatggtgt cattctcact	660
gccttgttcc tgctttactg caagcggggc agaaagaagc tgctgtatat cttcaagcag	720
cccttcatgc ggcccgtgca gacaaccag gaggaagacg gctgctcatg tagatttcct	780
gaagaagaag aagggggctg tgaactgaga gtgaagtcca gcaggagcgc agacgcccc	840
gcgtaccagc agggccagaa ccagctctat aacgagctca atctaggacg aagagaggag	900
tacgatgttt tggacaagag acgtggccgg gaccctgaga tggggggaaa gccgagaagg	960
aagaaccctc aggaaggcct gtacaatgaa ctgcagaaag ataagatggc ggaggcctac	1020
agtgagattg ggatgaaagg cgagcgccgg aggggcaagg ggcacgatgg cctttaccag	1080
ggtctcagta cagccaccaa ggacacctac gacgcccttc acatgcaggc cctgccccct	1140
cgc	1143

<210> 81
 <211> 381
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Amino Acid Sequence NK39_5

<400> 81

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

44591144002SequenceListing.txt

1 5 10 15
 His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr
 20 25 30
 Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn
 35 40 45
 Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln
 50 55 60
 Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
 65 70 75 80
 Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly
 85 90 95
 Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
 100 105 110
 Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp
 115 120 125
 Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
 130 135 140
 Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro
 145 150 155 160
 Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
 165 170 175
 Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
 180 185 190
 Thr Arg Gly Leu Asp Phe Ala Cys Asp Pro Lys Leu Cys Tyr Leu Leu
 195 200 205
 Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Leu Thr Ala Leu Phe Leu

44591144002SequenceListing.txt

210

215

220

Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln
 225 230 235 240

Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser
 245 250 255

Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys
 260 265 270

Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln
 275 280 285

Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu
 290 295 300

Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg
 305 310 315 320

Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met
 325 330 335

Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly
 340 345 350

Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp
 355 360 365

Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
 370 375 380

<210> 82
 <211> 965
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> DNA Sequence NK39_6

44591144002SequenceListing.txt

<400> 82
atggctctgc ccgtcaccgc actgctgctg cctctggctc tgctgctgca cgccgcacga 60
ccactgttca atcaggaagt ccagatcccc ctgacagagt cttactgcgg cccatgtccc 120
aagaactgga tctgctacaa gaacaattgt tatcagttct ttgacgagag caagaactgg 180
tatgagtccc aggcctcttg catgagccag aatgcctctc tgctgaaggt gtacagcaag 240
gaggaccagg atctgctgaa gctggtgaag tcctatcact ggatgggcct ggtgcacatc 300
cctacaaacg gctcttgga gtgggaggac ggctccatcc tgtctcaaaa tctgctgacc 360
atcatcgaga tgcagaaggg cgattgcgcc ctgtacgcca gctccttcaa gggctatatc 420
gagaactgct ccacacccaa tacctacatc tgtatgcaga ggaccgtgac cacaaccctc 480
gcaccacgcc cccctacacc agcacctacc atcgcaagcc agcctctgtc cctgcggcca 540
gaggcatgta gaccagcagc aggaggagca gtgcacacaa gaggcctgga cttgcctgac 600
gatcccaaac tctgctacct gctggatgga atcctcttca tctatggtgt cattctcact 660
gccttgttcc tgctttactg caagcggggc agaaagaagc tgctgtatat cttcaagcag 720
cccttcatgc ggcccgtgca gacaaccag gaggaagacg gctgctcatg tagatttcct 780
gaagaagaag aagggggctg tgaactgggc ggaggaggca gcggcggcgg cggcagcggc 840
ggcggcggca gcatgcagga tgaggacggc tacatgacc tgaacgtgca gagcaagaag 900
aggagcagcg cccagaccag ccagctgacc ttcaaggact acagcgtgac cctgcactgg 960
taca 965

<210> 83
<211> 322
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> Amino Acid Sequence NK39_6

<400> 83

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

44591144002SequenceListing.txt

His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr
 20 25 30

Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn
 35 40 45

Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln
 50 55 60

Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
 65 70 75 80

Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly
 85 90 95

Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
 100 105 110

Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp
 115 120 125

Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
 130 135 140

Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro
 145 150 155 160

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
 165 170 175

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
 180 185 190

Thr Arg Gly Leu Asp Phe Ala Cys Asp Pro Lys Leu Cys Tyr Leu Leu
 195 200 205

Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Leu Thr Ala Leu Phe Leu
 210 215 220

44591144002SequenceListing.txt

Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln
 225 230 235 240

Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser
 245 250 255

Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Gly Gly Gly
 260 265 270

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Met Gln Asp Glu
 275 280 285

Asp Gly Tyr Met Thr Leu Asn Val Gln Ser Lys Lys Arg Ser Ser Ala
 290 295 300

Gln Thr Ser Gln Leu Thr Phe Lys Asp Tyr Ser Val Thr Leu His Trp
 305 310 315 320

Tyr Lys

<210> 84
 <211> 927
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> DNA Sequence NK39_7

<400> 84
 atggctctgc ccgtcaccgc actgctgctg cctctggctc tgctgctgca cgccgcacga 60
 ccactgttca atcaggaagt ccagatcccc ctgacagagt cttactgcgg cccatgtccc 120
 aagaactgga tctgctacaa gaacaattgt tatcagttct ttgacgagag caagaactgg 180
 tatgagtccc aggctcttg catgagccag aatgcctctc tgctgaaggt gtacagcaag 240
 gaggaccagg atctgctgaa gctggtgaag tcctatcact ggatgggcct ggtgcacatc 300
 cctacaaacg gctcttggca gtgggaggac ggctccatcc tgtctcaaaa tctgctgacc 360

44591144002SequenceListing.txt

atcatcgaga tgcagaaggg cgattgcgcc ctgtacgcca gctccttcaa gggctatatc 420
gagaactgct ccacacccaa tacctacatc tgtatgcaga ggaccgtgac cacaaccctt 480
gcaccacgcc cccctacacc agcacctacc atcgcaagcc agcctctgtc cctgcggcca 540
gaggcatgta gaccagcagc aggaggagca gtgcacacaa gaggcctgga cttgcctgct 600
gatcccaaac tctgctacct gctggatgga atcctcttca tctatggtgt cattctcact 660
gccttgttcc tgctttactg caagcggggc agaaagaagc tgctgtatat cttcaagcag 720
cccttcatgc ggcccgtgca gacaaccag gaggaagacg gctgctcatg tagatttcct 780
gaagaagaag aagggggctg tgaactgggc ggaggaggca gcggcggcgg cggcagcggc 840
ggcggcggca gcaagacaaa tadcaggtct agcaccgcg actggaagga tcacaagttt 900
aagtggcggga aggaccctca ggataag 927

<210> 85
<211> 309
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> Amino Acid Sequence NK39_7

<400> 85

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr
20 25 30

Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn
35 40 45

Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln
50 55 60

Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
65 70 75 80

44591144002SequenceListing.txt

Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly
 85 90 95

Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
 100 105 110

Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp
 115 120 125

Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
 130 135 140

Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro
 145 150 155 160

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
 165 170 175

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
 180 185 190

Thr Arg Gly Leu Asp Phe Ala Cys Asp Pro Lys Leu Cys Tyr Leu Leu
 195 200 205

Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Leu Thr Ala Leu Phe Leu
 210 215 220

Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln
 225 230 235 240

Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser
 245 250 255

Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Gly Gly Gly
 260 265 270

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Lys Thr Asn Ile
 275 280 285

44591144002SequenceListing.txt

Arg Ser Ser Thr Arg Asp Trp Lys Asp His Lys Phe Lys Trp Arg Lys
 290 295 300

Asp Pro Gln Asp Lys
 305

<210> 86
 <211> 933
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> DNA Sequence NK39_8

<400> 86
 atggccctgc ccgtgacagc tctgctgctg cctctggccc tgctgctgca tgccgctaga 60
 cccttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct 120
 aaaaactgga tatgttaca aaataactgc taccaatfff ttgatgagag taaaaactgg 180
 tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa 240
 gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt 300
 ccaacaaatg gatccttgga gtgggaagat ggctccattc tctcacccaa cctactaaca 360
 ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata 420
 gaaaactgtt caactccaaa tacgtacatc tgcatgcaaa ggactgtgac caccaccct 480
 gctcccagac ccctacacc tgcccctaca atgccagcc agcccctgag cctgagacct 540
 gaggcctgca gacctgctgc tggaggcgct gtgcacacaa ggggcctcga cttgcctgctg 600
 gaccccaaac tctgctacct gctggatgga atcctcttca tctatggtgt cattctcact 660
 gccttgttcc tgctttactg caagcggggc agaaagaagc tgctgtatat cttcaagcag 720
 cccttcatgc ggcccgtgca gacaaccag gaggaagacg gctgctcatg tagatttcct 780
 gaagaagaag aagggggctg tgaactgcga ctgaagatcc aagtgcgaaa ggcagctata 840
 accagctatg agaaatcaga tgggtgtttac acgggcctga gcaccaggaa ccaggagact 900
 tacgagactc tgaagcatga gaaaccacca cag 933

44591144002SequenceListing.txt

<210> 87
 <211> 311
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Amino Acid Sequence NK39_8

<400> 87

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1 5 10 15

His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr
 20 25 30

Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn
 35 40 45

Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln
 50 55 60

Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
 65 70 75 80

Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly
 85 90 95

Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
 100 105 110

Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp
 115 120 125

Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
 130 135 140

Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro
 145 150 155 160

44591144002SequenceListing.txt

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
 165 170 175

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
 180 185 190

Thr Arg Gly Leu Asp Phe Ala Cys Asp Pro Lys Leu Cys Tyr Leu Leu
 195 200 205

Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Leu Thr Ala Leu Phe Leu
 210 215 220

Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln
 225 230 235 240

Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser
 245 250 255

Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Leu Lys
 260 265 270

Ile Gln Val Arg Lys Ala Ala Ile Thr Ser Tyr Glu Lys Ser Asp Gly
 275 280 285

Val Tyr Thr Gly Leu Ser Thr Arg Asn Gln Glu Thr Tyr Glu Thr Leu
 290 295 300

Lys His Glu Lys Pro Pro Gln
 305 310

<210> 88
 <211> 1605
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> DNA Sequence NK39_9

<400> 88

44591144002SequenceListing.txt

atgagaat	tt	cga	aaccaca	tttgaga	agt	tttccat	cc	agtgctact	tt	gtgtttact	tt	60	
ctaaacag	tc	at	tttctaac	tgaagct	ggc	at	catgtct	tcatttt	ggg	ctgtttcag	t	120	
gcagggct	tc	ctaaa	acaga	agccaact	gg	gtcaac	gtga	ttagcgatt	t	gaagaaa	atc	180	
gaggacct	ta	tacagt	ctat	gcatatt	gac	gctacact	gt	atactgag	ag	tgatgtac	ac	240	
ccgtcctg	ta	aggtaac	ggc	catgaa	atgc	tttctt	ctgg	agctccag	gt	catcagct	t	300	
gagtctgg	ggg	acgcaag	cat	ccacgata	cg	gttgaaa	acc	tcatcat	cct	tg	cgaca	ac	360
tctctct	cat	ctaatg	gaaa	cgttacag	ag	agtgggt	gta	aggagt	gcga	agagtt	ggaa	420	
gaaaaaa	aca	tcaaaga	aatt	tcttca	atcc	ttcgtt	caca	tagtgca	aat	gttcatta	ac	480	
acgtccgg	cg	gaggagg	cag	cggcggc	ggc	ggcagc	ggcg	gcggcgg	cag	cttatt	caac	540	
caagaagt	tc	aaattcc	cctt	gaccgaa	agt	tactgtg	ggcc	catgtc	cctaa	aaactgg	ata	600	
tgttaca	aaa	ataact	gcta	ccaatt	tttt	gatgag	agta	aaaact	ggta	tgagag	ccag	660	
gcttctt	gta	tgtctca	aaa	tgccagc	cctt	ctgaa	agtat	acagca	aaaga	ggaccag	gat	720	
ttactta	aac	tggtga	agtc	atatcatt	gg	atggg	actag	tacacatt	cc	aacaa	tggaa	780	
tcttggc	agt	gggaag	atgg	ctccatt	ctc	tcacca	aacc	tactaaca	aat	aattgaa	atg	840	
cagaagg	gag	actgtg	cact	ctatgc	cctcg	agcttta	aaag	gctata	tataga	aaactgt	tca	900	
actcca	ata	cgta	catctg	catgca	aaagg	actgtg	acca	cgacgc	cagc	gccgcg	acca	960	
ccaacac	cgg	cgccc	acat	cgcg	tcgag	cccctg	tccc	tcgccc	caga	ggcgtg	ccgg	1020	
ccagcgg	cgg	ggggc	gcagt	gcacac	gagg	gggctg	gact	tcgcct	gtga	tatctac	atc	1080	
tgggcgc	cct	tggcc	gggac	ttgtg	gggtc	cttctc	ctgt	cactgg	tat	caccctt	ac	1140	
tgcaaac	ggg	gcagaa	agaa	actcct	gtat	atattca	aac	aaccatt	tat	gagacc	agta	1200	
caactac	tc	aagagga	aaga	tggctg	tagc	tgccgat	ttc	cagaaga	aaga	agaagg	agga	1260	
tgtgaac	tga	gagtga	agtt	cagcagg	agc	gcagac	gccc	ccgcg	tacca	gcaggg	ccag	1320	
aaccag	ctct	ataac	gagct	caatct	tagga	cgaagag	agg	agtacg	atgt	tttgga	caag	1380	
agacgtg	ggc	gggacc	ctga	gatggg	gggga	aagccg	agaa	ggaaga	accc	tcagga	aggc	1440	
ctgtaca	atg	aactgc	agaa	agataa	gatg	gcggag	gcct	acagtg	agat	tgggat	gaaa	1500	
ggcga	gcgc	ggaggg	gcaa	ggggc	acgat	ggcctt	tacc	agggtc	tcag	tacagc	cacc	1560	

aaggacacct acgacgccct tcacatgcag gccctgcccc ctcgc

1605

<210> 89
 <211> 535
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Amino Acid Sequence NK39_9

<400> 89

Met Arg Ile Ser Lys Pro His Leu Arg Ser Ile Ser Ile Gln Cys Tyr
 1 5 10 15

Leu Cys Leu Leu Leu Asn Ser His Phe Leu Thr Glu Ala Gly Ile His
 20 25 30

Val Phe Ile Leu Gly Cys Phe Ser Ala Gly Leu Pro Lys Thr Glu Ala
 35 40 45

Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys Ile Glu Asp Leu Ile
 50 55 60

Gln Ser Met His Ile Asp Ala Thr Leu Tyr Thr Glu Ser Asp Val His
 65 70 75 80

Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe Leu Leu Glu Leu Gln
 85 90 95

Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile His Asp Thr Val Glu
 100 105 110

Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu Ser Ser Asn Gly Asn Val
 115 120 125

Thr Glu Ser Gly Cys Lys Glu Cys Glu Glu Leu Glu Glu Lys Asn Ile
 130 135 140

Lys Glu Phe Leu Gln Ser Phe Val His Ile Val Gln Met Phe Ile Asn

44591144002SequenceListing.txt

355

360

365

Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly
 370 375 380

Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val
 385 390 395 400

Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu
 405 410 415

Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp
 420 425 430

Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn
 435 440 445

Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg
 450 455 460

Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly
 465 470 475 480

Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu
 485 490 495

Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu
 500 505 510

Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His
 515 520 525

Met Gln Ala Leu Pro Pro Arg
 530 535

<210> 90
 <211> 1122
 <212> DNA
 <213> Homo sapiens

44591144002SequenceListing.txt

<220>

<221> misc_feature

<223> DNA Sequence NKG2D-Ox40-CD3z

<400> 90

```
atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg      60
ccgttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct      120
aaaaactgga tatgttaca  aaataactgc taccaatfff ttgatgagag taaaaactgg      180
tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa      240
gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt      300
ccaacaaatg gatccttgga gtgggaagat ggctccattc tctcaccaa cctactaaca      360
ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata      420
gaaaactgtt caactccaaa tacgtacatc tgcattgcaa ggactgtgac cacgacgcca      480
gcgccgagac caccaacacc ggcgcccacc atcgcgtcgc agcccctgtc cctgcgcca      540
gaggcgtgcc ggccagcggc ggggggagca gtgcacacga gggggctgga cttgcctgt      600
gatatctaca tctgggcgcc cttggccggg acttgtgggg tccttctcct gtcactggtt      660
atcaccttt actgccggag ggaccagagg ctgcccccg atgccacaa gcccctggg      720
ggaggcagtt tccggacccc catccaagag gagcaggccg acgcccactc caccctggcc      780
aagatcagag tgaagttcag caggagcgcg gacgcccccg cgtaccagca gggccagaac      840
cagctctata acgagctcaa tctaggacga agagaggagt acgatgtttt ggacaagaga      900
cgtggccggg accctgagat ggggggaaag ccgagaagga agaaccctca ggaaggcctg      960
tacaatgaac tgcagaaaga taagatggcg gaggcctaca gtgagattgg gatgaaaggc     1020
gagcgcggga ggggcaaggg gcacgatggc ctttaccagg gtctcagtac agccaccaag     1080
gacacctag acgcccttca catgcaggcc ctgccccctc gc                               1122
```

<210> 91

<211> 341

<212> PRT

<213> Homo sapiens

<220>

44591144002SequenceListing.txt

<221> MISC_FEATURE

<223> Amino Acid Sequence NKG2D-OX40-CD3z

<400> 91

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1 5 10 15

His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr
 20 25 30

Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn
 35 40 45

Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln
 50 55 60

Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
 65 70 75 80

Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly
 85 90 95

Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
 100 105 110

Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp
 115 120 125

Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
 130 135 140

Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Glu Ser Lys Tyr
 145 150 155 160

Gly Pro Pro Cys Pro Ser Cys Pro Ile Tyr Ile Trp Ala Pro Leu Ala
 165 170 175

Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys
 180 185 190

44591144002SequenceListing.txt

Arg Arg Asp Gln Arg Leu Pro Pro Asp Ala His Lys Pro Pro Gly Gly
 195 200 205

Gly Ser Phe Arg Thr Pro Ile Gln Glu Glu Gln Ala Asp Ala His Ser
 210 215 220

Thr Leu Ala Lys Ile Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro
 225 230 235 240

Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly
 245 250 255

Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro
 260 265 270

Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr
 275 280 285

Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly
 290 295 300

Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln
 305 310 315 320

Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln
 325 330 335

Ala Leu Pro Pro Arg
 340

<210> 92
 <211> 1143
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> DNA Sequence NKG2D-CD28 - CD3z

<400> 92

44591144002SequenceListing.txt

```

atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg      60
ccgttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct      120
aaaaactgga tatgttacia aaataactgc taccaatfff ttgatgagag taaaaactgg      180
tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa      240
gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt      300
ccaacaaatg gatccttgga gtgggaagat ggctccattc tctcacccaa cctactaaca      360
ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata      420
gaaaactggt caactccaaa tacgtacatc tgcattgcaa ggactgtgac cacgacgcca      480
gcgccgcgac caccaacacc ggcgcccacc atcgcgtcgc agccccctgc cctgcgccca      540
gaggcgtgcc ggccagcggc ggggggcgca gtgcacacga gggggctgga cttgcctgt      600
gatttttggg tgctggtggt ggttggtgga gtcctggctt gctatagctt gctagtaaca      660
gtggccttta ttattttctg ggtgaggagt aagaggagca ggctcctgca cagtgactac      720
atgaacatga ctccccgccg ccccgggccc acccgcaagc attaccagcc ctatgccccca      780
ccacgcgact tcgcagccta tcgctccaga gtgaagttca gcaggagcgc agacgcccc      840
gcgtaccagc agggccagaa ccagctctat aacgagctca atctaggacg aagagaggag      900
tacgatgttt tggacaagag acgtggccgg gaccctgaga tggggggaaa gccgagaagg      960
aagaaccctc aggaaggcct gtacaatgaa ctgcagaaag ataagatggc ggaggcctac     1020
agtgagattg ggatgaaagg cgagcgccgg aggggcaagg ggcacgatgg cctttaccag     1080
ggtctcagta cagccaccaa ggacacctac gacgcccttc acatgcaggc cctgccccct     1140
cgc                                                                              1143

```

```

<210> 93
<211> 381
<212> PRT
<213> Homo sapiens

```

```

<220>
<221> MISC_FEATURE
<223> Amino Acid Sequence NKG2D-CD28 - CD3z

```

```

<400> 93

```

44591144002SequenceListing.txt

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1 5 10 15

His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr
 20 25 30

Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn
 35 40 45

Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln
 50 55 60

Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
 65 70 75 80

Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly
 85 90 95

Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
 100 105 110

Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp
 115 120 125

Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
 130 135 140

Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro
 145 150 155 160

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
 165 170 175

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
 180 185 190

Thr Arg Gly Leu Asp Phe Ala Cys Asp Phe Trp Val Leu Val Val Val
 195 200 205

44591144002SequenceListing.txt

Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile
 210 215 220

Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr
 225 230 235 240

Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln
 245 250 255

Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys
 260 265 270

Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln
 275 280 285

Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu
 290 295 300

Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg
 305 310 315 320

Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met
 325 330 335

Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly
 340 345 350

Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp
 355 360 365

Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
 370 375 380

<210> 94
 <211> 1269
 <212> DNA
 <213> Homo sapiens

<220>

44591144002SequenceListing.txt

<221> misc_feature

<223> DNA Sequence NKG2D - CD28 - 41BB - CD3z

<400> 94

```
atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg      60
ccgttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct      120
aaaaactgga tatgttacia aaataactgc taccaatttt ttgatgagag taaaaactgg      180
tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa      240
gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt      300
ccaacaaatg gatccttgga gtgggaagat ggctccattc tctcaccaa cctactaaca      360
ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata      420
gaaaactgtt caactccaaa tacgtacatc tgcatgcaaa ggactgtgac cacgacgcca      480
gcgccgcgac caccaacacc ggcgcccacc atcgcgtcgc agcccctgtc cctgcgccca      540
gaggcgtgcc ggccagcggc ggggggcgca gtgcacacga gggggctgga cttcgctgt      600
gatttttggg tgctggtggt ggttggtgga gtcctggctt gctatagctt gctagtaaca      660
gtggccttta ttattttctg ggtgaggagt aagaggagca ggctcctgca cagtgactac      720
atgaacatga ctccccgccg ccccgggccc acccgcaagc attaccagcc ctatgccccca      780
ccacgcgact tcgcagccta tcgctccaaa cggggcagaa agaaactcct gtatatattc      840
aaacaacat ttatgagacc agtacaaact actcaagagg aagatggctg tagctgccga      900
ttccagaag aagaagaagg aggatgtgaa ctgagagtga agttcagcag gagcgcagac      960
gccccgcgt accagcaggg ccagaaccag ctctataacg agctcaatct aggacgaaga     1020
gaggagtacg atgttttggg caagagacgt ggccgggacc ctgagatggg gggaaagccg     1080
agaaggaaga accctcagga aggcctgtac aatgaactgc agaaagataa gatggcggag     1140
gcctacagtg agattgggat gaaaggcgag cgccggaggg gcaaggggca cgatggcctt     1200
taccaggtc tcagtacagc caccaaggac acctacgacg cccttcacat gcaggccctg     1260
ccccctcgc                                     1269
```

<210> 95

<211> 423

<212> PRT

44591144002SequenceListing.txt

<213> Homo sapiens

<220>

<221> MISC_FEATURE

<223> Amino Acid Sequence NKG2D - CD28 - 41BB - CD3z

<400> 95

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1 5 10 15

His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr
 20 25 30

Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn
 35 40 45

Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln
 50 55 60

Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
 65 70 75 80

Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly
 85 90 95

Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
 100 105 110

Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp
 115 120 125

Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
 130 135 140

Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro
 145 150 155 160

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
 165 170 175

44591144002SequenceListing.txt

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
 180 185 190

Thr Arg Gly Leu Asp Phe Ala Cys Asp Phe Trp Val Leu Val Val Val
 195 200 205

Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile
 210 215 220

Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr
 225 230 235 240

Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln
 245 250 255

Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Lys Arg Gly
 260 265 270

Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val
 275 280 285

Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu
 290 295 300

Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp
 305 310 315 320

Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn
 325 330 335

Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg
 340 345 350

Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly
 355 360 365

Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu
 370 375 380

44591144002SequenceListing.txt

Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu
 385 390 395 400

Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His
 405 410 415

Met Gln Ala Leu Pro Pro Arg
 420

<210> 96
 <211> 1038
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> DNA Sequence NKG2D(short hinge) - 41BB - CD3z

<400> 96
 atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg 60
 ccgttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct 120
 aaaaactgga tatgtttaca aaataactgc taccaatttt ttgatgagag taaaaactgg 180
 tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa 240
 gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt 300
 ccaacaaatg gatcttggca gtgggaagat ggctccattc tctcaccaa cctactaaca 360
 ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata 420
 gaaaactggt caactccaaa tacgtacatc tgcatgcaaa ggactgtgga gtccaaatat 480
 ggtcccccat gccatcatg cccaatctac atctgggctc ccttggccgg gacttgtggg 540
 gtccttctcc tgtcactggt taccacctt tactgcaaac ggggcagaaa gaaactcctg 600
 tatatattca aacaaccatt tatgagacca gtacaaacta ctcaagagga agatggctgt 660
 agctgccgat ttccagaaga agaagaagga ggatgtgaac tgagagtgaa gttcagcagg 720
 agcgcagacg cccccgcgta ccagcagggc cagaaccagc tctataacga gctcaatcta 780
 ggacgaagag aggagtacga tgttttggac aagagacgtg gccgggacct tgagatgggg 840

44591144002SequenceListing.txt

ggaaagccga gaaggaagaa ccctcaggaa ggcctgtaca atgaactgca gaaagataag 900
atggcggagg cctacagtga gattgggatg aaaggcgagc gccggagggg caagggggcac 960
gatggccttt accaggtct cagtacagcc accaaggaca cctacgacgc cttcacatg 1020
caggccctgc cccctcgc 1038

<210> 97
<211> 346
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> Amino Acid Sequence NKG2D(short hinge) - 41BB - CD3z

<400> 97

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
1 5 10 15

His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr
20 25 30

Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn
35 40 45

Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln
50 55 60

Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
65 70 75 80

Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly
85 90 95

Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
100 105 110

Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp
115 120 125

44591144002SequenceListing.txt

Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
130 135 140

Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Glu Ser Lys Tyr
145 150 155 160

Gly Pro Pro Cys Pro Ser Cys Pro Ile Tyr Ile Trp Ala Pro Leu Ala
165 170 175

Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys
180 185 190

Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met
195 200 205

Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe
210 215 220

Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg
225 230 235 240

Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn
245 250 255

Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg
260 265 270

Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Ang Lys Asn Pro
275 280 285

Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala
290 295 300

Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Ang Gly Lys Gly His
305 310 315 320

Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp
325 330 335

44591144002SequenceListing.txt

Ala Leu His Met Gln Ala Leu Pro Pro Arg
 340 345

<210> 98
 <211> 1044
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> DNA Sequence NKG2D (SH)-CD28 - CD3z

<400> 98
 atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg 60
 ccgttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct 120
 aaaaactgga tatgttacaa aaataactgc taccaatttt ttgatgagag taaaaactgg 180
 tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa 240
 gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt 300
 ccaacaaatg gatccttgga gtgggaagat ggctccattc tctcaccaa cctactaaca 360
 ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata 420
 gaaaactggt caactccaaa tacgtacatc tgcattgcaa ggactgtgga gtccaaatat 480
 ggtcccccatt gcccatcatg cccattttgg gtgctggtgg tggttggtgg agtcctggct 540
 tgctatagct tgctagtaac agtggccttt attattttct ggggtgaggag taagaggagc 600
 aggctcctgc acagtgacta catgaacatg actccccgcc gccccgggcc caccgcaag 660
 cattaccagc cctatgcccc accacgcgac ttgcagcct atcgctccag agtgaagttc 720
 agcaggagcg cagacgcccc cgcgtaccag cagggccaga accagctcta taacgagctc 780
 aatctaggac gaagagagga gtacgatggt ttggacaaga gacgtggccg ggaccctgag 840
 atgggggggaa agccgagaag gaagaaccct caggaaggcc tgtacaatga actgcagaaa 900
 gataagatgg cggaggccta cagtgagatt gggatgaaag gcgagcgccg gaggggcaag 960
 gggcacgatg gcctttacca gggctctcagt acagccacca aggacaccta cgacgccctt 1020
 cacatgcagg ccctgcccc tcgc 1044

44591144002SequenceListing.txt

<210> 99
 <211> 348
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> Amino Acid Sequence NKG2D (SH)-CD28 - CD3z

<400> 99

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1 5 10 15

His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr
 20 25 30

Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn
 35 40 45

Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln
 50 55 60

Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
 65 70 75 80

Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly
 85 90 95

Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
 100 105 110

Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp
 115 120 125

Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
 130 135 140

Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Glu Ser Lys Tyr
 145 150 155 160

44591144002SequenceListing.txt

Gly Pro Pro Cys Pro Ser Cys Pro Phe Trp Val Leu Val Val Val Gly
 165 170 175

Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile
 180 185 190

Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met
 195 200 205

Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro
 210 215 220

Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe
 225 230 235 240

Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu
 245 250 255

Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp
 260 265 270

Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys
 275 280 285

Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala
 290 295 300

Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys
 305 310 315 320

Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr
 325 330 335

Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
 340 345

<210> 100
 <211> 1023
 <212> DNA

44591144002SequenceListing.txt

<213> Homo sapiens

<220>

<221> misc_feature

<223> DNA Sequence NKG2D (SH) - OX40 - CD3z

<400> 100

```

atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg      60
ccgttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct      120
aaaaactgga tatgtttaca aaataactgc taccaatttt ttgatgagag taaaaactgg      180
tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa      240
gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt      300
ccaacaaatg gatcttggca gtgggaagat ggctccattc tctcaccaa cctactaaca      360
ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata      420
gaaaactgtt caactccaaa tacgtacatc tgcattgcaa ggactgtgga gtccaaatat      480
ggtcccccat gccatcatg cccaatctac atctgggagc cttggccgg gacttgtggg      540
gtccttctcc tgtcactggt taccacctt tactgccgga gggaccagag gctgcccccc      600
gatgccaca agccccctgg gggaggcagt ttccggacct ccatccaaga ggagcaggcc      660
gacgcccact ccaccctggc caagatcaga gtgaagttca gcaggagcgc agacgcccccc      720
gctaccagc agggccagaa ccagctctat aacgagctca atctaggacg aagagaggag      780
tacgatgttt tggacaagag acgtggccgg gaccctgaga tggggggaaa gccgagaagg      840
aagaaccctc aggaaggcct gtacaatgaa ctgcagaaag ataagatggc ggaggcctac      900
agtgagattg ggatgaaagg cgagcgccgg aggggcaagg ggcacgatgg cctttaccag      960
ggtctcagta cagccaccaa ggacacctac gacgcccttc acatgcaggc cctgccccct     1020
cgc                                                                              1023

```

<210> 101

<211> 346

<212> PRT

<213> Homo sapiens

<220>

44591144002SequenceListing.txt

<221> MISC_FEATURE

<223> Amino Acid Sequence NKG2D (SH) - OX40 - CD3z

<400> 101

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1 5 10 15

His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr
 20 25 30

Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn
 35 40 45

Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln
 50 55 60

Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
 65 70 75 80

Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly
 85 90 95

Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
 100 105 110

Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp
 115 120 125

Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
 130 135 140

Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Glu Ser Lys Tyr
 145 150 155 160

Gly Pro Pro Cys Pro Ser Cys Pro Phe Trp Val Leu Val Val Val Gly
 165 170 175

Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile
 180 185 190

44591144002SequenceListing.txt

Phe Trp Val Arg Ser Arg Arg Asp Gln Arg Leu Pro Pro Asp Ala His
 195 200 205

Lys Pro Pro Gly Gly Gly Ser Phe Arg Thr Pro Ile Gln Glu Glu Gln
 210 215 220

Ala Asp Ala His Ser Thr Leu Ala Lys Ile Arg Val Lys Phe Ser Arg
 225 230 235 240

Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn
 245 250 255

Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg
 260 265 270

Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro
 275 280 285

Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala
 290 295 300

Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His
 305 310 315 320

Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp
 325 330 335

Ala Leu His Met Gln Ala Leu Pro Pro Arg
 340 345

<210> 102
 <211> 1125
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> DNA Sequence NKG2D-CD3TM -CD28 - CD3z

<400> 102

44591144002SequenceListing.txt

atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg 60
ccgttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct 120
aaaaactgga tatgttacia aaataactgc taccaatttt ttgatgagag taaaaactgg 180
tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa 240
gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt 300
ccaacaaatg gatccttgga gtgggaagat ggctccattc tctcacccaa cctactaaca 360
ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata 420
gaaaactgtt caactccaaa tacgtacatc tgcattgcaa ggactgtgac cacgacgcca 480
gcgccgcgac caccaacacc ggcccccacc atcgcgtcgc agcccctgtc cctgcgccca 540
gaggcgtgcc ggccagcggc ggggggcgca gtgcacacga gggggctgga cttgcctgt 600
gatcccaaac tctgctacct gctggatgga atcctcttca tctatggtgt cattctcact 660
gccttgttcc tgaagaggag caggctcctg cacagtgact acatgaacat gactccccgc 720
cgccccgggc ccaccgcaa gcattaccag ccctatgccc caccacgca cttcgcagcc 780
tatcgtcca gagtgaagtt cagcaggagc gcagacgccc ccggtacca gcagggccag 840
aaccagctct ataacgagct caatctagga cgaagagagg agtacgatgt tttggacaag 900
agacgtggcc gggaccctga gatgggggga aagccgagaa ggaagaacct tcaggaaggc 960
ctgtacaatg aactgcagaa agataagatg gcggaggcct acagtgagat tgggatgaaa 1020
ggcgagcgcc ggaggggcaa ggggcacgat ggcctttacc aggttctcag tacagccacc 1080
aaggacacct acgacgcct tcacatgcag gccctgcccc ctcgc 1125

<210> 103
<211> 375
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> Amino Acid Sequence NKG2D-CD3TM -CD28 - CD3z
<400> 103

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu

44591144002SequenceListing.txt

1 5 10 15
 His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr
 20 25 30
 Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn
 35 40 45
 Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln
 50 55 60
 Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
 65 70 75 80
 Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly
 85 90 95
 Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
 100 105 110
 Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp
 115 120 125
 Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
 130 135 140
 Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro
 145 150 155 160
 Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
 165 170 175
 Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
 180 185 190
 Thr Arg Gly Leu Asp Phe Ala Cys Asp Pro Lys Leu Cys Tyr Leu Leu
 195 200 205
 Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Leu Thr Ala Leu Phe Leu

44591144002SequenceListing.txt

210

215

220

Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg
 225 230 235 240

Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg
 245 250 255

Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp
 260 265 270

Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn
 275 280 285

Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg
 290 295 300

Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly
 305 310 315 320

Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu
 325 330 335

Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu
 340 345 350

Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His
 355 360 365

Met Gln Ala Leu Pro Pro Arg
 370 375

<210> 104
 <211> 36
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> DNA Sequence IgG 4 hinge

<400> 104
gagtccaaat atggtccccc atgcccatca tgccca

36

<210> 105
<211> 29
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> Amino Acid Sequence CD28 Transmembrane domain

<400> 105
Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu
1 5 10 15

Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser
 20 25

<210> 106
<211> 39
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> Amino Acid Sequence CD28 IC domain

<400> 106
Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg
1 5 10 15

Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg
 20 25 30

Asp Phe Ala Ala Tyr Arg Ser
 35

<210> 107
<211> 37
<212> PRT

44591144002SequenceListing.txt

<213> Homo sapiens

<220>

<221> MISC_FEATURE

<223> Amino Acid Sequence OX40 IC Domain

<400> 107

Arg Arg Asp Gln Arg Leu Pro Pro Asp Ala His Lys Pro Pro Gly Gly
 1 5 10 15

Gly Ser Phe Arg Thr Pro Ile Gln Glu Glu Gln Ala Asp Ala His Ser
 20 25 30

Thr Leu Ala Lys Ile
 35

<210> 108

<211> 1140

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> NKG2D-P-frag/CD8a/4-1BB/CD3z

<400> 108

atggccttac cagtgaccgc cttgctcctg ccgctggcct tgctgctcca cgccgccagg 60
 ccgttattca accaagaagt tcaaattccc ttgaccgaaa gttactgtgg cccatgtcct 120
 aaaaactgga tatgttaca aaataactgc taccaatttt ttgatgagag taaaaactgg 180
 tatgagagcc aggcttcttg tatgtctcaa aatgccagcc ttctgaaagt atacagcaaa 240
 gaggaccagg atttacttaa actggtgaag tcatatcatt ggatgggact agtacacatt 300
 ccaacaaatg gatccttgga gtgggaagat ggctccattc tctcaccaa cctactaaca 360
 ataattgaaa tgcagaaggg agactgtgca ctctatgcct cgagctttaa aggctatata 420
 gaaaactggt caactccaaa tacgtacatc tgcattgcaa ggactgtgac cacgacgcca 480
 gcgccgagac caccaacacc ggcgcccacc atcgcgtcgc agcccctgtc cctgagccca 540
 gaggcgtgcc ggccagcggc ggggggagca gtgcacacga gggggctgga cttgcctgt 600

44591144002SequenceListing.txt

gatatctaca tctgggcgcc cttggccggg acttgtgggg tccttctcct gtcactgggtt 660
 atcacccctt actgcaaacg gggcagaaag aaactcctgt atatattcaa acaaccattt 720
 atgagaccag taaaactac tcaagaggaa gatggctgta gctgccgatt tccagaagaa 780
 gaagaaggag gatgtgaact gagagtgaag ttcagcagga gcgcagacgc ccccgctac 840
 cagcagggcc agaaccagct ctataacgag ctcaatctag gacgaagaga ggagtacgat 900
 gttttggaca agagacgtgg ccgggaccct gagatggggg gaaagccgag aaggaagaac 960
 cctcaggaag gcctgtacaa tgaactgcag aaagataaga tggcggaggc ctacagtgag 1020
 attgggatga aaggcgagcg ccggaggggc aaggggcacg atggccttta ccagggtctc 1080
 agtacagcca ccaaggacac ctacgacgcc cttcacatgc aggccctgcc ccctcgctaa 1140

<210> 109
 <211> 374
 <212> PRT
 <213> Homo sapiens

<220>
 <221> MISC_FEATURE
 <223> NKG2D-V2-OX40-CD3z

<400> 109

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1 5 10 15

His Ala Ala Arg Pro Leu Phe Asn Gln Glu Val Gln Ile Pro Leu Thr
 20 25 30

Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn
 35 40 45

Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln
 50 55 60

Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys
 65 70 75 80

Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr His Trp Met Gly

44591144002SequenceListing.txt

85

90

95

Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser
 100 105 110

Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met Gln Lys Gly Asp
 115 120 125

Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser
 130 135 140

Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val Thr Thr Thr Pro
 145 150 155 160

Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
 165 170 175

Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
 180 185 190

Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu
 195 200 205

Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr
 210 215 220

Cys Arg Arg Asp Gln Arg Leu Pro Pro Asp Ala His Lys Pro Pro Gly
 225 230 235 240

Gly Gly Ser Phe Arg Thr Pro Ile Gln Glu Glu Gln Ala Asp Ala His
 245 250 255

Ser Thr Leu Ala Lys Ile Arg Val Lys Phe Ser Arg Ser Ala Asp Ala
 260 265 270

Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu
 275 280 285

Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp

44591144002SequenceListing.txt

290

295

300

Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu
 305 310 315 320

Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile
 325 330 335

Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr
 340 345 350

Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met
 355 360 365

Gln Ala Leu Pro Pro Arg
 370